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Abstract
The aim of this project was to investigate the possible mechanism(s) underlying the
attenuated hypothalamic-pituitary-adrenal (HPA) axis response to stressors during
pregnancy at the level of the anterior pituitary. We found that the reduced HPA axis
activity during pregnancy was not due to changes in the sensitivity of corticotrophs in
the anterior pituitary, but to the decreased secretion particularly of vasopressin and
possibly corticotropin-releasing hormone (CRH) from the hypothalamus. The reduced
CRH and vasopressin secretion during pregnancy is a result of action of neurosteroid
metabolites of progesterone as a 5a-reductase inhibitor reversed the attenuated
adrenocorticotrophic hormone (ACTH) secretory response to stress.
By in situ hybridisation, we found a progressive decrease in proopiomelanocortin
(POMC) mRNA expression in the anterior pituitary during pregnancy. However, there
was no change in ACTH content. Compared with expression in the anterior pituitary
of virgin rats, in late pregnancy (day 21), CRH receptor subtype 1 (CRHR1) mRNA
expression was not changed, vasopressin receptor subtype lb (VlbR) mRNA
expression was reduced, and glucocorticoid receptor (GR) mRNA was increased. We
also measured large conductance potassium channel (BK) and the splice variant of the
BK channel, STREX, mRNA expression and found no change during pregnancy.
Corticotropin-releasing hormone binding protein (CRHBP) mRNA expression was
elevated by 30 min restraint stress in the anterior pituitary, but there were no
differences between virgin and pregnant rats.
In vivo, a CRHR1 antagonist, antalarmin, decreased ACTH secretion in response to
swimming stress in both virgin and pregnant rats. However, a Vla/b receptor
antagonist decreased the ACTH response to this stressor in virgin rats only.
Exogenous vasopressin or CRH injection alone increased ACTH secretion more in
virgin than in pregnant rats. Injection of CRH and vasopressin together had a similar
stimulatory action on ACTH secretion in virgin and pregnant rats. Thus the attenuated
ACTH stress response during pregnancy is primarily a result of reduced vasopressin
secretion during stress.
Ill
To investigate whether corticotroph sensitivity to CRH and vasopressin is modulated
during pregnancy, we incubated anterior pituitary cells with different concentrations
of CRH, vasopressin, a combination of CRH and vasopressin, or cAMP. We found a
dose related augmentation of CRH stimulation of ACTH secretion by vasopressin.
The sensitivity of corticotrophs to CRH was greater in pregnancy and the
augmentation by vasopressin of the effects of a low concentration of CRH was greater
for corticotrophs from pregnant than from virgin rats. A greater effect of cAMP
suggests changes in post receptor signalling mechanisms in pregnancy.
GABAergic mechanisms inhibit the HPA axis via GABAa receptors on CRH
neurones and their inputs. Alloprcgnanolone, the neurosteroid metabolite of
progesterone, acts as a major GABAa receptor allosteric modifier, so enhancing the
action of GABA. To investigate such a possible enhanced GABAergic action by
allopregnanolone on CRH and vasopressin secretion during pregnancy, we prevented
the inhibitory action of the metabolic product of progesterone by blocking production
via 5a-reductase with 4-MA. 4-MA prevented the attenuated ACTH secretory
response to swimming stress in pregnant rats and had no effect directly on the
corticotrophs.
The reduced stress- induced ACTH response during pregnancy is predominantly the
consequence of reduced vasopressin release, with secondary changes in corticotrophs.
The central changes may be due to the inhibitory action of allopregnanolone on CRH
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General introduction Chapter 1
Chapter 1
General introduction
1.1 Stress and the hypothalamus-pituitary-adrenal (HPA) system
Selye defined Stress as 'a non-specific response of the body to any demand made on it'
(Selye 1975). However, this non-specific concept has been modified as the ways in
which different stressors are processed have become understood. The stress response
system consists of central and peripheral components (Figure 1.1). The hypothalamus-
pituitary-adrenal axis (HPA) is the most prominent system mediating physiological
adaptations to stress. Central components include: the corticotrophin-releasing
hormone (CRH) and arginine-vasopressin parvocellular neurones of the
paraventricular nuclei (PVN) of the hypothalamus; nuclei of the medulla including the
catecholaminergic neurones of the locus coeruleus (LC) and other cells groups of the
medulla and the pons. Peripheral components include the anterior pituitary-adrenal
axis and the efferent sympathetic/adrenomedullary systems (Stratakis & Chrousos
1995). The endpoint of the stress response of the HPA system, an elevation of plasma
corticosteroid (in rat and mouse, or Cortisol in human) levels is usually considered to
be definitive of a state of stress.
The activity of the HPA axis is regulated by a variety of stimulatory and inhibitory
factors. The former are CRH, vasopressin, oxytocin and other stimulatory factors, the
latter are glucocorticoids by negative feedback, brain inhibitory transmitters, local
negative modulation such as CRH-binding protein and other inhibitory factors
including atrial natriuretic peptide (Figure 1.1).
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Stressors may arise in the external or internal environments. Stressors are classified
into two types: social/emotional and physical stressors. Forced swimming and
restraint belong to the former, and painful stress or footshock belong to the latter.
Also from the external environment are micro-organisms, which if they invade the
body and stimulate an immune response, activate the HPA axis through signalling by
immune cells. Stressors within the body, for example hypoxia or hypotension, also
trigger HPA activation.
1.2 Anatomy of HPA axis
The HPA axis consists of the hypothalamus, anterior pituitary and adrenal cortex.
1.2.1 The hypothalamus and the PVN
The hypothalamus is a region of the brain that controls an immense number of bodily
functions. It is located in the middle of the base of the brain, and encapsulates the
ventral portion of the third ventricle. There are 16 nuclei distinguished in the rat
hypothalamus. The anterior hypothalamus includes the periventricular hypothalamic
nucleus, suprachiasmatic nucleus, anterior hypothalamic nucleus, supraoptic nucleus
(SON), PVN and retrochiasmatic area. The PVN lies at the caudal portion of the
anterior hypothalamus, and contains CRH and vasopressin parvocellular neurones
projecting to the median eminence and magnocellular vasopressin and oxytocin
neurones projecting to the posterior pituitary or centrally (Michael & Freeman 2000).
The SON contains magnocellular oxytocin neurones and vasopressin neurones in the
dorsal and ventral portion of the nucleus respectively, all projecting to the posterior
pituitary (Michael & Freeman 2000). The middle hypothalamus contains the arcuate
nucleus, ventromedial nucleus, dorsomedial nucleus, and perifomical nucleus.
The median eminence is a tiny structure in the hypothalamus about 1.7-2.0 x 0.7-1.2 x
0.2-0.3 mm in rats, containing the efferent neurosecretory fibres of the hypothalamus
that regulate the anterior pituitary or project to the posterior pituitary. The internal
layer contains the fibres mainly from the magnocellular oxytocin and vasopressin
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neurones in the PVN and SON, terminating in the posterior pituitary. The external
layer contains the fibres originating from various hypothalamic nuclei including
parvocellular CRH and vasopressin neurones and these neurone terminals abut on the
pericapillary space surrounding the fenestrated capillaries of the primary pituitary
portal plexus in the external zone of the median eminence and the hormones are
released into the hypothalamic portal blood to get to the anterior pituitary (Holmes et
al. 1986; Michael & Freeman 2000).
1.2.2 Anatomy of the pituitary gland
The pituitary gland, also known as the hypophysis, is a roundish organ that lies in the
hypophyseal fossa of the sphenoid bone flanked on either side by the cavernous sinus
and above by the optic chiasm, and is connected to the hypothalamus by the pituitary
stalk. The human pituitary gland can be divided into two parts, the posterior pituitary
is a direct extension of the central nervous system, whereas the anterior pituitary is
derived from Rathke's pouch. But in rodents, the pituitary can be divided into three
parts: the anterior (pars distalis), the intermediate (pars intermedia) and the posterior
(pars nervosa) pituitary (Figure 1.2) (Michael & Freeman 2000).
1.2.2.1 The anterior pituitary
The anterior pituitary is formed of several cell types producing a range of hormones.
An essential component in the organisation and function of the anterior pituitary is the
close relationship between the cells and the capillary bed. Ready access to the
circulation promotes uptake of the substrates for hormone synthesis and allows
efficient release of hormones into the systemic circulation. The activity of the cells of
the anterior pituitary is controlled by releasing factors present in the capillary blood.
The releasing factors are produced by hypothalamic neurones and released into the
hypothalamo-hypophyseal portal circulation, i.e the secretion of ACTH from the
anterior pituitary is stimulated by CRH and vasopressin. There are five distinct types
of endocrine cells, distributed either throughout the anterior pituitary or localised to
particular parts. Corticotrophs are found throughout the anterior lobe in the rodents,
secreting ACTH, (3-lipotrophin, a-melanocyte stimulating hormone and P-endorphin
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Figure 1.2 Anatomy of the pituitary
which are all products of the proopiomelanocortin (POMC) gene (Lowry et al. 1980;
Chretien & Seidah 1981; Lundblad & Roberts 1988; King & Baertschi 1990). The
other cells produce growth hormone, thyroid stimulating hormone, prolactin, follicle
stimulating hormone and luteinising hormone (Michael & Freeman 2000).
1.2.2.2 The intermediate and posterior pituitary
The cells of the intermediate lobe also produce POMC-derived peptides (Michael &
Freeman 2000). The posterior lobe or neurohypophysis contains terminals of
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magnocellular SON and PVN neurones, releasing either oxytocin or vasopressin
(Michael & Freeman 2000).
1.2.2.3 Blood supply
The pituitary gland derives its blood supply from the superior and inferior
hypophyseal arteries that are connected by a portal system of small vessels and
capillaries. There are specialised vascular structures located in the median eminence
of the hypothalamus that consist of short terminal arterioles draining into portal veins
that course down the pituitary stalk to join the sinusoidal capillaries of the anterior
lobe. Releasing factors from the hypothalamus enter small openings in the capillaries
to flow from the hypothalamus to the anterior pituitary (Michael & Freeman 2000).
1.2.3 Adrenal glands
The adrenal glands are paired triangular shaped structures located immediately rostral
to the kidneys to which they are loosely attached. Each adrenal gland consists of two
parts, the outer cortex and the inner medulla. Adrenal cortical tissue comprises large
glandular cells arranged together in what appear to be loose cords separated by
sinusoids. Three distinct zones are recognised: the inner layer zona reticularis and the
middle layer zona fasciculata synthesise glucocorticoids and sex hormones, and the
outermost layer zona glomerulosa synthesises mineralocorticoids. All adrenal cortical
hormones are steroid hormones that are released as required. The major
mineralocorticoid is aldosterone. The major glucocorticoids include Cortisol in many
species and corticosterone in rats. In contrast, the adrenal medulla comprises modified
nerve cells known as chromaffin cells. They are equivalent to sympathetic
postganglionic neurones. They synthesise and secrete two closely related hormones,
adrenaline and noradrenaline. The adrenal medulla functions essentially as an
endocrine adjunct to the sympathetic nervous system for rapid stress response.
Release of adrenaline and noradrenaline are under the control of pre-ganglionic fibres
which fire when the sympathetic nervous system is activated, for example during
exercise, cold stress or haemorrhage (DeGroot 1995).
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1.3 Stimulatory factors of ACTH secretion
1.3.1 CRH
1.3.1.1 CRH characterisation
The major stimulatory regulator of pituitary ACTH secretion is CRH (Figure 1.1)
(Antoni 1986a). This 41 amino acid was characterised by Vale and his colleagues in
1981 from extracts of sheep hypothalamic fragments (Vale et al. 1981). Subsequently,
rat CRH was isolated and the primary structure of rat CRH was established to be: H-
Ser-Glu-Glu-Pro-Pro-Ile-Ser-Leu-Asp-Leu-Thr-Phe-His-Leu-Leu-Arg-Glu-Val-Leu-
Glu-Met-Ala-Arg-Ala-Glu-Gln-Leu-Ala-Gln-Gln-Ala-His-Ser-Asn-Arg-Lys-Leu-
Met-Glu-Ile-Ile-NH2. The close structural relationship between rat and ovine
hypothalamic CRH is indicated by an 83% sequence homology (Rivier et al. 1983).
Subsequently, the cDNA of the CRH gene was cloned (Furutani et al. 1983;
Shibahara et al. 1983). Rat CRH is identical to human CRH, and differs from ovine
CRH by seven amino acids. Mammalian CRH has homologies with two peptides
found in lower animal forms, the peptides sauvagine from frog and urotensin from
fish. Both have potent CRH activity (Okawara et al. 1988; Stenzel-Poore et al. 1992).
A mammalian CRH related peptide, urocortin, is related to urotensin (63% sequence
identity) and CRH (45% sequence identity). Synthetic urocortin evokes secretion of
ACTH both in vitro and in vivo, binds and activates type 1 CRH receptors (the
subtype expressed by pituitary corticotrophs) and type 2 CRH receptors (Vaughan et
al. 1995).
1.3.1.2 Distribution of CRH
The PVN of the hypothalamus was first convincingly implicated as the source of
hypophysiotropic CRH activity in the lesion studies (Makara et al. 1981). The
majority of CRH neurosecretory cells are located within the dorsal medial
parvocellular subdivision of the PVN (Swanson & Kuypers 1980; Swanson et al.
1983). These neurones project their axons to the capillary plexus in the external zone
of the median eminence, from where the CRH is release into the hypothalamo-
hypophysial portal circulation (Antoni 1986a). About 2,000 CRH immunoreactive
cells are distributed throughout the PVN, a majority (80%) of the cells are localised in
the parvocellular division and a smaller number (about 15%) are found in the
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magnocellular division. Most of the CRH stained fibres in the external zone of the
median eminence appear to arise in the PVN (Swanson et al. 1983).
CRH has a broad distribution throughout the brain and periphery and has been shown
to be present in certain human tumors (Parkes et al. 1993b). A series of cell groups in
the basal telencephalon, hypothalamus, and brain stem that are known to play a role in
the mediation of autonomic responses contain CRH immunoreactive neurones: the
central nucleus of the amygdala, substantia innominata, bed nucleus of the stria
terminalis, medial and lateral preoptic areas, lateral hypothalamic area, central gray,
laterodorsal tegmental nucleus, locus coeruleus, parabrachial nucleus, dorsal vagal
complex, and regions containing the Al and A5 catecholamine cell groups. Scattered
CRH-stained cells are also found throughout most areas of the cerebral cortex, dorsal
parts of the dentate gyrus and Ammon's horn (Swanson et al. 1983).
1.3.1.3 Physiological functions of CRH
Brain CRH is involved in coordinating the pituitary and autonomic nervous system
responses to stress (Brown et al. 1985). CRH synthesised in the parvocellular PVN of
the hypothalamus is transported in the axons of these neurones, projecting to the
median eminence and released into the portal vessels (King & Baertschi 1990). The
concentration of CRH in the portal blood of anaesthetised rats is about 0.1 nM, which
is identical to that necessary for significant stimulation of ACTH secretion by CRH in
vitro (Vale et al. 1981; Gibbs & Vale 1982). Substantial studies have shown that CRH
originating from neurones within the PVN is the predominant regulator of stress-
induced ACTH secretion. These include PVN lesion (Baertschi et al. 1983; Bruhn et
al. 1984a), synthetic ovine CRH administration in vitro (Gibbs et al. 1983), and
intravenous rabbit antiserum to ovine CRH injection (Rivier et al. 1982) studies.
Intracerebroventricular injections of ovine CRH results in a 50-100% increase in
POMC mRNA expression in the anterior pituitary (Bruhn et al. 1984b). Intravenous
injections of ovine CRH also increase POMC mRNA expression in the anterior
pituitary (Bruhn et al. 1984b) and plasma ACTH levels in rats (Hylka et al. 1984).
Intravenous administration of rabbit antiserum to ovine CRH markedly reduces the
CRH-induced rise of plasma ACTH in intact nonstressed rats, and blocks the ether
stress- or adrenalectomy- induced increases in ACTH levels by more than 75%
(Rivier et al. 1982). A bilateral ablation of the PVN results in a parallel 75% reduction
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of both stalk-median eminence CRH-like immunoreactivity and plasma ACTH levels
(Bruhn et al. 1984b). The presence of CRH receptor in the corticotrophs (Potter et al.
1994) and attenuated lipopolysaccharide-induced ACTH secretion by intravenous
injection of CRH receptor antagonist (Watanabe et al. 1994), a-helical CRH, also
indicate a role of CRH in stimulating ACTH secretion.
CRH is also involved, within the brain, in physiological regulation other than of
ACTH secretion, such as decreasing food intake and body-weight gain (Hotta et al.
1991).
1.3.1.4 Regulation of CRH synthesis and release
The mechanisms controlling the expression and release of CRH by PVN neurones are
complex, with a number of stimulatory factors (Antoni 1986a) including
catecholamines (Guillaume et al. 1987; Plotsky et al. 1989), cytokines (Barbanel et al.
1990; Rivier & Rivest 1993), serotonin (Bagdy et al. 1989), histamine (Calogero
1995), acetylcholine (Jones et al. 1987), angiotensin II (Suda et al. 1985), opioids
(Buckingham & Cooper 1986) and inhibitory factors, including glucocorticoids and
gamma-aminobutyric acid (GABA) (Jones et al. 1987), being implicated. CRH
neurones also receive dense adrenergic and noradreneragic innervation from the brain
stem, and adrenergic receptors including al-, a2-, (31-, (32 have been identified in the
PVN (Ixibowitz et al. 1982; Cummings & Seybold 1988; Al Damluji 1993).
Glucocorticoid receptors are localised in the parvocellular neurones of the PVN where
CRH is produced (Liposits et al. 1987), which indicates the PVN is a direct site of
glucocorticoid action. Basal CRH mRNA expression in the PVN is under the
inhibitory influence of glucocorticoids, as shown by the marked increases in ir-CRH
and CRH mRNA following adrenalectomy (Antoni 1986a; Young, III et al. 1986;
Sawchenko 1987; Swanson & Simmons 1989). Corticosteroid feedback reduces CRH
mRNA levels in a dose-dependent manner, although even prolonged administration of
very high doses does not abolish CRH transcripts completely. Adrenalectomy
increases hypothalamic CRH mRNA expression, while dexamethasone administration
reverses this adrenalectomy effect (Jingami et al. 1985; Beyer et al. 1988; Imaki et al.
1991; Imaki et al. 1995) in the PVN to basal levels. Glucocorticoid feedback also
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inhibits CRH gene expression in the PVN after stress, as adrenalectomy augmented
and dexamethasone pretreatment inhibited both CRH hnRNA and mRNA induction in
the PVN after the acute stress (Imaki et al. 1995).
The activation of the PVN CRH neurones during acute stress is usually followed by
variable increases in CRH synthesis as indicated by increases in CRH mRNA
expression as well as CRH release (Suda et al. 1988b; Harbuz & Lightman 1989;
Imaki et al. 1991). CRH mRNA levels in the PVN were determined after exposure to
a variety of acute physical and psychological stresses. CRH mRNA in the PVN
measured by in situ hybridisation increases in response to intraperitoneal injection of
hypertonic saline, restraint and swim stress but not to cold stress which suggests that
different afferent pathways and hypothalamic neurotransmitters may be involved in
mediating the hypothalamic response to different physical and psychological stresses
(Harbuz & Lightman 1989; Imaki et al. 1995). Many types of chronic stress also
enhance CRH mRNA expression (Imaki et al. 1991; Bartanusz et al. 1993; Kiss &
Aguilera 1993; Lightman & Harbuz 1993).
CRH secretion is also regulated by itself. By intraventricular injection, CRH shows an
augmentation effect of stress on CRH release (Ono et al. 1985a) and increases CRH
mRNA expression in the PVN (Parkes et al. 1993a).
Some evidence indicates that CRH gene expression in the PVN is also regulated by
sex steroids. Estrogen stimulates CRH mRNA expression in the PVN, whereas
progesterone reverses the effect of estrogen in vivo. Measured by in situ hybridisation,
after chronic sex steroid replacement, CRH mRNA in the PVN is increased by 2-fold
in the 17P-estradiol-replaced ovariectomised rhesus monkey compared with untreated
ovariectomised controls, but is not different compared with the controls after 17(3-
estradiol plus progesterone replacement (Roy et al. 1999). In vitro, estradiol, oestriol
and oestrone potentiate the effect of acetylcholine or 5-hydroxytryptamine on the
production of CRH from the isolated hypothalamus, but progesterone, testosterone,
androsterone and androstenedione have no such effects (Buckingham 1982).
10
General introduction Chapter 1
1.3.1.5 CRH receptors
1.3.1.5.1 Characterisation of CRH receptors
CRH as a regulator of ACTH secretion by the pituitary corticotropins acts through
specific plasma membrane receptors (Figure 1.1). Two major subtypes of CRH
receptor, differing in their pharmacological properties and distribution, and the
products of distinct genes, have been identified. CRH receptor type 1 (CRF1R1), the
main subtype in pituitary and brain, and CRH receptor subtype 2 (CRHR2).
The molecular weights of rat and mouse brain CRHRls are 76-80 kDa and 79-83 kDa
respectively, whereas the molecular weights for CRHR1 from rat and mouse pituitary
are 59-72kDa (Radulovic et al. 1998). Other studies also show that brain and pituitary
CRH receptors have similar pharmacological characteristics but different molecular
weights (brain, 58 kDa; anterior pituitary, 75 kDa) (Grigoriadis & De Souza 1989a;
Grigoriadis & De Souza 1989b).
CRHR1 cDNA was cloned from a human corticotropin tumor library (Chen et al.
1993) and from rat pituitary (Perrin et al. 1993). This encodes a 415-amino acid
protein comprising seven putative membrane-spanning domains and is structurally
related to the calcitonin/vasoactive intestinal peptide/growth hormone-releasing
hormone subfamily of G protein-coupled receptors. The receptor binds rat/human
CRH with high affinity (Kd = 3.3 ± 0.45 nM) and is functionally coupled to adenylate
cyclase (Chen et al. 1993). The rat CRHR1 is 97% identical at the amino acid level to
the human pituitary tumor CRH receptor, differing by only 12 amino acids.
CRHR2 cDNA was cloned from rat and human brain (Lovenberg et al. 1995; Liaw et
al. 1996), and encodes a 411-amino acid protein with approximately 70% identity to
CRHR1 over the entire coding region. For the CRHR2 subtype, at least 2 splice forms
with different 5'-coding sequences (CRHR2a and CRHR2p) have been identified
(Lovenberg et al. 1995; Palchaudhuri et al. 1999).
The activation of these receptors by CRH and known CRH-like agonists stimulates
cAMP production. In response to CRH and the CRH-related peptides sauvagine and
urotensin, adenylate cyclase activity is stimulated in a dose-dependent manner. The
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rank order of potencies of agonist peptides are CRH = sauvagine = urocortin =
urotensin at CRHR1, and urocortin = sauvagine > urotensin > CRH at CRHR2 (Smart
et al. 1999).
1.3.1.5.2 Distribution of CRH receptors
In the pituitary, using radioiodinated ovine CRH, the distribution of CRH binding
sites was found mainly in the clusters of corticotrophs in the anterior lobe and the
opiomelanocortin-producing cells in the intermediate pituitary (De Souza et al. 1984).
Moderate levels of CRHR1 mRNA expression are detected throughout the
intermediate lobe and in corticotrophs in the anterior lobe (Potter et al. 1994)
(Chalmers et al. 1995).
CRHR1 is also expressed in discrete brain areas including the cerebral cortex, several
regions related to the limbic system and peripheral tissues (De Souza et al. 1985;
Udelsman et al. 1986; Millan et al. 1987; Primus et al. 1997; Baigent & Lowry
2000a). By in situ hybridisation CRHR1 expression in the forebrain is dominated by
widespread signal throughout all areas of the neo-, olfactory, and hippocampal
cortices, and subcortical limbic structures in the septal region and amygdala. Low
levels of expression are seen in a few discrete ventral thalamic and medial
hypothalamic nuclei. CRHR1 expression in hypothalamic neurosecretory structures,
including the PVN and median eminence, is generally low. In the brainstem, certain
relay nuclei associated with the somatic (including trigeminal), auditory, vestibular,
and visceral sensory systems, constitute prominent sites of CRHR1 mRNA
expression. In addition, high levels of this transcript are present in the cerebellar
cortex and deep nuclei, along with many precerebellar nuclei (Potter et al. 1994).
CRHR1 mRNA is also found in thymus, spleen, thecal cells of mature follicles and
moderately in small antral follicles (Asakura et al. 1997; Baigent & Lowry 2000a).
In the brain CRHR2 mRNA is widely distributed including the olfactory bulb,
amygdaloid nuclei, the PVN and SON of the hypothalamus, and the bed nucleus of
the stria terminalis. But there is no CRHR2 expression detected in the pituitary
(Chalmers et al. 1995; Primus et al. 1997).
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This heterogeneous distribution of CRHR1 and CRHR2 mRNAs suggests distinctive
functional roles for each receptor in CRH-related systems. The CRH1 receptor may
be regarded as the primary neuroendocrine pituitary CRH receptor and important in
cortical, cerebellar and sensory roles of CRH. The anatomical distribution of CRH2
receptor mRNA indicates a role for this receptor in hypothalamic neuroendocrine,
autonomic and general behavioural actions of central CRH.
1.3.1.5.3 The cAMP pathway
The action of CRH on ACTH secretion is mediated by CRHR1: after binding to its
receptors on the corticotrophs, CRH stimulates ACTH secretion through the cAMP
pathway.
cAMP is a classical second messenger, initiating a cascade of intracellular events
leading to a physiological response, synthesised from ATP on the inner surface of the
plasma membrane. Fleischer and colleagues first found that cAMP is involved in the
release of ACTH from the anterior pituitary (Fleischer et al. 1969). CRH binding to
the CRH receptors on the corticotroph stimulates the guanine nucleotide-binding
protein (Gs), and subsequently, adenylate cyclase (Perrin et al. 1986; Battaglia et al.
1987) is activated by Gs to convert Mg2+ATP to cAMP. cAMP then activates protein
kinase A (PKA) and is degraded by cAMP-dependent phosphodiesterase. PKA
modulates POMC gene transcription, translation, processing and/or ACTH release
(Aguilera et al. 1986; King & Baertschi 1990), although the substrates of PKA are not
fully elucidated. CRH increases secretion of ACTH from corticotrophs by stimulating
exocytosis with an increase in cell surface area accompanied by a decrease in patches
of ACTH immunostaining within the cells (Westlund et al. 1985; Kubba & McNicol
1987).
The release of ACTH induced by CRH from the corticotrophs is largely dependent on
cAMP-mediated stimulation of Ca2+ influx through voltage-gated L-type Ca2+
channels (Luini et al. 1985; Aguilera et al. 1986; Guerineau et al. 1991). CRH
depolarises the cell, increasing firing frequency in spontaneously active cells and
inducing action potentials in quiescent cells. The CRH-induced membrane
depolarisation is due to in part inhibition of large-conductance Ca2+-activated K+-
channels (BK-channel) by PKA.
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Among the PKA targets in AtT20 cells, L-type Ca2+ channels and the BK-channels
are two significant functional targets. PKA activates L-type calcium channels
increasing the probability of channel opening and prolonging the opening state of L-
type channels upon depolarisation (Wang et al. 1993) through PKA-dependent
phosphorylation of either the channel subunits directly or other closely associated
channel proteins (Rougon et al. 1989; Charnet et al. 1995; Puri et al. 1997). In AtT20
cells PKA-mediated phosphorylation inhibits the opening of BK-channels (Shipston
et al. 1996). The resulting Ca2+ influx raises the cytosol Ca2+and triggers the calcium
sensor element of the exocytotic apparatus, stimulating the secretion of ACTH.
Although there is evidence that cAMP-mediated phosphorylation acts in synergy with
Ca2+to stimulate ACTH release, the exact mechanism(s) are not known (Guild 1991).
1.3.1.5,4 Regulation of anterior pituitary CRHR1 gene expression
CRHR1 gene expression is evidently regulated by CRH and vasopressin. Intravenous
and subcutaneous infusion of CRH for 48 h in intact rats caused the pituitary CRH
receptor concentration to decrease (Wynn et al. 1988). Minipump infusion of CRH
caused a decrease in the anterior pituitary CRH receptor concentration. Exogenous
vasopressin infusion reduces anterior pituitary CRHR1 contents in Brattleboro (di/di)
rats. In S-D strain rats, CRH or vasopressin infusion also reduces CRH contents in the
anterior pituitary and vasopressin potentiates CRH effect when infused together
(Holmes et al. 1987). When the parvocellular vasopressinergic system is activated by
repeated restraint stress, there is a significant enhancement in the ability of CRH to
decrease anterior pituitary CRH receptors, however, activation of the magnocellular
vasopressinergic system by water deprivation has no effect on the anterior pituitary
CRH receptor concentration (Hauger & Aguilera 1993).
In cultured rat anterior pituitary cells, CRH and vasopressin treatment decreases
CRHR1 mRNA levels in a time- and concentration-dependent manner (Sakai et al.
1996; Pozzoli et al. 1996). In vitro incubation of quartered pituitaries with vasopressin
or CRH or both peptides (Holmes et al. 1987) confirms that vasopressin synergises
with the effect of CRH on CRHR1 downregulation.
14
General introduction Chapter 1
In the presence of both vasopressin and CRH, vasopressin potentiates the CRH effect
on CRHR1 mRNA expression (Pozzoli et al. 1996). However, in vivo a single
vasopressin injection, as well as repeated injection for 14 day, increase CRHR1
mRNA expression in the anterior pituitary (Rabadan-Diehl et al. 1996).
During prolonged or acute immobilisation, anterior pituitary CRH receptor content is
down- regulated (Hauger et al. 1988; Hauger et al. 1990; Makino et al. 1995a).
However, changes in expression can be quite rapid. In situ hybridisation studies
showed biphasic changes in CRHR1 mRNA expression in the anterior pituitary after
immobilisation stress with a decrease by 2 h, increase at 4 and 8 h after the initiation
of the stress, and a return to near basal levels by 12 and 18 h. A different pattern was
observed, with a decrease by 4 h and levels similar to controls by 12 and 18 h after a
single intraperitoneal injection of hypertonic saline (1.5 M NaCl). Binding
autoradiography shows significant increases in pituitary CRH binding 4, 10, and 12 h
after immobilisation stress, but significant decreases 4, 12, and 18 h after
intraperitoneal hypertonic saline injection. In contrast, repeated immobilisation or
intraperitoneal hypertonic saline for 8 or 14 days increases pituitary CRHR1 mRNA
expression (Rabadan-Diehl C et al. 1996).
In both adrenalectomised rats with corticosterone pellet replacement (39 mg;
adrenalectomy with corticosterone replacement rats) and control, acute (2 h) and
repeated (2 h daily for 14 days) immobilisation stress (which produce a large increase
in plasma corticosterone in control rats) decreases CRHR1 mRNA in the anterior
pituitary. However, adrenalectomised rats given corticosterone consistently have
higher levels of CRHR1 mRNA in the anterior pituitary than control rats after stress
(Makino et al. 1995a).
Glucocorticoids or dexamethasone decrease in a dose-dependent manner CRH
binding in the anterior pituitary in vivo and in vitro (Childs et al. 1986). In cultured
rat anterior pituitary cells, dexamethasone and corticosterone cause a dose- and time-
dependent decrease in CRHR1 mRNA levels (Pozzoli et al. 1996; Sakai et al. 1996).
Elevations in plasma corticosterone (in the range altered during acute stress) by
subcutaneous injection of corticosterone (10 mg), caused CRHR1 mRNA expression
to return to near basal values by 6 h, after a 52% and 39% decrease at 2 h and 4 h
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(Ochedalski et al. 1998). Chronic corticosterone injection (10 mg/rat.day, for 7 days)
also decreases CRHR1 mRNA in the anterior pituitary.
Adrenalectomy also decreases CRHR1 mRNA expression in the anterior pituitary
(Makino et al. 1995a), but pituitary CRHR1 mRNA levels are not affected by long
term adrenalectomy (Luo et al. 1995; Rabadan-Diehl et al. 1997c). The CRHR1
mRNA level in anterior pituitary falls to 20% of the control level 1 day after
adrenalectomy and returned to the control level after 14 days (Sakai et al. 1996). After
adrenalectomy, the concentration of CRH receptor in the pituitary decreases (Wynn et
al. 1985). This decrease is not entirely due to occupancy by endogenous CRH, since
high dose infusions of CRH (300-500 ng/min) for 30 min before pituitary membrane
preparation reduced CRH-binding sites by only 40%, while CRH receptor
concentration in the pituitary decreases by over seventy percent 2 days after
adrenalectomy, which increases CRH secretion. Such decreases in CRH receptors in
adrenalectomised rats are prevented by dexamethasone treatment (Wynn et al. 1985)
and completely prevented by medial basal hypothalamic lesioning, indicating that
receptor down-regulation is dependent on the release of CRH or/and other
hypothalamic factors(Wynn et al. 1988).
A single injection of CRH decreases CRHR1 mRNA levels in adrenalectomised rats,
but not in glucocorticoid-replaced adrenalectomised rats (Rabadan-Diehl C et al.
1996). In the absence of glucocorticoids in adrenalectomised rats, acute stress results
in prolonged CRHR1 mRNA loss, suggesting that interactions between
glucocorticoids and hypothalamic factors are critical for regulation of CRHR1 mRNA
expression (Rabadan-Diehl et al. 1996). After a single or repeated injection of CRH,
CRHR1 mRNA in the anterior pituitary decreased by 2 h, returning to basal values by
4 h, however, CRH injection in adrenalectomised rats decreased CRHR1 mRNA for
up to 6 h, suggesting that glucocorticoids are permissive for the recovery of CRHR1
mRNA expression (Ochedalski et al. 1998).
In summary, CRH decreases CRHR1 mRNA expression in the anterior pituitary, and
vasopressin potentiates this CRH effect. Glucocorticoids also decrease CRHR1
mRNA expression, but are permissive for the recovery of CRH-decreased CRHR1
mRNA expression.
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1.3.2 Vasopressin
1.3.2.1 Vasopressin characterisation and physiological roles
Vasopressin is produced in parvocellular CRH neurones of the PVN and
magnocellular neurones of the PVN and SON as part of a larger precursor protein that
is cleaved in the secretory granules to produce vasopressin, neurophysin and co-peptin
(William 1987) (Figures 1.1 and 1.3). Vasopressin synthesised in parvocellular
neurones of the PVN is responsible for stimulating ACTH secretion, after transport
via nerve fibres in the external zone of the median eminence and release into the
capillaries of the portal system, whereas vasopressin produced in magnocellular
neurones of the PVN and SON is transported to the pituitary neural lobe and secreted
into the peripheral circulation, in response to osmotic and other stimuli (Antoni
1986a; Holmes et al. 1986; Antoni et al. 1990). Osmotic activation of the
magnocellular vasopressin system is accompanied by reduced responsiveness of the
corticotrophs. This effect is not due to increased glucocorticoid feedback since similar
blunted ACTH responses to acute immobilisation stress are observed in
adrenalectomised rats receiving corticosterone replacement. Similarly, hypothalamic
CRH is not deficient as the ir-CRH content in the median eminence and its release
under stress are similar in control and water-deprived rats. These studies suggest that
the magnocellular vasopressinergic system does not play an important role in the
regulation of ACTH secretion during chronic osmotic stimulation (Aguilera et al.
1993). However, some evidence also demonstrates that vasopressin from
magnocellular neurones, released by axons in the median eminence, participates in
ACTH secretion regulation (Antoni 1993).
17
General introduction Chapter 1
Figure 1.3 The hypothalamic sources of vasopressin input to the pituitary
Figure 1.3 The hypothalamic sources of vasopressin input to the pituitary.
Vasopressin of parvocellular origin is released into the portal blood to regulate ACTH secretion
from the anterior pituitary. Vasopressin of magnocellular origin is transported to the posterior
lobe, stored there and released in response to osmotic stimulation. AP= anterior pituitary; ME=
median eminence; PP= posterior pituitary; m= magnocellular neurones; p= parvocellular neurones,
small amount of vasopressin may be leaked to the median eminence when transported from
magnocellular neurones to the posterior pituitary.
18
General introduction Chapter 1
Vasopressin and CRH are co-localised in parvocellular neurones of the PVN of the
hypothalamus and are capable of potentiating each others' action on ACTH secretion
by freshly prepared anterior pituitary fragments or cells in vitro (Makara 1992). About
50% of the parvocellular CRH perikarya contain vasopressin under basal conditions
(Whitnall et al. 1985) and the proportion of vasopressin immunoreactive- and mRNA-
positive neurones increases following adrenalectomy and chronic stress paradigms
associated with hypersensitivity of the HPA axis (Whitnall 1988; Whitnall 1989; de
Goeij et al. 1992c; Bartanusz et al. 1993; Paulmyer-Lacroix et al. 1994).
Vasopressin alone is a less effective stimulator of ACTH secretion in rodents, but it is
reported to produce greater ACTH biosynthetic and secretory responses than does
CRH in sheep anterior pituitary cells (van de Pavert et al. 1997). The actions of
vasopressin on ACTH secretion from corticotrophs are mediated by plasma
membrane receptors belonging to the guanyl nucleotide binding protein (G-protein
family), vasopressin receptor subtype lb (Jard et al. 1986) (see Chapter 1.3.2.3). CRH
is a potent inducer of POMC mRNA transcription, while vasopressin alone does not
increase expression of this gene (Antoni 1993) or it even inhibits basal and CRH-
stimulated POMC transcription in vitro (Levin et al. 1989). However, one recent
study shows that vasopressin may have a stimulatory effect on POMC gene
expression by activating POMC promoter activity via PKC (Aoki et al. 1997). A
vasopressin antagonist decreases the plasma ACTH levels in ether-stressed rats
(Rivier & Vale 1983). Vasopressin antiserum microinjection into the third ventricle
decreases the elevation of plasma ACTH induced by ether and restraint stresses
(Linton et al. 1985). This inhibitory action of the vasopressin antiserum on ACTH
release may be mediated intrahypothalamically by blocking the stimulatory action of
vasopressin on CRH neurones and/or also in part by direct blockade of the stimulatory
(augmentation) action of vasopressin on the pituitary (Ono et al. 1985b).
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1.3.2.2 Regulation of vasopressin secretion and gene expression in the
hypothalamus
Parvocellular vasopressin secretion is regulated by different stress paradigms. Release
of vasopressin within the PVN is significantly increased in response to emotional
stressors (Wotjak et al. 1996). During emotional stress vasopressin gene transcription
in the PVN and SON increases (Priou et al. 1993). Intraperitoneal injection of
hypertonic saline for 14 days causes enhanced parvocellular activity as indicated by
increases in vasopressin immunostaining in the external zone of the median eminence
(Kiss & Aguilera 1993): this may be due to the painful stress of the injection. Chronic
immobilisation stress exposure results in a significant increase in the average cellular
level of CRH and vasopressin mRNAs in the parvocellular PVN, and the number of
vasopressin-expressing parvocellular neurones is approximately doubled (Bartanusz
et al. 1993; Herman et al. 1995). Acute ether stress provokes rapid and transient
increases in CRH hnRNA: this peaks at 5 min and is followed by a delayed
upregulation of vasopressin hnRNA (120 min) in parvocellular neurones of the PVN
(Kovacs & Sawchenko 1996). Parvocellular vasopressin hnRNA responses to a single
hypertonic saline injection are slower and more prolonged than for CRH, and
vasopressin mRNA levels increase by 4 h and remain elevated 12 h later.
Parvocellular vasopressin hnRNA expression is at basal levels after 14 days
hypertonic saline injection, but vasopressin mRNA levels remain elevated as during
acute stimulation (Ma & Aguilera 1999b).
It has been revealed that glucocorticoid negative feedback during stress selectively
targets vasopressin transcription in the parvocellular neurones that is likely mediated
by interaction of glucocorticoid receptors and immediate-early gene products (Kovacs
1998). Acute immobilisation causes a significant increase in CRH, but not
vasopressin, mRNA levels in the parvocellular PVN in sham rats, while this acute
immobilisation increases both CRH and vasopressin mRNA levels in the PVN in the
adrenalectomised rats with a moderate dose of corticosterone replacement. These data
indicate that PVN vasopressin mRNA levels are more sensitive to glucocorticoid
negative feedback than are the levels of CRH mRNA (Makino et al. 1995b). After
adrenalectomy, levels of vasopressin hnRNA show biphasic changes: grain density
increases 11.5- fold over sham-operated controls by 6 h, declines to 2-fold by 18 h, to
increase again to 10- and 20-fold by 48 and 72 h, respectively. Vasopressin hnRNA
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levels increased only transiently by 15 min after corticosterone administration to
adrenalectomised rats, and then decreased below basal (near sham-adrenalectomy
levels) by 2 h. The data show that in normal conditions the responsiveness of
parvocellular neurones to stress is under marked inhibition by the low resting levels of
glucocorticoids (Ma & Aguilera 1999a).
In contrast, vasopressin expression in the magnocellular neurones is regulated by
osmotic changes. Vasopressin mRNA levels measured by in situ hybridisation within
magnocellular neurones of the SON and PVN increase after chronic water deprivation
(Meeker et al. 1991; Kiss et al. 1994). Intraperitoneal injection of hypertonic saline
for 14 days causes increases in plasma vasopressin, and marked increases in
vasopressin mRNA and ir-vasopressin in magnocellular cell bodies in the
hypothalamus (Kiss & Aguilera 1993). Increases in vasopressin mRNA and ir-
vasopressin in magnocellular cell bodies depend on the intensity and duration of the
stimulation with a range of stimuli (Burbach et al. 1984; Meeker et al. 1991).
In summary, vasopressin expression in the parvocellular neurones in the PVN is
increased by physical or emotional stressors and is inhibited by glucocorticoid
negative feedback. In contrast vasopressin expression in the magnocellular neurones
in the PVN and SON is regulated by osmotic challenges.
1.3.2.3 Vasopressin receptors
The actions of vasopressin are mediated through plasma membrane receptors (Figure
1.1) belonging to the guanyl nucleotide binding protein (G protein) superfamily
consisting of seven hydrophobic transmembrane a-helices joined by alternating
intracellular and extracellular loops, an extracellular N-terminal domain, and a
cytoplasmic C-terminal domain. So far three receptor subtypes encoded by different
genes have been identified and cloned: Via receptors, Vlb receptors and kidney V2
receptors.
1.3.2.3.1 Characterisation of vasopressin receptors
The Vlb receptor was first identified on the basis of its pharmacology (Jard et al.
1986), and characterised in the anterior pituitary (Lolait et al. 1995), where it links to
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phospholipase C to regulate vasopressin-mediated ACTH release by potentiating the
effect of CRH.
The cDNA encoding the Vlb receptor has been isolated and characterised from
human, rat, and mouse (de Keyzer et al. 1994; Lolait et al. 1995; Ventura et al. 1999).
The structure of the Vlb receptor gene contains at least three exons and two introns
(Rabadan-Diehl et al. 2000). The human Vlb receptor comprises a 424 amino acids
sequence and seven putative transmembrane domains and an overall sequence
homology of 45, 39, and 45% with sequences of Via, V2 and oxytocin receptors,
respectively (Sugimoto et al. 1994). The rat Vlb receptor is a protein of 421- or 425-
amino acid that has 37-50% identity with the Via and V2 receptors, having the
highest identity with the human Vlb (81%) (Saito et al. 1995).
The Vlb receptor gene has two splice variants in rats, as suggested by Northern blot
analysis. A 363 bp 32P-labelled fragment of the rat Vlb receptor cDNA coding
sequence revealed two mRNA bands of about 3.7 and 3.2 Kb, whereas a probe
directed to the 5' untranslated region (5'-UTR) recognised only the 3.7 Kb band. The
3.7 Kb splice variant encodes a bioactive vasopressin receptor, but the function of the
3.2 Kb splice variant is not clear. However both splice variants are expressed in
parallel during the manipulation of HPA axis activity (Rabadan-Diehl et al. 1995).
The Via receptor purified from rat and pig liver has a molecular weight of 58-60 kD,
mediating the vasoconstrictor and hepatic glycogenolytic action of vasopressin
(Fishman et al. 1987; Estrada et al. 1991). The human Via receptor has been cloned
(Morel et al. 1992), and encodes a 418-amino acid polypeptide with seven putative
transmembrane domains typical of G protein-coupled receptors. Its amino acid
sequence identity with the rat liver Via vasopressin receptor, the human and rat V2
vasopressin receptors, and the human oxytocin receptor is 72, 36, 37, and 45%,
respectively (Thibonnier et al. 1994). Vasopressin action through the Via receptor is
mediated by activating phospholipase C, which increases phosphatidylinositol
turnover to increase intracellular calcium. Via receptor mRNA is localised in the
liver, kidney, vascular smooth muscle, platelets, renal medulla, renal cortex, and in
many brain areas including the hippocampal formation, central amygdala, dorsolateral
septum, lateral hypothalamus, suprachiasmatic, ventromedial, dorsomedial, and
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arcuate nuclei of the hypothalamus, nucleus of the solitary tract, cerebellum, spinal
nucleus of the trigeminal tract, reticular formation, inferior olivary nucleus, and
choroid plexus. Rare labelled cells are seen along the periphery of the posterior
pituitary (Ostrowski et al. 1992).
The V2 receptor is predominantly expressed in the kidney and mediates the
antidiuretic effect of vasopressin by regulating water re-absorption in the collecting
duct and medullary thick ascending limb of the loop of Henle via the activation of
adenylate cyclase. V2 receptor transcripts have not been detected in the liver or brain,
but are present in high amounts in the inner and outer renal medulla, primarily
associated with the collecting ducts in kidney (Ostrowski et al. 1992).
1.3.2.3.2 Distribution of the Vlb receptor
The Vlb receptor is expressed in the majority of pituitary corticotrophs (de Keyzer et
al. 1994; Ventura et al. 1999), but not in the mouse corticotropin tumor cell AtT20
line (Ventura et al. 1999). Double Vlb receptor and POMC mRNA in situ
hybridisation detects that the majority of the Vlb receptor expressing cells are POMC
mRNA positive and only a few of them do not express the POMC gene (Lolait et al.
1995). These non-corticotroph Vlb receptor- expressing cells are thought to be
thyrotrophs because vasopressin is reported to act as a thyrotropin-releasing hormone
(Michael et al. 1986). Vlb receptors are not detected in the intermediate pituitary.
The Vlb receptor is also located in neurones in multiple brain regions (Hernando et
al. 2001): the olfactory bulb, forebrain (the piriform and tenia taecta), in
hypothalamus (suprachiasmatic nucleus, arcuate nucleus), hippocampus, in midbrain
(substantia nigra, red nucleus, entorhinal cortex and paphe nucleus), thalamus, dorsal
motor nucleus of the vagus, the choroid plexus, lateral septum, bed nucleus of stria
terminalis, accumbens nucleus, central nucleus of amygdala, nucleus of the solitary
tract, area postrema, superior colliculus, and inferior olivary nuclei (Phillips et al.
1988; Hurbin et al. 1998; Vaccari et al. 1998). Recently, the Vlb receptor mRNA was
also detected in the magnocellular neurones in the PVN and SON of the
hypothalamus (Hurbin et al. 1998).
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A number of peripheral tissues, including kidney, thymus, heart, lung, spleen, uterus,
pancreas, colon and breast, express VIb receptors (de Keyzer et al. 1994; Lolait et al.
1995).
1.3.2.3.3 The PI pathway
Vasopressin regulates ACTH secretion through stimulation of phosphatidyl inositol
turnover, as suggested by measurements of the incorporation of 32Pi or 3H-inositol
into membrane phospholipids in cultured anterior pituitary cells (Raymond et al.
1985; Guillon et al. 1987; Todd & Lightman 1987).
When vasopressin binds to VIb receptors on corticotrophs coupled through G protein
to phospholipase C, phosphatidylinositol 4,5-biphosphate, a minor lipid constituent of
the plasma membrane, is cleaved into inositol-1,4,5 trisphosphate (IP3) and
diacylglycerol. IP3 diffuses to the cytoplasm to mobilise internal sequestered calcium
stores leading to increased cytosolic free calcium then to the activation of calcium-
dependent processes, and is degraded by a phosphatase to IP2. Diacylglycerol remains
within the plasma membrane where it activates protein kinase C (PKC) translocated
from the cytoplasm to the plasma membrane by increased cytosolic free calcium.
PKC phosphorylates some unknown proteins leading to increasing secretion and (or)
ACTH biosynthesis. Diacylglycerol can also be hydrolysed to arachidonic acid by
phospholipase A2and arachidonic acid is further metabolised into prostaglandins and
thromboxanes through the cyclooxygenase pathway forming an inhibitor, or
leukotrienes through the lipoxygenase pathway forming a stimulator of ACTH
secretion (King & Baertschi 1990).
Calcium signalling is also involved in vasopressin stimulated ACTH secretion
through the IP pathway. This involves the generation of IP3 with consequent release
of sequestered intracellular Ca2+ (Guillemette et al. 1987) and generation of
diacylglycerol and activation of PKC with consequent extracellular Ca2+ influx
through L-type voltage-sensitive Ca2+ channels (Nishizuka 1984; Won et al. 1990).
This increased intracellular Ca2+ then triggers ACTH secretion from the corticotrophs.
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1.3.2.3.4 Potentiating effect of vasopressin on ACTH secretion
Although vasopressin is a weak secretagogue alone, it is able to potentiate the action
of CRH on ACTH secretion from corticotropins. In 1982 Gillies et al first reported that
CRH effect on ACTH secretion is potentiated by several times by vasopressin in
isolated primary anterior pituitary (Gillies et al. 1982). Simultaneous addition of
arginine-vasopressin (10"10 M) to the incubation medium containing CRH (5.0 x 10" -
2.0 x 10"7 M) enhanced the ACTH response of the pituitary segments to CRH and
increased the slope of its dose-response curve (Buckingham 1985). This potential
effect is also confirmed in vivo (Fischman & Moldow 1984). The ovine fetal pituitary
in vivo responds separately and synergistically to vasopressin and CRH (Norman &
Challis 1987). The CRH-induced elevation of cAMP is potentiated (by an order of
magnitude) by stimulators of PKC in a concentration dependent manner, which
suggests that PKC, activated by Vlb receptor stimulation, can modulate CRH
receptor coupling to the adenylate cyclase (Cronin et al. 1986; Abou-Samra et al.
1987b). cAMP degradation is also decreased by inhibiting phosphodiesterase activity
after PKC stimulation (Giguere & Labrie 1982; Abou-Samra et al. 1987b). Incubation
of tissues with the phorbol ester phorbol myristate acetate (PMA), which depletes cell
stores of PKC, selectively potentiated CRH-stimulated ACTH secretion and cAMP
formation by anterior pituitary cells, but it failed to similarly affect AtT-20 cells
exposed to CRH (Lutz-Bucher et al. 1990). However, AtT20 cells lack Vlb receptor,
and may lack the signalling mechanism that in corticotrophs "cross-talk" to the
CRHR1 signalling pathway (Figure 1.1).
1.3.2.3.5 Regulation Vlb receptor gene expression in the anterior pituitary and
its functions
During chronic stress, there is a parallel relationship between Vlb receptor content
and responsiveness of the corticotrophs. Vasopressin binding is reduced after water
deprivation and 2% saline administration where ACTH secretion is decreased, but it is
increased after repeated intraperitoneal hypertonic saline injections which are painful,
and repeated immobilisation where ACTH secretion is increased (Aguilera et al.
1994). Vlb receptor mRNA levels are significantly increased after 8 and 14 days of
repeated immobilisation or intraperitoneal hypertonic saline injection.
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However, notably, changes in VIb receptor mRNA levels are not always correlated
with changes in vasopressin receptor content. In response to acute stress, Vlb receptor
mRNA expression is increased after immobilisation, but is reduced 4 h after a single
intraperitoneal hypertonic saline injection. While the content of Vlb receptor in the
pituitary increases after a single immobilisation, it is also increased after
intraperitoneal hypertonic saline injection (Rabadan-Diehl et al. 1995). The decrease
in Vlb receptor mRNA expression following a single intraperitoneal hypertonic saline
injection is prevented by pretreatment with a VI receptor antagonist, suggesting that
increased vasopressin secretion and other factors secreted into the hypophysial portal
or peripheral circulation during this stress may account for the decrease of Vlb
receptor expression (Rabadan-Diehl et al. 1995). The high rate of mRNA utilisation
or a transient transcriptional inhibition may account for the prolonged Vlb receptor
mRNA downregulation, while recruitment of receptors from intracellular pools or an
increase in receptor synthesis at the posttranslational level may play a role in
increasing vasopressin binding (Aguilera & Rabadan-Diehl 2000). The lack of
parallelism between Vlb receptor mRNA and vasopressin binding indicates that
regulation of steady-state levels of Vlb receptor mRNA is not a primary determinant
in the control of pituitary vasopressin receptor concentration during stress.
Chronic injection of dexamethasone decreases vasopressin binding but increases Vlb
receptor mRNA expression (Rabadan-Diehl et al. 1997a; Rabadan-Diehl & Aguilera
1998). This suggests that glucocorticoids increase Vlb receptor mRNA expression by
stimulating gene transcription or/and by increasing mRNA stability, but decrease
receptor number at the translational or posttranslational levels (Aguilera & Rabadan-
Diehl 2000). Removal of circulating glucocorticoids by adrenalectomy transiently
decreases pituitary Vlb receptor mRNA levels by 18 h, which return to basal levels
after 6 days, but results in sustained reduction in binding (Rabadan-Diehl et al.
1997a). The decrease in vasopressin binding could reflect a direct action of
glucocorticoids on the pituitary (Lutz-Bucher et al. 1986) or an increase in receptor
occupancy and receptor internalisation, because glucococorticoid deficiency results in
increased concentrations of vasopressin and CRH in the pituitary portal blood due to
removal of glucocorticoid negative feedback. However these increased concentrations
of vasopression and CRH in the pituitary portal blood are unlikely to be the
explanation for the reduced Vlb receptor mRNA 18 h after adrenalectomy, because
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PVN lesions or median eminence deafferentation does not prevent the transient Vlb
receptor mRNA downregulation (Rabadan-Diehl et al. 1997a).
In vitro studies demonstrate that activation of ACTH secretion by vasopressin is
insensitive to feedback inhibition by glucocorticoids (Abou-Samra et al. 1986;
Bilezikjian et al. 1987). While glucocorticoid administration results in pituitary
vasopressin receptor loss (Koch & Lutz-Bucher 1985; Lutz-Bucher et al. 1986), so it
is supposed that vasopressin receptor activity is enhanced by glucocorticoids. In the
absence of glucocorticoids in the adrenalectomised rats, the loss of vasopressin
receptor is accompanied by a blunting of the pituitary inositol-1,4,5 triphosphate
(IP3) response to vasopressin; however, daily administration of dexamethasone (40
micrograms/day) reverses this effect of adrenalectomy (Todd & Lightman 1987).
Rabadan-Diehl et al found that glucocorticoid treatment potentiated vasopressin
stimulated IP3 formation in cultured anterior pituitary cells and this potentiating effect
of glucocorticoids is considered to result from facilitation of Vlb receptor coupling to
phospholipase C (Rabadan-Diehl & Aguilera 1998).
In summary, different stress types have different influence on Vlb receptor
expression, and it is not clear the roles of CRH and vasopressin in regulating this gene
expression. Glucocorticoids increase Vlb receptor mRNA expression and enhance
Vlb receptor activity in corticotrophs.
1.3.3 Oxytocin
The oxytocin precursor gene has similar exon-intron organisation to that of the
vasopressin gene (Ivell & Richter 1984). Oxytocin is mainly synthesised in the
magnocellular neurones in the PVN and SON of the hypothalamus (Rhodes et al.
1981), and minimally in the parvocellular neurones (Pretel & Piekut 1990). Oxytocin
is transported through the internal layer of median eminence to the nerve terminals of
the posterior pituitary, where it is released into the peripheral circulation. However,
there are few oxytocin fibres detected in the external layer (Hoffman et al. 1989;
Villar et al. 1994). Antoni et al. reported that a substantial amount of oxytocin in
portal blood may be a consequence of preterminal release from supraoptic nuclei
projections in the internal zone of the median eminence (Antoni et al. 1990).
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Oxytocin secretion into pituitary portal plasma is increased by ovarian steroids,
prolactin, and the suckling stimulus (Sarkar et al. 1992). Oxytocin secretion is also
increased in rats in response to stress. Acute exposure of rats to immobilisation stress
results in an increase in oxytocin mRNA level in magnocellular neurones (Jezova et
al. 1995). Magnocellular neurones of the PVN, but not evidently the SON, are
essential for oxytocin release during immobilisation stress (Jezova et al. 1995). The
secretion of oxytocin in response to stress is inhibited by endogenous opioids
(Douglas et al. 2000) and this inhibitory effect is greater in pregnant rats than in
virgin rats (Douglas et al. 1998).
The functions of circulating oxytocin in uterine contraction during parturition and
milk ejection during lactation are well established (Russell & Leng 1998). Oxytocin is
also involved in the regulation of ACTH secretion from the anterior pituitary (Won et
al. 1990). In the rats, oxytocin can potentiate the stimulatory effect of CRH in ACTH
secretion in vitro (Gibbs et al. 1984). The injection of anti-oxytocin antiserum which
completely neutralises the increase in plasma oxytocin levels during tail-hang stress
causes a decrease in plasma ACTH concentration (Gibbs 1985). Brain oxytocin, in
contrast to circulating oxytocin, inhibits basal and stress-induced HPA axis activity
(Neumann et al. 2000b). In pregnancy, this brain effect on basal and stress-induced
HPA axis activity is lost (Neumann et al. 2000a).
Receptors for oxytocin are present in the rat anterior pituitary (Antoni 1986b).
However, oxytocin stimulates ACTH secretion via a receptor(s) other than the
oxytocin receptor itself. Neither the oxytocin receptor agonist Thr4Gly7 oxytocin nor
the oxytocin receptor antagonist des-Gly(NH2)9d(CH2)5-[Tyr(Me)2 Thr4]OVT has any
influence on basal ACTH release, and des-Gly(NH2)9d(CH2)5-[Tyr(Me)2 Thr4]OVT
does not interfere with oxytocin-induced ACTH release. A vasopressin receptor
antagonist, dP[Tyr(Me)2]vasopressin completely abolishes oxytocin-induced increases
in ACTH release (Schlosser et al. 1994), suggesting that vasopressin Vlb receptors
mediate the actions of oxytocin on ACTH secretion.
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1.4 Regulation of proopiomelanocortin (POMC) and ACTH synthesis
ACTH belongs to a family of peptides derived from a common precursor protein
encoded by the proopiomelanocortin (POMC) gene (Chretien & Seidah 1981; King &
Baertschi 1990). The POMC gene has been cloned and sequenced (Nakanishi et al.
1981; Cochet et al. 1982; Notake et al. 1983; Takahashi et al. 1983; Uhler & Herbert
1983; Drouin et al. 1985). The human POMC gene is about 11.6 kb and consists of
three exons, in which the second and third exons encode the opiomelanocortin peptide
(Cochet et al. 1982; Lundblad & Roberts 1988; King & Baertschi 1990). The
upstream POMC gene DNA sequences have a glucocorticoid receptor-binding site,
which probably mediates inhibition of the POMC gene transcription by glucocorticoid
(Drouin et al. 1985). The POMC gene is strongly expressed in the anterior and
intermediate pituitary gland (Civelli et al. 1982), and lesser amounts broadly
distributed in the brain including the hypothalamus especially the arcuate nucleus,
amygdala, cerebral cortex (Civelli et al. 1982), and in many peripheral tissues
(Jingami et al. 1984; Pintar et al. 1984).
The POMC molecule is posttranslationally processed to different biologically active
peptides. The cleavage of the POMC precursor is tissue specific: in the anterior
pituitary corticotrophs, it is cleaved into ACTH (Figure 1.1), (3-lipotropin and small
amounts of (3-endorphin (Lazarus et al. 1976; Lowry et al. 1980; Chretien & Seidah
1981; Lundblad & Roberts 1988; King & Baertschi 1990); in the intermediate lobe
and other tissues, the processing continues to form a-melanocyte-stimulating
hormone (a-MSH) and corticotropin-like intermediate lobe peptide from ACTH and
y-lipotropin and (3-endorphin from (3-lipotropin (Eipper & Mains 1980; Lundblad &
Roberts 1988; King & Baertschi 1990). Opiomelanocortin peptides are stored within
membrane-bound granules located mainly along the plasma membrane, and are
released concomitantly in equimolar amounts upon stimulation with secretagogues
(Moriarty & Halmi 1972; Allen et al. 1978; Vale et al. 1978; Westlund et al. 1985).
Stress increases POMC gene expression in corticotrophs. Intermittent electrical
footshocks increase POMC mRNA levels in the anterior pituitary approximately 2-
fold after three days treatment and this remains elevated for seven days (Hollt et al.
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1986). Three weeks of chronic arthritis pain causes an 80% increase in anterior
pituitary POMC mRNA levels (Millan et al. 1986). This stress-stimulated POMC
expression may be due to the enhanced hypothalamic PVN CRH and vasopressin
inputs. The treatment of primary anterior pituitary cells or AtT20 cells with CRH
causes an increase in the levels of POMC mRNA. CRH exposure for eight hours
stimulates POMC mRNA levels approximately 3-fold in AtT20 cells, an effect
mimicked by the addition of 8-bromo-cAMP (a cAMP analogue) (Affolter & Reisine
1985). Both CRH and forskolin also increase the levels of POMC mRNA in primary
anterior pituitary cell culture (Loeffler et al. 1985). In vivo studies show that PVN
lesions decrease the levels of POMC mRNA in the anterior pituitary (Bruhn et al.
1984a), indicating that hypothalamic inputs during stress are responsible for the
increased POMC expression. The potentiation of CRH- stimulated ACTH secretion
by vasopressin is well established (Gillies et al. 1982). However, in vitro studies
indicate that vasopressin does not potentiate CRH-induced accumulation of either
cytoplasmic POMC mRNA (Suda et al. 1989c) or hnRNA (Levin et al. 1989).
POMC mRNA levels are regulated negatively by plasma glucocorticoid levels.
Nakanishi et al first reported that adrenalectomy caused increases in POMC mRNA
activity in a time dependent manner measured with the use of a cell-free protein-
synthesising system, and in ACTH release in the anterior pituitary, which can be
prevented by glucocorticoid replacement (Nakanishi et al. 1977). In situ hybridisation
studies have found similar observations of adrenalectomy and dexamethasone or
glucocorticoid replacement on pituitary POMC mRNA expression (Bimberg et al.
1983; Fremeau, Jr. et al. 1986). The treatment of primary anterior pituitary cells or
AtT20 cells with either corticosterone or dexamethasone causes a decrease in the
levels of POMC mRNA (Roberts et al. 1979; Eberwine & Roberts 1984).
1.5 Inhibitory factors of ACTH secretion
1.5.1 Glucocorticoid feedback
Glucocorticoids are synthesised in the zonae fasciculata/reticularis of the adrenal
cortex and released into the circulation in response to a wide range of stressful
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stimuli. Glucocorticoids have a vast array of functions within the body, including
regulation of intermediary metabolism, and repression of immune responses. To
maintain homeostasis, glucocorticoid secretion is also regulated by negative feedback.
Negative feedback, or end-product inhibition, the most important homeostatic control
mechanism of the HPA axis system is an autoregulatory feedback by glucocorticoids
that can inhibit ACTH secretion both directly and indirectly.
1.5.1.1 Glucocorticoid metabolism
Upon entry through the cell membrane glucocorticoids encounter a major
metabolising enzyme broadly distributed in the body, lip-OH steroid dehydrogenase
(lip-HSD), which inter-converts glucocorticoids and its inactive metabolites (Stewart
et al. 1987; Funder et al. 1988; Krozowski et al. 1995). ll(3-HSDs are responsible for
glucocorticoid degradation. It comes in two isoforms, type 1 (11P-HSD1) and type 2
(llp-HSD2) with distinct and important roles. 11P-HSD2 almost irreversibly
inactivates Cortisol and corticosterone, oxidising their ll|3-hydroxy group to the 11-
keto forms, which are respectively, cortisone and 11-dehydrocorticosterone, and these
bind only weakly to MRs and GRs. llp-HSDl catalyses both the oxidising
(inactivating) and reducing (activating) reactions and so can reactivate the 11-keto
steroids. The direction of the reaction depends on the presence of the co-factor,
NADP(H), in the cells (Seckl & Walker 2001).
1.5.1.2 Types of glucocorticoid negative feedback
Corticosteroid action in the HPA axis system is classified on the basis of the time of
onset of the biological actions on the release of ACTH by the anterior pituitary gland:
rapid (within 30 min), delayed (1-2 h), and slow (more than 2 h) (Dayanithi & Antoni
1989; Nicholson & Gillham 1989). At the pituitary level feedback inhibition of
ACTH secretion by adrenal glucocorticoids is exerted via type II, glucocorticoid
receptors (GR), involving reduction of POMC synthesis. However, the breakdown of
POMC mRNA, POMC protein and stored ACTH is not changed by glucocorticoid
treatment (Phillips & Tashjian 1982; Roberts et al. 1987).
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1.5.1.3 Mechanism(s) of glucocorticoid negative feedback
The mechanisms underlying rapid glucocorticoid inhibition of ACTH secretion from
anterior pituitary corticotrophs are likely to involve the disruption of stimulus-
secretion coupling independently of effects on ACTH biosynthesis, storage, or
degradation because overwhelming evidence reveals that the predominant effect of
glucocorticoids is to inhibit stimulated, rather than basal ACTH secretion (Clark &
Kemppainen 1994; Shipston et al. 1996). Though some studies revealed inhibition of
CRH-induced cAMP accumulation in vitro at the slow stage (Bilezikjian & Vale
1983; Bilezikjian et al. 1987), other studies show no change of CRH or stress-induced
cAMP accumulation in vivo or in vitro in either the slow inhibition (Giguere et al.
1982; Kant et al. 1989) or rapid inhibition (Woods et al. 1992). Studies have shown
that ACTH secretion stimulated by a direct activator of PKA or PKC is inhibited by
glucocorticoids (Phillips & Tashjian 1982; Oki et al. 1991; Woods et al. 1992), but
glucocorticoids do not prevent cAMP-induced activation of PKA (Miyazaki et al.
1984).
In vitro studies have shown that activation of ACTH secretion by vasopressin is less
sensitive to feedback inhibition by glucocorticoids than that to CRH (Bilezikjian et al.
1987). In vivo, chronic dexamethasone treatment decreases the binding of [ H]-
vasopressin to pituitary membranes, in contrast, it increases Vlb receptor mRNA and
vasopressin-stimulated IP3 formation as mentioned in Chapter 1.3.2.3.5 (Rabadan-
Diehl et al. 1997a).
Glucocorticoids also inhibit Ca2+-dependent ACTH secretion (Oki et al. 1991) by
influencing the activation of either PKA or PKC, but not nVCa2+-mediated ACTH
release. Whole cell path clamp recordings indicate that glucocorticoids limit Ca2+
influx by enhancing a transient outward A-type K+ current (Pennington et al. 1994).
Patch-clamp studies show that the synthetic glucocorticoid dexamethasone prevents
the inhibitory effect of PKA on BK-channels (Shipston et al. 1996).
In the PVN, Kovacs and her colleagues demonstrated that it is the vasopressin, and
not the CRH, gene that is the principal target of glucocorticoid-mediated
transcriptional suppression during stress (Kovacs et al. 2000).
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1.5.1.4 Corticosteroid-binding globulin (CBG)
The circulating plasma level of corticosteroid-binding globulin (CBG), the major
glucocorticoid transport protein, is an important factor regulating glucocorticoid
availability to target tissues. Variations in plasma CBG levels will affect the free
concentrations of glucocorticoids in the plasma and therefore influence the bioactive
efficacy of the glucocorticoid signal. During the course of the normal diurnal cycle
approximately 90% of corticosterone is bound to CBG in the circulation (Hammond
et al. 1987). CBG belongs to the serine protease inhibitor family (Hammond et al.
1987). The majority of CBG is synthesised in the liver but CBG mRNA and protein
have also been detected in rodents in the proximal tubules of the kidney (Scrocchi et
al. 1993a). In mice and rats foetal hepatic CBG mRNA expression and plasma CBG
concentrations are very high at mid-gestation and then drop to almost undetectable
levels around birth (Smith & Hammond 1989; Scrocchi et al 1993b). The anterior
pituitary contains an intracellular CBG, transcortin, derived from plasma CBG (de
Kloet & McEwen 1976; Koch et al. 1976). It exists in a membrane bound form as
well as in the cytosol (Koch et al. 1978), where it functions much like plasma CBG in
that it sequesters free corticosterone and decreases binding to GR in the anterior
pituitary. Adrenalectomy increases, while chronic corticosterone treatment decreases
plasma CBG levels (Feldman et al. 1979; Levin et al. 1987). Acute stress can
decrease plasma and intracellular CBG levels 24 h after the end of the stress
(Tannenbaum et al. 1997). Plasma CBG levels are also increased during pregnancy
(Seal & Doe 1967; Smith & Hammond 1989).
1.5.1.5 Glucocorticoid receptor (GR)
The inhibitory effects of corticosterone on HPA axis function are believed to be
transduced primarily by intracellular steroid receptors that function as hormone-
activated transcription factors (Figure 1.1). Two different corticosteroid receptors
have been cloned and sequenced: glucocorticoid receptor (GR, type II corticosteroid
receptor) (Hollenberg et al. 1985) and mineralocorticoid receptor (MR, type I
corticosteroid receptor) (Arriza et al. 1987). MR has a high affinity for both the
mineralocorticoid, aldosterone, and the glucocorticoids, Cortisol and corticosterone,
and a lower affinity for the synthetic glucocorticoid dexamethasone (Beaumont &
Fanestil 1983; Reul & de Kloet 1985; Sutanto & de Kloet 1987). GR has a high
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affinity for dexamethasone, and a lower affinity for corticosterone and aldosterone
(Veldhuis et al. 1982; Reul & de Kloet 1985).
GR cDNA has been cloned from rat (Miesfeld et al. 1984), mouse (Danielsen et al.
1986) and human (Hollenberg et al. 1985), and two protein forms of 111 (alpha) and
742 (beta) amino acids are predicted from hGR cDNA, differing at their carboxy
terminal part with alternative splicing of exons 9a and 9(3 (Hollenberg et al. 1985).
Both hGR isoforms share the same amino acid sequence through amino acid 727 but
diverge beyond this position, hGRa with an additional 50 amino acids and hGR(3 with
an additional non-homologous 15 amino acids (Oakley et al. 1996). There are few
studies about the function and distribution of hGR(3 so far. hGR(3 is largely ignored
because it is not found to bind ligand or activate transcription of glucocorticoid-
response reporter gene (Hollenberg et al. 1985; Giguere et al. 1986). From in vitro
studies, hGR(3 is considered as a dominant negative regulator of hGRa transactivation
(Oakley et al. 1996; Oakley et al. 1997).
1.5.1.5.1 Distribution of MR and GR
Double immunohistochemical techniques and in situ hybridisation have revealed that
GR mRNA is expressed in almost 99% of growth hormone cells and corticotrophs,
and in 67% of thyroid stimulating hormone-producing cells. Almost all of the
folliculostellate cells (93%), marginal layer cells (94%) in the anterior pituitary, and
pituicytes (96%) in the posterior pituitary are colocolised with GR (Ozawa et al.
1999).
MRs are mainly present in the hippocampus and dorsolateral septum. The pattern of
MR mRNA expression in the hippocampus is similar to that shown by in vitro
autoradiography of MR binding, with highest levels in the CA1-CA2, pyramidal layer
of CA3 and granular layer of the dentate gyrus (Van Eekelen et al. 1988; Herman et
al. 1989).
GR immunoreactivities are present in the parvocellular part of the PVN, in the
anterior periventricular hypothalamic nucleus, in the ventral part of the mediobasal
hypothalamus, and in the CA1 and CA2 subregion of the hippocampal formation.
Within the PVN a substantial overlap exists between the ir-GR area and the ir-CRH
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area (Fuxe et al. 1985). Medium to high densities of GR immunoreactive neurones are
present all over the cortical hemispheres, and in many thalamic nuclei and in the
central amygdaloid nucleus (Fuxe et al. 1985). GR mRNA exists within the pyramidal
neurones of the CA1 and CA2 areas of the hippocampal formation, in the granular
cells of the dentate gyrus, in the parvocellular neurones of the PVN, and in the cells of
the arcuate nucleus. It is also detected in a large number of neurones within layers II,
III, and VI of the neocortex, in many thalamic nuclei, all over the granular layer of the
cerebellar cortex, and the entire locus coeruleus and the mesencephalic raphe nuclei,
rich in noradrenaline and 5-hydroxytryptamine cell bodies in the lower brainstem.
There is a close correlation between the distribution of GR mRNA and the
distribution of ir-GR (Aronsson et al. 1988; Van Eekelen et al. 1988; Yang et al.
1988).
1.5.1.5.2 Mechanism of glucocorticoid action via GR and MR
This dual receptor system for a single class of hormones is advantageous in dealing
with the manifold physiological functions of glucocorticoids. Under resting
conditions, plasma corticosterone levels undergo characteristic circadian fluctuations,
ranging within 100 pg/ml. When homeostasis is disturbed by stressors, the
corticosterone levels may fluctuate over a wide range (almost 50-fold) to several
hundreds pg/ml. With two different type receptors, GR and MR, a sufficient flexible
dynamic range is available. Reul and de Kloet have revealed that, in rats killed early
in the morning (at the trough of the HPA axis diurnal rhythm; plasma corticosterone
level <15 pg/ml), more than 80% MRs are already occupied by endogenous ligand,
whereas GRs are only about 10% occupied (Reul & de Kloet 1985). In contrast, GRs
become substantially occupied only under conditions of higher plasma corticosterone
levels (>50-100 pg /ml) such as occur at the circadian peak and during stress (Reul &
de Kloet 1985; Reul et al. 1987). So it is believed that GRs mediate the negative
feedback of elevated glucocorticoid levels to restrain HPA drive, whereas MRs
mediate the tonic inhibitory control of the hippocampus on HPA activity of basal
activity (de Kloet & Reul 1987; Reul et al. 2000).
In the absence of ligand, the GR and MR are maintained in an inactive state, forming
a heterooligomer with immunophilins (Tai et al. 1992), or with heat shock proteins
(Pratt et al. 1988; Vamvakopoulos & Chrousos 1994). When glucocorticoids enter
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target cells by passive diffusion, they bind to their cognate receptors (GR, MR) in the
cytosol. However, there is some evidence (Harrison et al. 1979) suggesting that
glucocorticoid entry into cells is a regulated process involving specific membrane-
associated receptors distinct from the classical intracellular GRs. After intranuclear
translocation, the GR-GR, MR-MR homodimers or the GR-MR heterodimer are
constituted, depending on the relative levels of GR and MR and the concentrations of
their ligands. The receptor dimers bind to glucocorticoid response elements (GREs)
in the flanking region of target genes and regulate transcription of hormone-regulated
genes (Trapp et al. 1994).
1.5.1.5.3 Regulation of GR expression in the anterior pituitary
In vivo studies have shown that adrenalectomy or CRH treatment alone does not
change pituitary GR binding capacity (McEwen 1979) or GR mRNA (Sheppard et al.
1990), whereas CRH decreases and dexamethasone increases GR mRNA in the
adrenalectomised rat pituitary (Sheppard et al. 1990), which suggests that the CRH-
induced GR mRNA down-regulation is reversed by corticosterone in vivo. In the
AtT20 cell line model, CRH treatment leads to a rapid time-dependent decrease in GR
mRNA levels which precedes a dose- and time-dependent decrease in GR binding
capacity. The relative proportion of nuclear vs. cytoplasmic localised
[3H]dexamethasone-bound GR does not differ between control and CRH-treated
cultures, indicating that CRH does not interfere with GR nuclear translocation.
Treatment with either forskolin or 8-bromo-cAMP, mimics the CRH-induced
decrease in GR binding, and in addition forskolin decreases GR mRNA levels
(Sheppard et al. 1991).
Sustained elevations of circulating corticosterone, whether by repeated stress or
exogenous corticosterone administration, do not change receptor affinity for
[3H]dexamethasone, or receptor number in the pituitary (Sapolsky et al. 1984;
Sapolsky & McEwen 1985). In contrast, equivalent doses of dexamethasone down-
regulate pituitary corticosterone receptor numbers (Sapolsky & McEwen 1985).
However, anterior pituitary GR mRNA expression increases after chronic
glucocorticoid treatment (two 100 mg corticosterone pellets for 6 days, subcutaneous
implant) (Sheppard et al. 1990). This discrepancy between GR binding assays and
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mRNA studies may be explained in terms of translational efficiency and/or
posttranslational modification.
Chronic treatment (5 days) with a small dose of dexamethasone (0.25 pg/ml), but not
corticosterone (25 pg/ml), increases anterior pituitary GR mRNA levels in the
adrenalectomised animals (Sheppard et al. 1990). These differences in the response to
dexamethasone and corticosterone may partially be explained by the presence of
steroid-binding proteins and/or modifying enzymes found in the pituitary (de Kloet et
al. 1977; Koch et al. 1976). Both CBG and other CBG-like binding proteins would in
effect lower the local concentration of corticosterone, but not dexamethasone, thus
decreasing the ability of corticosterone to bind to corticosteroid receptors. The
presence of modifying enzymes such as 11(3-HSD is another factor that could
decrease the local concentration of corticosterone, but not dexamethasone.
Sex steroids are also involved in GR gene expression regulation. Ovariectomy
resulted in an approximately 2-fold increase in GR mRNA concentrations in the
anterior pituitary. Administration of 17P-estradiol completely reverses the
ovariectomy- induced increase in GR mRNA content of the pituitary gland (Peiffer &
Barden 1987). Treatment of rats with corticosterone does not influence the
ovariectomy-induced increase in glucocorticoid receptor mRNA content, indicating
that this increase is not mediated via effects on circulating glucocorticoid levels or
availability. GR receptor contents in the pituitary are also regulated by sex steroids.
Gonadally intact females have less 3H-dexamethasone binding than intact males.
However, there is no difference in receptor concentration between ovariectomised
females and gondadectomised males. Estrogen is able to reverse the effect of
ovariectomy: ovariectomised females receiving estrogen have fewer receptors than
intact males. Progesterone does not antagonise the effect of estrogen in the pituitary
(Turner 1990).
1.5.2 Neurosteroids
The term "neurosteroid" was introduced by Baulieu in 1981 to describe a steroid
hormone, dehydroepiandrosterone sulphate, that was found at high levels in the body
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long after gonadectomy and adrenalectomy (Baulieu 1981). Androsterone,
pregnenolone, tetrahydro- metabolites of progesterone, deoxycorticosterone (DOC),
dehydroepiandrosterone, their sulphates, and lipid derivatives are identified as
neurosteroids (Jung-Testas et al. 1989; Majewska 1992; Corpechot et al. 1993).
Within this large family of neurosteroids, these hormones and their metabolites have a
broad range of effects and the functions of these neurosteroids have been extensively
studied. Allopregnanolone and 3a,21-dihydroxy-5a-pregnan-20-one
(tetrahydrodeoxycorticosterone, THDOC) act as allosteric modulators of
neurotransmitter receptors such as GABAa, N-methyl-D-asparate (NMDA) and sigma
receptors (Irwin et al. 1994; Monnet et al. 1995; Baulieu 1998). Neurosteroids also
modulate glycine-activated chloride channels (Prince & Simmonds 1992), neural
nicotinic acetylcholine receptors (Valera et al. 1992) and voltage-activated calcium
channels (ffrench-Mullen et al. 1994), and consequently regulate electrical activity of
neurones (Dubrovsky et al. 1982; Dubrovsky et al. 1985; Rupprecht 1997).
Neurosteroids have been shown to modulate behaviour and mood, with anti-anxiety
(Crawley et al. 1986), hypnotic (Mendelson et al. 1987), and anti-aggressive actions
(Kavaliers 1988). They facilitate repair of myelin (Baulieu 1998; Morfin et al. 1992).
Pregnenolone and its metabolites enhance memory in male mice, which suggests
pregnenolone may facilitate the transcription of immediate early genes (Flood &
Roberts 1988; Flood et al. 1992).
Neuroactive steroids are present in brain independently of peripheral sources (Robel
& Baulieu 1995), so they can be produced by brain tissue (Jung-Testas et al. 1989;
Papadopoulos et al. 1992; Melcangi et al. 1993). In the brain these neurosteroids are
synthesised by oligodendrocytes and glial cells (Baulieu & Robel 1990; Melcangi et
al. 1993). The majority of allopregnanolone and THDOC are derived from circulating
progesterone, but they are also synthesised in the brain de novo from choleserol via
pregnenolone (Corpechot et al. 1993; Cheney et al. 1995; Genazzani et al. 1998).
The brain expresses enzymes (3a- and 3(3-hydroxysteroid oxidoreductase and 5a-
steroid reductase) that catalyse the metabolism of pregnenolone and other steroid
derivatives that are active at GABAa receptors (Kabbadj et al. 1993; Melcangi et al.
1993). Allopregnanolone is synthesised from progesterone by a two-step reaction. The
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first step is irreversible and is conversion of progesterone to 5a-pregnanedione
catalysed by a 5a-reductase. The second step is reversible, and is conversion of 5a-
pregnanedione to allopregnanolone mediated by 3a-hydroxysteroid oxidoreductases.
THDOC is converted from progesterone to deoxycorticosterone, then to THDOC
catalysed by a 5a-reductase. 17(3-N,N-diethylcarbomyl-4-aza-4-methyl-5a-androstan-
3-one (4-MA) is a 5a-reductase inhibitor, which blocks allopregnanolone and
THDOC production (Figure 1.4).
Pharmacological doses of neurosteroids, derivatives of progesterone such as
allopregnanolone, also elicit sedative-hypnotic, anti-convulsant, and anti-conflict
actions on mice and rats (Belelli et al. 1989; Bitran et al. 1991; Wieland et al. 1991;
Kokate et al. 1994). These effects of 3a-hydroxysteroids have been related to their
ability to facilitate GABA action at the GABAa receptor-coupled-Cl" channels
(Majewska et al. 1986). Allopregnanolone and THDOC are the most potent and
efficacious endogenous compounds known that are able to enhance GABAa receptor
function. Allopregnanolone is a high affinity, positive allosteric modulator of the
GABAa receptor associated with a CI- ionopore (Gee et al. 1988; Gee 1988; Peters et
al. 1988; Turner et al. 1989; Puia et al. 1990). Allopregnanolone is active at
nanomolar concentrations (Peters et al. 1988; Turner et al. 1989; Puia et al. 1990;
Puia et al. 1993) and is 500-fold (Majewska 1992) more potent than progesterone at
modulating the GABAa receptor.
Both brain extract and plasma neurosteroid concentrations are markedly increased
shortly after application of different stress paradigms (Purdy et al. 1991; Korneyev et
al. 1993; Barbaccia et al. 1994; Barbaccia et al. 1998). In particular, during the stress
response brain content of allopregnanolone increases (Korneyev et al. 1993; Purdy et
al. 1991) and may be significantly higher in some brain regions for instance in the
olfactory bulb (Korneyev et al. 1993). These data indicate that neurosteroids such as
allopregnanolone are part of the negative feedback mechanism in the stress response.
Pretreatment of rats with a single dose of allopregnanolone significantly attenuates the
elevation of plasma ACTH after emotional stress and attenuates the increase in
vasopressin mRNA levels in the ventromedial subdivision of the hypothalamic PVN
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the prefrontal cortex and hippocampus, in a dose-dependent manner. At a dose of 10
pg, allopregnanolone also completely prevents the increase in hippocampal
acetylcholine release induced by foot-shock stress (Dazzi et al. 1996). Baseline
plasma levels of ACTH are not affected by diazepam (an allosteric modifier at
GABAa receptors), but both ether- and restraint-induced release of ACTH is reduced
by diazepam (Bernet et al. 2000). Bilateral microinjection of muscimol (a GABAa
receptor agonist) into either the PVN prior to air stress reduces the associated
increases in plasma ACTH (Stotz-Potter et al. 1996). Intracerebroventricular injection
of 10 pi of anti-allopregnanolone serum significantly potentiates the plasma
corticosterone response to an acute cold water swimming stress (Guo et al. 1995).
THDOC (5 mg/kg) attenuates mild stress- induced increases in plasma corticosterone
concentrations via GABAergic mechanisms (Owens et al. 1992).
The release of CRH from the hypothalamus is decreased by activation of GABAa
receptors, therefore, these neurosteroids may inhibit CRH release and subsequent
ACTH release via GABAa receptor sites in the hypothalamus (Gram & Christensen
1986; Calogero et al. 1988b; Calogero et al. 1988a; Owens et al. 1992). A number of
experimental studies clearly suggest that benzodiazepines attenuate CRH secretion
possibly through inhibitory GABAergic mechanisms in human. The administration of
alprazolam leads to a highly significant attenuation of the ACTH and Cortisol increase
following the "stress interview". Following administration of CRH, the ACTH
augmentation is only slightly affected following alprazolam, while there are no
changes in Cortisol or prolactin secretion (Rohrer et al. 1994).
A vast majority of CRH neurones (>94.5%) are found to express transcripts for al, pi
and p2 subunits of the GABAa receptor, and mRNAs for al and P2 subunits of the
GABAa receptor are detected within 53.3% and 65.7% of PVN CRH neurones,
respectively (Cullinan 2000). The subunit composition of GABAa receptors at this
key regulatory locus may affect the efficacy of a major inhibitory input, and thus the
magnitude and/or duration of stress-induced glucocorticoid secretion. Measurements
of the steady-state levels of CRH mRNA in the PVN by quantitative in situ
hybridisation shows that allopregnanolone is as potent as corticosterone in preventing
adrenalectomy-induced up-regulation CRH mRNA expression (Patchev et al. 1994).
Allopregnanolone does not alter the basal release of CRH from the hypothalamus in
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vitro, but suppresses the stimulatory effect on CRH release by the al-adrenergic
agonist methoxamine (Patchev et al. 1994).
In vitro studies show that the neurosteroids dehydroepiandrosterone, pregnenolone
and pregnanolone do not affect POMC mRNA levels on pituitary AtT 20 cells, even
at the highest concentrations employed, suggesting that neurosteroids do not control
POMC gene expression at the level of the pituitary corticotroph (Vedder et al. 1993).
In cortical neurones allopregnanolone positively modulates GABA elicited CI"
currents (Puia et al. 1993). This neurosteroid has also been found to protect against
seizures that arise from blockade of the GABA- CI" channel complex.
Allopregnanolone induced a significant increase in 36C1" uptake within 10 s compared
with that induced by exposure to 100 pM GABA (Brinton 1994).
In summary, the metabolites of progesterone, allopregnanolone and THDOC, exert
inhibitory effects on the HPA system, by inhibiting CRH and vasopressin production,
but it is unlikely these neurosteroids have direct action on corticotrophs.
1.6 Other ACTH secretion regulation factors
Besides the factors discussed above, other stimulatory factors (review, (King &
Baertschi 1990)) such as angiotensin II, vasoactive intestinal peptide, and
catecholamines, and inhibitory factors (review, (Jessop 1999)) such as opioids, leptin,
lipocortin, somatostatin, prepro-thyrotrophin- releasing hormone, substance P, nitric
oxide, endothelins and adrenomedullin are also involved in regulating ACTH
secretion from corticotrophs. CRH binding protein (CRHBP) is known to inhibit
ACTH secretion by binding to CRH (Suda et al. 1988a). Atrial natriuretic peptide
(ANP) is considered as an inhibitory factor of ACTH secretion (Kovacs & Antoni
1990), however, its role in regulating ACTH secretion is still controversial.
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1.6.1 CRH binding protein (CRHBP)
CRHBP is a protein that binds CRH to modulate ACTH secretion from corticotrophs
(Figure 1.1), but is not a receptor, and is found in the anterior pituitary, brain and
other tissues. In particular, it is secreted into blood from placenta during human (but
not rat) pregnancy.
In the late 1980's, CRHBP was found in both normal human plasma (Orth & Mount
1987; Potter et al. 1991) and late gestational maternal plasma (Perkins et al. 1995b).
In addition to human placenta, CRHBP is also secreted in the intrauterine tissues
(maternal decidua, amnion, and chorion) (Petraglia et al. 1993) and peritoneal fluid
(Petraglia et al. 1997), but not in human ovarian follicles (Asakura et al. 1997).
1.6.1.1 Characterisation of CRHBP
Human CRHBP, a 37-38 Kd protein, is a glycoprotein that contains asparagine N-
linked-type oligosaccharides, and such oligosaccharide chains are important for
CRHBP binding (Suda et al. 1988a; Behan DP et al. 1989; Suda et al. 1989b). Human
CRHBP binds specifically to CRH, but it is unlikely that CRHBP is a CRH receptor,
because the estimated molecular weight of the CRHBP is smaller than the reported
size of CRH receptors (anterior pituitary: 75 Kd; brain: 58 Kd (Grigoriadis & De
Souza 1989b; Grigoriadis & De Souza 1989a)), and CRHBP has low affinity for the
ovine CRH (Suda et al. 1988a; Sutton et al. 1995). The rank orders of affinity of the
CRH family members for human CRHBP are: carp urotensin » human CRH =
rat/ovine urocortin > human urocortin » frog sauvagine » ovine CRH (Baigent &
Lowry 2000b; Behan et al. 1996c).
CRHBP cDNA has been isolated (Behan DP et al. 1989) and cloned from rat (Potter
et al. 1991), mouse (Cortright et al. 1995), sheep (Behan et al. 1996a; Cortright et al.
1997), and Xenopus (Valverde et al. 2001). The rat and human CRHBP gene spans
almost 12000 bp and contains 7 exons and 6 introns encoding 322 amino acids with 5
tandem disulphide bridges which are essential for the binding of CRH (Behan et al.
1995; Behan et al. 1996b; Cortright et al. 1997; Zhao et al. 1997).
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In primates the CRHBP gene is expressed in the anterior pituitary, brain, liver and
placenta, whereas in rodents it is produced only in the brain and pituitary (Behan et al.
1995).
1.6.1.2 CRHBP localisation in the anterior pituitary and brain
In the anterior pituitary, CRHBP is expressed predominantly and extensively in
corticotrophs and colocalises with ir-ACTH in a majority of corticotrophs (Potter et
al. 1992).
CRHBP expression in the hypothalamus appears largely limited to the ventral
premammillary and dorsomedial nuclei; only isolated CRHBP-stained cells are
apparent in neurosecretory cell groups. Dual immunostaining for CRH and CRHBP
reveals a partial colocalisation in some of these regions. Prominent CRHBP-stained
terminal fields have been identified in association with CRH-expression cell groups in
circumscribed hypothalamic and limbic structures. However, the PVN and median
eminence, the hypothalamic sites of CRH synthesis and secretion, respectively, have
only sparsely scattered ir-CRHBP fibres (Potter et al. 1992).
CRHBP is also expressed predominantly in the cerebral cortex, subcortical limbic
system structures (amygdala, bed nucleus of the stria terminalis). Within the cerebral
cortex and the hippocampal formation, the colocalisation of the CRH- and CRHBP-
immunoreactivities is only in relative small subsets of neurones at a limited number of
sites. More extensive instances of CRHBP and CRH peptide colocalisation are in the
olfactory bulb, the ventral part of the lateral septal nucleus, the bed nucleus of the
stria terminalis, the medial preoptic area, the central nucleus of the amygdala, the
mesencephalic central gray, the interpeduncular nucleus, the lateral dorsal tegmental
nucleus, the inferior colliculus, and the lateral reticular nucleus (Potter et al. 1992).
In the brain, CRHBP is associated with the intracellular membrane(s) (Behan et al.
1995). In the anterior pituitary ir-CRHBP is distributed diffusely throughout the
cytoplasm of corticotrophs, but is associated with membrane-bound vesicular and
vacuolar structures and in particular lysosomes and multivesicular bodies. Labelling
for ir-CRHBP in the anterior pituitary is most prominently associated with the
lysosomal system. These display either an otherwise homogeneous and finely
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granular content (primary lysosomes) and are often seen in association with the Golgi
apparatus or larger granules and/or vesicular structures (secondary lysosomes)
distributed more widely in the cytoplasm. There is no association of ir-CRHBP with
secretory granules (Peto et al. 1999).
There is no CRHBP in secretory granules in the pituitary cells, suggesting that it is not
co-secreted with ACTH (Peto et al. 1999). This is consistent with no report of basal or
stimulated CRHBP secretion from the anterior pituitary. The predominant association
of the ir-CRHBP with secondary lysosomes, multivesicular bodies, and endosome-
like vesicular structures in corticotroph cells suggests a principle role for the CRHBP
in the processing and/or degradation of CRH or of ligand-receptor complex. CRHBP
is in a position to participate in the signal transduction of the CRH/receptor complex.
The roles of CRHBP are considered to be facilitating dissociation of the complex,
with consequent freeing of the receptor for recycling to the cell surface, and/or acting
as chaperone to direct internalised CRH to the lysosomal system of digestion (Peto et
al. 1999).
1.6.1.3 Physiological functions of CRHBP
In primates, plasma CRHBP levels increase during pregnancy which completely
abolish the ACTH releasing activity of CRH by binding with CRH forming a stable
dimer to keep the normal ACTH response to stress (Linton et al. 1990; Woods et al.
1994b).
CRHBP inhibits CRH-induced ACTH secretion from cultured rat anterior pituitary
cells at concentrations commonly found in late gestational maternal plasma (1.5 and
100 ng/ml, human CRH and CRHBP respectively) (Behan DP et al. 1989; Linton et
al. 1990). In transgenic mice with CRHBP deficiency, the basal ACTH and
corticosterone concentrations and the pattern of increased corticosterone and ACTH
after restraint stress do not change (Karolyi et al. 1999). However, in the transgenic
mice expressing elevated levels of CRHBP, a significant attenuation of ACTH
secretion was observed at 3 h after lipopolysaccharide injection (Lovejoy et al. 1998).
These data suggest that HPA axis regulation is significantly affected only with very
high circulating levels of CRHBP. However, another model of transgenic study found
the transgenic mice expressing elevated levels of CRHBP show similar ACTH
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response to stress compared with normal mice (Burrows et al. 1998). The stress-
induced CRH release into the hypothalamic portal system may be not quenched
completely by the excess CRHBP, because the concentration of CRH released is high,
and the exposure time before reaching the pituitary corticotrophs is low. As CRH and
vasopressin mRNA levels increase by 82 and 35% respectively in the PVN of
transgenic mice expressing elevated levels of CRHBP compared with the controls,
respectively, this suggests increased CRH and vasopressin release compensates for
the excess CRHBP (Burrows et al. 1998).
Since long term secretion of placental CRH into the peripheral circulation occurs
during the third trimester of human pregnancy, the presence of circulating CRHBP
may explain how markedly elevated plasma levels of CRH coexist with normal
ACTH levels at this time (Suda et al. 1988a; Suda et al. 1989a).
1.6.1.4 CRHBP gene expression regulation
The mechanism of CRHBP gene expression regulation is not clear, however, there are
some studies which suggest that CRHBP mRNA expression in the anterior pituitary is
positively regulated by cAMP, CRH, stress and glucocorticoids (Cortright et al. 1997;
McClennen et al. 1998). cAMP response element (CRE)-binding sites have been
identified in the CRHBP promoter sequence and CRHBP promoter activity is
positively regulated by cAMP and CRH via these CRE-binding sites (Cortright et al.
1997). In AtT20 cells, CRH positively regulates CRHBP promoter activity via the
CRH receptor (Cortright et al. 1997). Forskolin, CRH, interleukin 6, and
dexamethasone increased CRHBP mRNA and protein expression in dissociated fetal
amygdalar cultures (Kasckow et al. 1999), whereas forskolin increases CRHBP
mRNA levels, but dexamethasone can repress forskolin- induced CRHBP hnRNA
levels in primary rat astrocyte cultures (McClennen & Seasholtz 1999). The
mechanism of regulation of CRHBP gene expression by glucocorticoids is not clear.
Two hours after restraint stress, CRHBP gene expression in the anterior pituitary
increases two-fold over the basal level. Adrenalectomy decreased CRHBP mRNA
expression level to 8% of the control level, but 30 min restraint stress may further
increase CRHBP gene expression in the adrenalectomised rats (McClennen et al.
1998). That the ir-CRHBP concentration in human plasma is regulated by
glucocorticoids is also suggested by clinical studies. However, the direction of control
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of circulating CRHBP is opposite to that of control of expression in the pituitary and
brain from the above studies. The CRHBP concentration is low in patients with
Cushing's syndrome, after surgical treatment, the plasma CRHBP concentration in
patients with Cushing's syndrome rose, peaked, and then decreased to the control
level. In patients with Addison's disease, the high plasma CRHBP concentration
decreased to the control level after hydrocortisone replacement (Ohmori et al. 1994;
Suda et al. 1990).
1.6.2 Atrial natriuretic peptide (ANP)
ANP is generally known to be important in maintaining electrolyte and fluid
homeostasis through inhibition of aldosterone and vasopressin release (Sonnenberg et
al. 1982; de Bold et al. 2001). ANP was first reported to attenuate basal ACTH
secretion from normal rat anterior pituitary by Shibasaki et al. (Shibasaki et al. 1986).
Evidence from in vivo studies (Kovacs & Antoni 1990; Fink et al. 1991; Antoni et al.
1992; Fink et al. 1992) also suggests that ANP may be an ACTH release inhibitor. Ir-
ANP is detected in some hypothalamic neurones, in the external zone of the median
eminence and in the portal blood (Skofitsch et al. 1985; Kawata et al. 1985; Standaert
et al. 1986; Sheward et al. 1991). ANP receptors are also found in the anterior
pituitary (Koch et al. 1988). However, its role in regulating ACTH secretion is still
controversial. Many studies have not found this inhibitory effect on ACTH secretion
in vivo or in vitro (Heisler et al. 1986; Abou-Samra et al. 1987a; Hashimoto et al.
1987; Bowman et al. 1997; Mulligan et al. 1997).
1.7 HPA function during pregnancy
1.7.1 Changes in HPA axis activity during pregnancy
Adrenal glucocorticoids play a crucial role in overall metabolic homeostasis and
allow the organism to respond adequately to various stressful stimuli. The adaptation
of this axis may be crucial to pregnancy maintenance, since this condition arguably
imposes the most dramatic and prolonged physiological stress encountered in normal
postnatal life.
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During pregnancy, the HPA axis respond to physical and emotional stress are
attenuated (Neumann et al. 1998). The effect of exogenous CRH on the ACTH and
corticosterone secretion is also reduced (Neumann et al. 1998).
Blood corticosterone levels were reported to fall, or not to change in early pregnancy,
followed by a return to pre-pregnancy levels and a further increase at the latest stage
of pregnancy in rats (Garland et al. 1987; Waddell & Atkinson 1994), mice (Montano
et al. 1991) and humans (Nolten & Rueckert 1981). This increase in blood
concentration may be attributed to either increased corticosterone production and/or
reduced corticosterone clearance rate (Waddell & Atkinson 1994) in late pregnancy.
Secondary endocrine and metabolic changes associated with pregnancy, i.e. increased
ovarian oestrogen secretion which occurs in rat pregnancy could also increase adrenal
corticosterone secretion by increasing sensitivity to ACTH. Corticosterone secreted
by the foetal adrenal glands can also make a contribution (Dupont et al. 1991).
Glucocorticoid levels are controlled by ACTH. There is no study to investigate the
clearance rate of ACTH during pregnancy so far, but it is reported that ACTH
clearance rate is not altered by sex steroids (Viau & Meaney 1991). Increased CBG
levels during pregnancy may reduce corticosterone clearance (Lin et al. 1990; Scott et
al. 1990), and in pregnancy, the sensitivity of the adrenal gland to ACTH is increased
(Waddell & Atkinson 1994). At the late stage of pregnancy, plasma corticosterone
concentrations are slightly increased, but morning basal plasma ACTH concentrations
do not change (Neumann et al. 1998). This also suggests that the sensitivity of the
adrenal cortex to ACTH is increased during pregnancy.
Although basal morning plasma ACTH concentrations do not change during
pregnancy, however there is a loss of the diurnal increase (Atkinson & Waddell
1995). The maternal placenta may be another source of circulating ACTH in the rat
(Chen et al. 1986), but the placenta does not release ACTH in response to maternal
stress (Ohkawa et al. 1991).
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1.7.2 Possible mechanisms of the attenuated HPA axis activity in pregnancy
The mechanisms of this attenuated HPA axis response are not clear.
There are changes in the brain including the hypothalamus, hippocampus and other
brain regions. Lower basal CRH and vasopressin mRNA expression in the PVN of
pregnant rats suggests reduced CRH and vasopressin availability for driving the
secretion of ACTH (Johnstone et al. 2000).
The sensitivity of corticotrophs during pregnancy may be changed as suggested from
receptor autoradiography studies: CRH and vasopressin receptor binding in the
anterior pituitary is decreased in pregnant rats compared with virgins (Toufexis et al.
1999; Neumann et al. 1998). cAMP levels in pituitary segments also show a pattern of
reduced basal level, and a lower increase after CRH stimulation in pregnant rats
(Neumann et al. 1998).
Glucocorticoid feedback may be involved in this change (Johnstone et al. 2000). GR
mRNA expression measured by in situ hybridisation in the dentate gyrus is reduced,
but not in the PVN, and 11(3-HSD1 activity is also increased in the PVN and anterior
pituitary at the late stage of pregnancy. This increase in the reductase, llp-HSDl,
may enhance the local intracellular glucocorticoid levels to exert negative feedback in
the HPA axis.
The changes in sex steroid concentration may be another cause of the attenuated HPA
axis activity. The effects of a subcutaneous implantation of progesterone and estradiol
in ovariectomised rats suggests that estradiol facilitates HPA activity while
progesterone inhibits such facilitatory effects (Carey et al. 1995). However, another
study shows HPA activity is suppressed by chronic low-level estrogen replacement
(Dayas et al. 2000). The inhibitory effect of progesterone may be through its
metabolites such as allopregnanolone (see Chapter 1.5.2). The concentration in the
brain of neuroactive steroids, allopregnanolone and THDOC (the metabolites of
progesterone) are also at peak values prior to parturition (Concas et al. 1999). These
neurosteroids exert an important inhibitory effect on the HPA system by interacting
with the GABAa receptor in brain (Chapter 1.5.2) (Breier et al. 1992; Owens et al.
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1992; Patchev et al. 1994; Patchev et al. 1996; Bernet et al. 2000; Cullinan 2000). So
these neurosteroids may exert important role in the attenuated HPA axis responses to
stress during pregnancy.
In the late 1980's, CRHBP was found in both normal human plasma (Orth & Mount
1987; Potter et al. 1991) and late gestational maternal plasma (Perkins et al. 1995b).
During human pregnancy, maternal plasma ir-CRH level increases progressively. A
significant amount of placenta CRH mRNA is detected and CRH protein is secreted
by the placenta (Shibasaki et al. 1982; Grino et al. 1987), indicating that the placenta
is a site of CRH biosynthesis during pregnancy. The secretion by the placenta results
in large concentrations of CRH appearing in the maternal blood during the third
trimester of pregnancy, reaching levels just before parturition similar to those found in
the hypothalamic portal blood during stress in experimental animals (Campbell et al.
1987). However plasma ACTH concentrations during human pregnancy remain
within the normal physiological range (Rees et al. 1975), and there is no correlation
between plasma Cortisol and CRH (Campbell et al. 1987). The excessive plasma CRH
in pregnant women is bound to CRHBP so is inactive, therefore plasma ACTH levels
do not increase to above the normal range (Suda et al. 1988a; Suda et al. 1989a). The
rodent placenta does not produce significant amounts of CRH, therefore, a binding
protein would not be required to protect the pituitary (Baigent & Lowry 2000a).
However, CRHBP is expressed predominantly and extensively in corticotrophs and
colocalises with ir-ACTH in a majority of corticotrophs in the anterior pituitary
(Potter et al. 1992), and CRHBP is distributed broadly in the brain, so regulation of
the HPA axis activity by CRHBP during pregnancy may change as well.
At the level of the anterior pituitary, the attenuated ACTH response to stress can be
due to two possibilities: changes in the production of stimulatory and inhibitory
factors from the brain or periphery, and changes in sensitivity of the corticotrophs to
these factors. In this thesis, we planned to investigate mainly changes in CRH and
vasopressin inputs from the hypothalamus and the cellular signalling changes in
corticotrophs.
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Aims of the thesis
Previous studies show that the attenuated HPA axis activity in pregnancy may be due
to reduced sensitivity of corticotrophs to secretagogues and reduced CRH and
vasopressin secretion from the hypothalamus.
The aims of this thesis were: 1) to determine whether changes in the anterior pituitary
corticotrophs underlie reduced stress responses in pregnancy. By in situ hybridisation,
we measured the expression of POMC, CRHR1, Vlb receptor, GR, BK channel, and
CRHBP mRNAs.
2) to determine whether ACTH secretion by anterior pituitary cells regulated by
cAMP, CRH and vasopressin in vitro is different in pregnancy.
3) to elucidate the roles of CRH and vasopressin in ACTH secretion in pregnancy. We
measured effects of CRH and vasopressin antagonists on ACTH responses to stress,
and of exogenous vasopressin, combined with CRH on ACTH secretion.
4) to investigate the role of progesterone metabolites on the HPA axis activity. We
blocked the production of allopregnanolone and THDOC by administering 4-MA and
measured ACTH concentrations in response to swimming stress.
The thesis is about testing the two hypotheses underlying the attenuated ACTH
response to stress during pregnancy: decreased sensitivity of the corticotrophs and/or
reduced production of CRH and vasopressin by the hypothalamus.
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2.1 In vivo studies
2.1.1 Animal maintenance
Adult female Sprague-Dawley rats (230-250 g) and female outbred MF1 mice
(obtained from Bantin and Kingman, UK), were used for all in vivo and in vitro studies.
The rats were caged in groups of 3-5 (to minimise stress-induced activation of the HPA
axis) under standard laboratory conditions (lights on 7:00 h, lights off 19:00 h; 21°C
with food and tap water ad libitum) and allowed to acclimatise in the MFAA unit,
Edinburgh University for a period of at least two weeks before experiments or being
mated. The animals were handled daily for a minimum of a week prior to an experiment
in order to reduce non-specific stress effects occurring during experimentation.
To obtain pregnant rats, adult female rats or mice were caged individually with a
sexually experienced male in mesh floored breeder cages. If a vaginal plug of semen
appeared on the underlying tray the next morning then that day was designated as day 1
of pregnancy. After mating, rats or mice were housed separately until the day of
experiment. The number of pups was counted post mortem and data were excluded if
less than four pups were found.
2.1.2 Surgery
2.1.2.1 Chronic jugular cannulation
Under halothane: nitrous oxide anaesthesia pregnant and virgin rats were implanted
with a jugular cannula for blood sampling. Using sterile procedures the right jugular
vein was carefully exposed through a small skin incision and a silastic catheter (ID 0.5
mm; OD 1 mm), containing sterile heparinised saline (20 U/ml heparin, 9% saline), was
inserted for a distance of 3.5 cm so that the tip lay within the right atrium of the heart.
To check that the cannula was in place, a small volume of blood was drawn back prior
to the cannula being secured in place with suture thread. The cannula was then
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exteriorised at the back of the neck, fixed in placed with a strip of adhesive tape which
was sutured to the skin and the cannula was sealed with a plug. The animals were then
allowed a minimum of three days to recover.
2.1.2.2 Intraperitoneal injection
The rat was restrained then the needle advanced parallel to the line of the thigh and
pushed through to the centre of the posterior quadrant of the abdomen into the
peritoneal cavity where the solution was injected.
2.1.2.3 Subcutaneous injection
A fold of the scuff of the neck skin was elevated and a needle was introduced into the
raised skin parallel to the body wall. Then the needle was advanced subcutaneously for
most of its length and the solution was injected quickly.
2.1.3 Stress
2.1.3.1 Forced swimming
Forced swimming represents a relevant complex physical and emotional stressor for
rats (Abel, 1994). With the extension tubing of the venous catheter still attached, rats
were forced to swim for 90 s in a red plastic cylinder (40 cm in diameter and 60 cm in
height) filled with tap water (19°C) to a depth of about 40 cm. After the swim, the rats
were gently dried using towels for 10 s and returned to their home cages.
2.1.3.2 Restraint
Rats were left in a Perspex cylinder (ID: 70 mm) and no free movement for 30 min, then
was decapitated. The pituitaries were removed quickly, frozen on dry ice and stored at
-70°C until in situ hybridisation (Johnstone et al. 2000).
58
Materials and methods Chapter 2
2.2 In vitro studies
2.2.1 Collection of the hypothalamus and median eminence and CRH assay
On the morning (09:00-10:00) of the experiment, immediately after the rat was
decapitated, the median eminence and the hypothalamus were dissected under a
binocular microscope. The brain was placed on a glass slide and the median
eminence, with the attached pituitary stalk was separated using microscissors. A block
containing the hypothalamus was then prepared with a scalpel blade (coronal cuts just
anterior to the optic chiasma and caudal to the mammilliary bodies; sagittal cuts along
the hypothalamic sulci, and a horizontal cut just ventral to the thalamus). The median
eminence and the hypothalamic blocks were snap-frozen on dry ice, and later
sonicated in a solution of 0.5 M acetic acid and 0.1 M HC1. The median eminence
contents were sonicated in 50 pi solution and the hypothalamus contents were in 250
pi solution. The sonicates were sent by airfreight on dry ice to Prof. Pierluigi Navarra
(Catholic University Medical School, Italy) for CRH radioimmunoassay (Dello et al.
2000; Navarra et al. 1991).
2.2.2 ACTH assay
2.2.2.1 Primary incubation of the rat anterior pituitary cells
Rats were decapitated with a guillotine, the anterior pituitary glands were quickly
removed and place in a plastic Petri dish with DMEM (Dulbecco's Modified Eagle's
Medium) supplemented with 25 mM HEPES pH7.4, and 0.25% w/v BSA
(DMEM-BSA). After the posterior pituitary gland with pars intermedia were removed,
the anterior pituitary glands were finely chopped with a straight-edged scalpel blade
and then pooled together with other pituitaries within each group. The pituitary pieces
were trypsinised by incubating with DMEM-BSA containing 0.25 mg/ml trypsin
(TRL) and 10 mg/ml DNase I for 25 min at 37°C, and triturated with a 1 ml Gilson
pipette tip attached to the end of a 5 ml polystyrene pipette every 5 min. The tissue
suspension was then added to DMEM-BSA containing 0.5 mg/ml Lima Bean Trypsin
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inhibitor and 100 kallikrein inhibitor units of aprotinin to inactivate the trypsin. The
suspension was then centrifuged at 150 g for 5 min. The supernatant was removed and
the pelleted cells were resuspended in DMEM-BSA, gently triturated approx. 35 times
with a 1 ml pipette, and filtered through a 100 pm nylon mesh pre-wetted with 4 ml
DMEM-BSA. The resulting suspension was then centrifuged at approximate 150 g for
5 min to pellet the cells. The supernatant was carefully removed and the cell pellet was
diluted with 1 ml DMEM-BSA. Then the cell suspension was made up to 10 ml with
DMEM-BSA and gently rotated for 2 h to allow the cells to equilibrate. Then the
suspension was centrifuged at approximate 150 g for 5 min, the cell pellet was
re-suspended in 1 ml DMEM-BSA. Cell density was determined with a
haemocytometer. Cell viability was assessed by Trypan Blue exclusion and was over
95%. The cell suspension was then diluted to 2 x 105 cells/200 pi per tube (Antoni &
Dayanithi 1990).
For ACTH secretion studies, the cells were then incubated a 400 pi solution containing
different concentrations of ACTH secretagogues (CRH and vasopressin), vehicle
(DMEM-BSA), or 0.5 mM 8-CPT-cAMP (a cell permeable cAMP analogue) for 1 h at
37°C in a shaking water bath. In the case of measurement of the effects of the Vla/b
receptor antagonist on ACTH secretion by corticotrophs from virgin rats, medium
containing [dP(Tyr(Me)2,Arg-NH29)AVP was added to tubes containing cells, which
were left on ice; 5 min later the secretagogues were then added, and the cells incubated
for 1 h at 37°C in a shaking water bath. To measure total ACTH content of cells, 200 pi
aliquots (100,000 cells) were frozen directly at -70°C without any incubation or
addition of secretagogues.
Each concentration was assayed in 4-6 replicate tubes. The secretion was stopped by
placing the tubes on ice for 15 min. Medium containing the secreted ACTH was
collected and spun briefly at 150 g to pellet any floating cells and 200 pi supernatant
was collected in tubes. The tubes were sealed with parafilm and stored at -70°C until
radioimmunoassay.
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2.2.2.2 Measurement of ACTH secretion from cell incubation in vitro
Duplicate 50 pi aliquots of experimental medium were assayed for immunoreactive
ACTH using a double antibody precipitation radioimmunoassay (Dayanithi & Antoni,
1989) after appropriate dilution in RIA buffer (0.05 M sodium phosphate buffer, pH
7.4, 0.1% BSA, 0.1% Triton-X-100, 2.5 mM EDTA and 100 kallikrein inhibitor units
of aprotinin per ml) (Antoni & Dayanithi 1990). Lyophilised 125I-ACTH (Phoenix
Pharmaceuticals Inc.) was resuspended in distilled water, aliquoted and stored at -20°C.
The concentration used gave between 12,000-15,000 cpm/lOpl when counted by a
gamma counter (LKB-Wallac 1272 Clinigamma with a single detector consisting of a
Nal crystal in a 3" aluminium tube of wall thickness 0.25 mm, Wallac Oy, Finland).
The assay was performed in pre-numbered 0.65 ml polystyrene tubes (LP2 tubes,
Luckman Ltd, UK). Fifty microlitres of sheep ACTH antiserum (a kind gift from Prof
P.J. Lowry, University of Reading) at a final titre of 1:100,000 in RIA buffer containing
6% polyethylene glycol 6000 (PEG-6000), were mixed with 50 pi of sample. The assay
mix was incubated with 10 pi of 125I-ACTH (as above 12,000 to 15,000 cpm in 10 pi
sodium phosphate buffer without PEG-6000) for 18 h at 4°C. Subsequently, donkey
anti-sheep IgG (Scottish Antibody Production Unit, SAPU, Lanarkshire) and
non-immune rabbit serum (SAPU) were added to a final titre of 1:25 and 1:400
respectively and incubated for 3 h at 4°C. Four hundred microlitres of ice-cold 6%
PEG-6000 were added and the bound label separated from free by centrifugation at
1,950 g for 25 min at 4°C. The resultant supernatant was decanted, and the radioactivity
remaining in the pellet counted on an autogamma counter. Standards were assayed in
triplicate. Rat samples were assayed in duplicate.
2.2.2.3 Calculation of radioimmunoassay results
To quantify the unknown ACTH concentrations of experimental samples, a standard
curve of bound radioactivity against known standard ACTH concentration was
compiled in the range 0.125 to 128.0 fmol ACTH/50 pi using human ACTH1"19 diluted
in RIA buffer as appropriate.
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Three other standards were also prepared for construction of the curve and assessing the
125
sensitivity and binding of the assay: total count (TC) contained an aliquot of I-ACTH
only, to determine total count of radioactivity added; non specific binding (NSB)
contained 125I-ACTH, first antibody, second antibody and excess unlabelled ACTH
(1280 fmole/50 pi in this study) or by omitting the ACTH antiserum to determine
non-specific binding of radioactivity, was typically <10% of the total bound counts; Bo
contained aliquots of 125I-ACTH trace, first and second antibody but no unlabelled
ACTH, to determine the maximum percentage binding of radioactivity.
A standard curve of bound radioactivity against known standard ACTH concentration
was constructed automatically by Wallac Ultroterm 2 software. ACTH contents of
inter-assay standards and rat plasma samples were then extrapolated from the standard
curve.
Figure 2.1 Standard Curve of bound radioactivity against known standard ACTH concentratsion
ACTH concentrations (fmole/ 50 fil)
The graph above is an example of the standard curve for the calculation of ACTH
concentrations.
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2.2.2.4 Assay sensitivity
The sensitivity of an assay is the minimum detection limit of an assay. It provides
information about the minimum acceptable sample concentration and was calculated
using the following equation:
[Bn-(2xSD) l - NSB
B0-NSB
SD is the standard deviation of the 125I-ACTH bound in the three B0 tubes. The value
obtained from this equation was then compared to the percentage of B0 radioactivity
bound by each standard (0.25-128 fmoles/50pl) calculated using the following
equation:
mean standard com - NSB
Bn-NSB
The sensitivity of the assay was taken at the point where the value obtained using the
first equation was greater than those values obtained from the second equation and
converted to a concentration in fmoles/50 pi. The assay sensitivity in this study was 0.5
fmoles/50 pi.
2.2.2.5 Measurement of plasma ACTH concentration with an ACTH kit
Plasma ACTH concentrations were measured with an ACTH kit (ICN Biomedicals,
Inc., USA). The standard samples and all lyophilised reagents were reconstituted in
ddH20 for 15 min at 4°C before the assays. NSB, contained 125I-ACTH, 0 pg/ml
unlabelled ACTH, to determine non-specific binding of radioactivity by omitting the
ACTH antibody; B0, contained aliquots of 123I-ACTH trace, antibody but no unlabelled
ACTH, to determine the maximum percentage binding of radioactivity. All Standard
concentrations were compiled in the range 10-990 pg/ml and assayed in duplicate. 100
pi of standards or plasma samples, ACTH antibody and human l25I ACTH was added to
respective assay tubes. Then the contents of these tubes were shaken thoroughly and
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incubated for 16-19 h at 4°C. After incubation, 500 |il precipitant solution was added to
all tubes and mixed thoroughly. The supernatant were decanted carefully after being
centrifuged at 950 g -1050 g for 15 min. Then the pellet left was counted with a gamma
counter.
The method of calculation of radioimmunoassay results is the same as that for
measurement of ACTH from incubation (details see 2.2.2.3). The assay sensitivity of
this study was 10 pg/ml.
2.2.3 In situ hybridisation
Hybridisation is a reaction whereby two single-stranded nucleic acid molecules
recognise one another and bind by means of hydrogen bonding of complementary base
pairs. In situ hybridisation uses a piece of nucleic acid that has been labelled with a
radioisotope, or an otherwise detectable molecule, which hybridises to a target nucleic
acid residing in a tissue section, permitting determination of the cells expressing that
particular gene.
In situ hybridisation histochemistry has become a powerful technique for the detection,
localisation and semi-quantification of specific mRNA within morphologically
preserved cells or tissue preparations.
2.2.3.1 Choice of probes
Two types of nucleic acid probes in in situ hybridisation are commonly used in
neuroendocrinology studies with different advantages and disadvantages.
Oligonucleotide probes are short (normally 15-50 base pairs long) single-stranded
DNA oligonucleotides. These probes are quick and easy to produce without complex
molecular knowledge. Their short probe length allows better penetration of the tissue
sections, however, it also means that less stringent hybridisation conditions have to be
employed leading to a loss of specificity. Riboprobes are single-stranded RNA
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molecules produced from a cloned cDNA that is introduced into a specifically designed
plasmid transcription system. We chose to use riboprobes for our in situ hybridisation
studies because there is no problem about reannealing since they are single-stranded,
the transcription reaction produces a labeled probe of a fixed length and high specific
activity which forms a highly stable hybrid. These probes have a tendency to hybridise
to non-specific sites in the tissue sections, however, pre- and post-hybridisation
techniques are employed to reduce this. As oligonucleotide probes are easy to use, we
also chose in some of the studies when there was no ready riboprobe available.
To be able to determine the specificity of the hybridisation signal of the probe, termed
the antisense probe, a heterologous probe, termed the sense probe, which has a similar
length, GC content and specific activity as the antisense probe was included in the in
situ hybridisation studies. The lack of signal with the sense probe verifies that probe
binding is a result of its base sequence and not its physical properties.
2.2.3.2 Choice of isotope
We used 35S- to prepare probes for in situ hybridisation. 3H, and32P, each has its own
or o
strengths and weaknesses when compared with S. H has a much lower specific
activity and is more expensive despite its slightly higher resolution at the light
microscopic level. 32P has a shorter half-life and poorer resolution, especially on film.
2.2.3.3 In situ hybridisation with riboprobes
In our experiments, mRNAs were the target, so it is essential that the pretreatments
were performed under RNase-free conditions. To prevent RNase contamination
solutions were prepared with double-distilled water with diethylpyrocarbonate (DEPC)
added and autoclaved. Glassware and slide racks were baked at 250°C for at least 4 h.
Gloves were worn throughout the whole procedure.
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2.2.3.3a. Slide preparation:
Microscope slides generally need to be subbed in a solution that provides some
adherence for the tissue sections, so that they will remain in place during subsequent
histological processing. In all the experiments with riboprobe, we used commercially
available poly-L-lysine coated slides (BDH, UK). As for the experiments with
oligonucleotides, we used the gelatin coated slides.
2.2.3.3b. Tissue collection
After the animals were killed by decapitation, the pituitaries were rapidly removed and
immediately frozen on dry ice and stored at -70°C. Coronal sections were cut to 14 pm
using a cryostat at -18°C, then mounted onto gelatin or poly-L-Lysine coated slides and
stored at -70°C until used for in situ hybridisation. Three sections were collected onto
each slide.
2.2.3.3c. Tissue preparation
To preserve tissue morphology to the greatest extent possible while maximising access
of the probe to the target RNA, sections were fixed with cold freshly made 4% (W/V)
paraformadehyde in 0.1 M phosphate buffered saline (PBS: 20 mM NaH2P04, 80 mM
Na2HP04, pH 7.4) for 10 min. Paraformadehyde is an alkylating agent which
cross-links nucleic acid and protein to form a network within a cell; it provides a
superior retention of RNA in sections and maintains the morphology during the long
hybridisation and wash procedures. Fixation was carried out at 0-4°C for 10 min to
inhibit endogenous ribonucleases. Paraformadehyde fixative was removed by washing
5 min twice in 1 x PBS. Sections were treated with 0.25% acetic anhydride in 0.1 M
triethanolamine (pH 8.0) for 10 min. The aim of this 'acetylation' protocol is to reduce
the non-specific binding of negatively charged nucleic acid to positively charged tissue
and microscope slide by acetylating amino groups. The sections were washed in lx
PBS for another 5 min, then dehydrated through a series of ethanols (70%, 80%, 95%
prepared with DEPC-treated water, 2 min each); the slides were then air-dried.
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2.2.3.3d. Prehybridisation
Prehybridisation is to reduce the background originating from non-specific binding.
The tissue equilibrates with components of the hybridisation buffer, and 'sticky' sites
are blocked by components such as pyrophosphate and unlabel led RNA or genomic
DNA. Prehybridisation was carried out in a saline medium (0.3 M NaCl, 5 mM
Tris-HCl pH 7.5, 0.5 mM EDTA pH 7.5, 0.5 x Denhardt's solution, 0.25 mg/ml sheared
single stranded salmon sperm DNA, 0.05 mg/ml yeast tRNA and 50% v/v deionised
formamide) to reduce non-specific binding sites. Salmon sperm DNA was also been
used to cut down the background by binding the chromosomes competing with labelled
probe. The slides were placed flat on 3 M Whatman paper soaked in box buffer (50%
deionised formamide, 20% 20 x SSC (3 M NaCl and 0.3 M sodium citrate pH 7.0) and
30% DEPC-treated water) in a humidified chamber, and then incubated with 200 pi 1 x
prehybridisation solution for 2 h at 50°C.
2.2.3.3e. Hybridisation
After prehybridisition, the slides were dried around the tissue with lens paper. To each
slide was carefully added 200 pi hybridisation solution. Hybridisation solution
comprised 50% (v/v) of deionised formamide, radiolabeled probe (10 x 106 cpm/ml)
mixed with 2 x hybridisation solution (0.6 M NaCl, 10 mM Tris-Hcl pH 7.5, 1 mM
EDTA pH 7.5, 1 x Denhardt's solution, 0.1 mg/ml denatured salmon sperm DNA, 0.1
mg/ml yeast tRNA and 10% dextran sulphate), mixed at 70°C for 10 min. Briefly
cooled on ice, 1 M Dithiothreitol (10 pl/ml of probe) was added to this mixture.
Dextran sulphate may be useful to accelerate the rate of probe association and hence
effectively increasing probe concentration. After adding 200 pi hybridisation solution,
all slides were placed in a humidified hybridisation box, sealed and incubated overnight
(around 16 h) at 50°C.
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2.2.3.3f. Posthybridisation wash
After hybridisation incubation, washing of the hybridised sections was carried out to
remove probe that had bound to sequences related to, but distinct from, the intended
target (for example, for mRNA conserved gene families) or non-specifically to other
cellular components. The critical requirement is use of stringency conditions to remove
only the non-specifically bound probe and treatment of the sections with RNAse A is
also important to reduce background. The slides were washed in a total of 3 changes of
2 x SSC (5 min each) at room temperature. Immediately after this, 200 pil of RNase A
solution (30 pg/ml in RNase buffer containing 10 mM Tris-HCl pH 7.5, ImM EDTA
pH 7.5 and 0.5 M NaCl in ddlFO) was applied to each slide. The slides were incubated
at 37°C for 1 h, afterwards, the slides were progressively washed with more stringency,
beginning with a 30 min wash in 2 x SSC at room temperature. Subsequently slides
were washed in 0.1 x SSC at 60°C for 90 min followed by another wash in 0.1 x SSC
starting at 60°C and allowed to cool to room temperature. The slides were then
dehydrated in a series of 50%, 70% and 90% ethanol in 0.3 M ammonium acetate for 2
min each and allowed to air dry.
2.2.3.3g. Visualisation of signal
Following post-hybridisation washing, the slides were apposed against Hyperfilm-|3
max for an appropriate time determined for each probe. The films were developed with
D-19 for 5 min, rinsed briefly in ddfTO, fixed in a 1:4 dilution of Ilford Hypam rapid
fixer for another 5 min and washed in ddH20 for 30 min. All development steps were
carried out at 15°C in a dark room.
2.2.3.3h. Quantification of autoradiographs
Analysis of autoradiographic film images was performed with a microscope (objective
x 5) linked to a computer based image analysis system. Film grain density was
measured (5x obj. in a 0.53 x 0.53 mm and 0.15 x 0.15 mm frame for the sections from
rats and mice respectively), placed over 2 regions per section. For each animal,
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measurements were made on six replicate sections. Background measurements were
made on areas adjacent to the pituitary and subtracted. The results are expressed as
silver grain density (ie. grain area per mm2).
Figure 2.2 Radioactive Curve
Estimated Tissue Equivalent Radioactive (kBq/g)
Standards curve of the film grain density was obtained by exposing the 14C polymer
strip (Amersham Pharmacia Biotech, UK) standard slides along with the samples for
the same time. The graph above is one example of estimated tissue equivalent
radioactivity and film grain density after film was exposed to the 14C standard slide for
14 days. In all in situ hybridisation slides we measured, grain density was in the
dynamic slope part of the standard curve, where the density changes quickly with the
change of quantity of labelled radioactive.
2.2.3.3.1 Preparation of competent E.coli: for riboprobe preparation
Bacteria treated with ice-cold solutions of CaCl2 and briefly heated were used to
transform bacteria with plasmid DNA (Cohen et al., 1972). This treatment induces a
transient state of "competence" in the recipient bacteria, during which they are able to
take up DNAs derived from a variety of sources.
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DH 5a (parental E Coli strain) was streaked from a stock onto a LB agar plate (Lennox
L Agar 35 g/L in ddhLO, autoclaved and cooled to form gel in the petri plates), and
incubated for 16 h at 37°C. Several well-isolated colonies were transferred into 250 ml
autoclaved 2 x TY (bacto-tryptone 1.6%, bacto-yeast extract 1% and NaCl 0.5%, pH
7.0 in ddLBO). The cells were grown in a shaking incubator at 37°C for 2-2.5 h until
they were in the mid-log phase detected as cloudiness and cloudy on swirling. Then this
solution was poured into four 50 ml falcon tubes, centrifuged at 3000 rpm for 10 min at
4°C, supernatant removed and pellet re-suspended in 250 ml ice cold 50 mM CaCB.
The solution was cooled on ice for 15 min, centrifuged as before and re-suspcndcd in 20
ml ice cold freezing mix (100 mM KC1, 50 mM CaCh, 10% glycerol (w/v), 10 mM
KOAc, autoclaved, pH 7.5). 200 pi aliquots were taken into sterile screw-cap
Eppendorfs placed on dry ice and stored at -70°C until use.
2.2.3.3.2 Transformation of competent E.coli
About 0.5 pg plasmid DNA was added into 200 pi competent cells (DH-5a E.coli) in an
incubation tube and mixed by swirling the tube gently several times and placed on ice
for 30 min (during this stage the cells take up the DNA). The tube was held in a water
bath (42°C) for 75 seconds (heat shock) and rapidly transferred onto ice to cool down
the contents to room temperature. 0.4 ml 2 x TY was added to the tube and incubated in
a shaking incubator for 30 min at 37°C. After incubation, 200 pi cells were transferred
onto an Ampicilllin plate (Lennox L Agar 35 g/L in ddtLO, and 50 mg/ml Ampicillin,
pH 7.0 in ddH20, autoclaved and cooled to form gel state). This plate was incubated
upside-down at 37°C for 12-16 h.
2.2.3.3.3 Extraction and preparation of plasmid DNA
The extraction of plasmid DNA was achieved by using a commercially available kit
(QIAgen, Germany). Briefly, after incubation, a single colony was picked from the
plate above and incubated first in 1.5 ml 2 x TY solution for 4-5 h, then transferred to
and grown in 50 ml autoclaved 2 x TY solution in a shaking incubator (300 rpm)
overnight. On the following morning the bacteria cell solution was centrifuged at 6000
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g for 15 min at 4°C. The supernatant was carefully removed and the bacterial pellet
re-suspended in 4 ml of buffer PI (50 mM Tris.Cl, pH 8.0, 10 mM EDTA, 100 pg/ml
RNase A) and mixed well by pipetting. Then 4 ml buffer P2 (200 mM NaOH, 1% SDS)
was added, mixed gently by inverting 4-6 times and this mixture was incubated at room
temperature for 5 min. Then 4 ml pre-chilled (4°C) buffer P3 (3 M potassium acetate,
pH 5.5) was added, mixed immediately and gently, and incubated on ice for 15 min.
After this incubation, the solution was centrifuged at 20,000 g for 30 min at 4°C and the
supernatant was re-centrifuged at 20,000 g for 15 min at 4°C. The supernatant was
applied to an equilibrated QIAgen-tip 500 (by a solution containing 750 mM NaCl, 50
mM MOPS, pH 7.0, 15% isopropanol), washed twice with 10 ml buffer QC (1.0 M
NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol). Plasmid DNA was then eluted with 5
ml of buffer QF (1.25 M NaCl, 50 mM Tris.Cl, pH 8.5, 15% isopropanol), precipitated
by adding 3.5 ml of isopropanol and centrifuged at 15,000 g for 30 min at 4°C. The
DNA pellet was washed with 2 ml 70% ethanol and centrifuged again at 15,000 g for 10
min, then the supernatant was carefully removed. The pellet was air-dried, dissolved in
an appropriate volume of ddHiO and stored at -20°C. The concentration of plasmid was
determined by measuring the absorbance at 260 nm wavelength (1 OD260 = 50 pg/ml
DNA).
2.2.3.3.4 Plasmid linearisation
The double-stranded DNAs were digested with a restriction enzyme to generate the
linear DNA. The resulting single-stranded DNAs were used as a template. Plasmid
DNA templates were completely cleaved, since trace amounts of supercoiled plasmid
DNA result in the generation of extremely long transcripts that include plasmid
sequences. These long transcripts incorporate radiolabel and increase background
hybridisation.
Rat glucocorticoid receptor (rGR)
The pGEM3 plasmid containing a 620 bp fragment of rat glucocorticoid receptor (rGR)
cDNA was linearised by incubation with either Ava I or EcoR I to generate the
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antisense or sense DNA fragments, respectively, for 2 h at 37°C. The plasmid was a
kind gift from Prof. JR.Seckl, Edinburgh, UK (Miesfeld et al., 1986).
Rat corticotropin-releasing hormone receptor 1 (rCRHRl)
The pGEM4Z plasmid containing a 606 bp fragment of rat corticotropin-releasing
hormone receptor 1 (rCRHRl) cDNA was linearised by incubation with either Hind III
or EcoR I to generate the antisense or sense DNA fragments, respectively, for 2 h at
37°C. The plasmid was a kind gift from Dr.Stephen J.Lolait, Bristol, UK (Perrin et al.,
1993).
Rat vasopressin receptor lb (rVlb)
The Bluescript II KS (+/-) plasmid containing a 464 bp fragment of rat vasopressin
receptor lb (rVlb) cDNA was linearised by incubation with either Hind III or EcoR I to
generate the antisense or sense DNA fragments, respectively, for 2 h at 37°C. The
plasmid was a kind gift from Dr.Stephen J. Lolait, Bristol, UK (Lolait et al., 1995).
Human corticotropin-releasing hormone-binding protein (CRHBP)
The Bluescript II KS (+/-) plasmid containing a 969 bp fragment of human
Corticotropin-releasing hormone-binding protein (hCRH-BP) cDNA was linearised by
incubation with either Xho I or Sac II to generate the antisense or sense DNA
fragments, respectively, for 2 h at 37°C. The plasmid was a kind gift from Prof. P.
Lowry, Reading, UK (Potter et al., 1991).
2.2.3.3.5 Phenol/chloroform extraction of plasmid
To remove proteins (enzymes), the templates were purified by extracting with
phenol:chloroform. To the template in a 1.5 ml Eppendorf tube, an volume equal to the
plasmid solution of phenol:chloroform:alcohol (24:25:1) was added, mixed vigorously
by inversion. The mixture was centrifuged at 12000 g for 5 min, the aqueous (upper,
containing DNA) phase was carefully removed and transferred to another 1.5 ml
Eppendorf. One volume phenol:chloroform (24:25) was added to this DNA solution,
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mixed vigorously by inversion, and centrifuged at 12000 g for 5 min. The upper
aqueous phase was removed carefully to a fresh Eppendorf tube, 0.1 volume of 3 M
sodium acetate (pH 4.8) and 2.5 volumes of absolute ethanol were added, and mixed by
inversion. This mixture was frozen on dry ice for 10 min. Then it was thawed and
centrifuged at 12000 g for 15 min and the supernatant was removed. The pellet was air
dried and re-suspended in appropriate volume of DEPC-treated H2O; 1 pi of the DNA
was electrophoresed on 1% agarose gel to check the purity of the linearised plasmid.
The remaining template was stored at -20°C.
2.2.3.3.6 In vitro transcription of 35S-UTP labelled cRNA probe
Sense and anti-sense hybridisation were used as a control procedure for in situ
hybridisations with riboprobes. Riboprobes were synthesised by transcription using
cDNA as a template. Antisense riboprobes were from cDNA inserts subcloned in the
transcription vector in the 3' to 5' direction relative to an RNA polymerase initiation
site. The anti-sense transcribed in the presence of a labelled nucleotide probe is
complementary to the cellular mRNA and binds to it during the hybridisation
incubation. Insertion of the cDNA in the opposite orientation relative to the RNA
polymerase initiation site transcribes the control sense riboprobe, a sequence identical
to the mRNA in the tissues which does not hybridise to this mRNA. As the sense and
anti-sense probes contain the same relative proportion of all of the nucleotides (A/Us or
G/Cs) in the same sequence, sense probe is an appropriate control (Cox et al, 1984). 1
fig of each of the linearised templates was incubated with 1.5 jil of mixed cold
nucleotides (10 mM of ATP, CTP and GTP), 0.5 |il of 200 mM freshly-made DTT, 0.5
jal of RNase inhibitor, 4 pi of 35S-UTP (40 mCi/1 ml), 1 pi of the specific RNA
polymerases in the presence of 5 x transcription buffer in a volume of -10 pi. The
reaction was carried out in an RNase-free Eppendorf tube. The incubation was carried
out at 37°C for T3 and T7, and 40°C for SP6 polymerases for approximately 1 h. After
the incubation, 1 pi of RNase-free DNase was added to the reaction mixture and
incubated for a further 15 min at 37°C. The reaction was stopped by placing the tube on
ice. The newly synthesised probe was purified through a Nick column (Sephadex G
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50). The column was first washed with 3 ml of TE, pH 8.0 in order to equilibrate the gel
bed. The reaction mix was applied to the column followed by 400 pi of TE buffer was
applied to the column and the eluant collected, as this contained the labelled probe.
2.2.3.3.7 Agarose gel electrophrosis
1% agarose was added tolOO ml lx TBE buffer (0.09 M Tris-borate, 0.002 M EDTA,
pH 8.0) in a baked flask and heated to dissolve the agarose. The solution was cooled to
55°C, and 3 pi of 10 mg/ml ethidium bromide was added. Enough lx TBE buffer was
added to cover the gel to a depth of about 1 mm. DNA samples mixed with gel loading
buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, and 40% (w/v) sucrose in
water) were loaded into the slots of the submerged gel. DNA migrated toward the anode
under an applied voltage of 100 mV. Electrophoresis was stopped when the
bromophenol blue and xylene cyanol FF migrated the appropriate distance through the
gel. The DNA bands in the gel were examined by ultraviolet light.
2.2.3.3.8 Polyacrylamide gel electrophoresis
To check the purity of radiolabelled riboprobes, we ran polyacrylamide elecrophoresis
and only those labelled probes showing clear bands on the film were used in in situ
hybridisation.
We prepared 10 ml 4% polyacrylamide gel with a SequeGel kit by mixing 1.6 ml
SequaGel Concentrated solution (23.75% w/v acrylamide, 1.25% w/v methylene
bisacrylamide and 8.3 M urea), 7.4 ml SequaGel Diluent solution (8.3 M urea), 1 ml
SequaGel Buffer (8.3 M urea in 1.0 M tris-Borate-20 mM EDTA buffer pH 8.3), 80 pi
10% (w/v) ammonium persulfate and 4 pi Temed. Gels were run for 2 h at 120 V in 1 x
TBE buffer (0.09 M Tris-borate, 0.002 M EDTA, pH 8.0) and autoradiographed.
2.2.3.4 In situ hybridisation with oligonucleotides
The method for in situ hybridisation with oligonucleotides is slightly different from that
for riboprobes. POMC antisense oligonucleotides were 48 base pairs complementary to
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part of the mRNA sequences coding for POMC peptides (Nakanishi et al. 1981). 48
base pairs of BK antisense oligonucleotides that were randomly complementary to the
mRNA sequences coding for non-STREX of BK (Shipston et al. 1999) were selected.
48 base pairs of STREX antisense oligonucleotides that were randomly complementary
to the mRNA sequences coding for STREX splice of BK (Shipston et al. 1999) were
selected. As the technique of ia situ hybridisation with the POMC oligonucleotide
probe is well established in our lab, we did not use a sense probe as a control in this
study. In BK and STREX mRNA measurements, we employed sense oligonucleotide
probe as control.
2.2.3.4.1 Preparation of coated slides and tissue collection
Slides were treated in chromic acid (200 g potassium dichromate, 2000 ml ddfTO, to
which 20 ml concentrated sulphuric acid slowly added) overnight, then rinsed
completely with cold running water for a few hours. Slides were mounted into racks,
rinsed in three changes of ddfbO then once in DEPC-treated ddtEO (1 ml diethyl
pyrocarbonate, 1000 ml ddHbO, autoclaved), dipped in 80% alcohol (in DEPC treated
water). The slides were dried in a 60°C oven and cooled to room temperature, then
dipped in chrome-alum/gelatin subbing solution (2.25 g gelatin and 0.23 g chromic
potassium sulphate in 800 ml distilled water) for 2 min, and placed on clean paper
towelling to drain and air-dried. The next day, each rack of slides was dipped briefly in
the subbing solution again. Dried slides were stored in dry, clean slides boxes until
required. The method of tissue collection for oligonucleotide probe was the same as
that for riboprobe (see 2.2.3.3c)
2.2.3.4.2 3'-end labelling of oligonucleotide probe
3' terminal labelling utilises the ability of terminal deoxynucleotidyl transferase (TdT)
to add on deoxyribonucleotides to the 3' ends of oligonucleotides. This allows the
addition of labelled nucleotides. In this study, we use a terminal transferase kit to label
the oligonucleotide probes. 27 pi ddPEO, 10 pi 5 x TdT buffer, 5 pi CoCE, 5 pi j5S
dATP and 2 pi oligonucleotides were mixed in a 0.5 ml Eppendorf tube, and 1 pi TdT
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enzyme added. The mixture was ensured by pippeting and was incubated in a 37°C
water bath for 1 h.
2.2.3.4.3 Purification of radiolabeled oligonucleotides
The radiolabeled oligonucleotides were purified with a QIAquick nucleotide removal
kit. The Eppendorf tube containing radiolabeled oligonucleotide probe was removed
from the water bath and 500 pi PN buffer added. The contents of the eppendorf were
transferred transfer to a spin column placed inside a 2 ml centrifuge tube. The solution
was centrifuged at 6000 rpm for 1 min. The inner column was remove and put into a
fresh centrifuge tube, 500 pi PE buffer was added and centrifuged at 6000 ipm for 1
min. Another 500 pi PE buffer was added and centrifuged at 13000 rpm for lmin. The
spin column was placed in an autoclaved eppendorf tube and 50 pi ddE^O was
carefully added to cover the resin filter in the base of the column. The labelled probe
was eluted by centrifugation at 13000 rpm for 1 min. The labelled probe was counted
by counting a 2 pi sample in 3.5 ml scintillation fluid with a P~ scintillation counter and
stored at -20°C.
2.2.3.4.4 Prehybridisation
Cryostat cut pituitary sections were removed from the -70°C freezer in their boxes
(keeping the lids on to prevent condensation) and dried at room temperature for 1-2 h.
The dry slides were placed in racks and passed through the following series: 5 min in
4% formaldehyde in 0.1 M PBS (pH 7.2), 5 min in 0.1 M PBS twice, 10 min in
triehanolamine/acetic anhydride (0.75 ml acetic anhydride, 4.47 ml triethanolamine,
1.26 ml 10 M HC1 in 300 ml autoclaved ddPbO), 2 min in ddPbO, 2 min in 70%
ethanol, 2 min in 95% ethanol, 1 min in 100% ethanol, 5 min in chloroform to delipidate
tissue, 2 min in 100% ethanol, 1 min 95% ethanol, then air-dried thoroughly.
To each slide was carefully added 45 pi hybridisation solution followed by incubation
overnight in a sealed humidified hybridisation box at 37°C. Hybridisation solution
comprised 50% (v/v) of deionised formamide, radiolabeled probe (0.1 x 10° cpm per
76
Materials and methods Chapter 2
pituitary section) mixed with 2 x hybridisation solution (1.2 M NaCl, 10 mM Tris-HCl
pH 7.6, 1 mM EDTA pH 7.5, 1 x Denhardt's solution, and 2.5% dextran sulphate, DTT,
0.1 mg/ml denatured salmon sperm DNA, 0.1 mg/ml yeast tRNA, 0.1 mg/ml yeast
tRNA, 0.1 mg/ml yeast total RNA, 0.1 mg/ml poly (A), and 50% v/v formamide).
2.2.3.4.5 Posthybridisation and visualisation
After hybridisation incubation, washing of the hybridised sections was carried out. The
slides were washed in four changes of 1 x SSC at 45°C (15 min each). Subsequently
slides were washed in 1 x SSC at room temperature for 30 min twice, followed by
rinsing in ddH^O and air-dried.
Visualisation of signal and Quantification of autoradiographs for oligonucleotide
probes are the same as for riboprobes.
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Chapter 3
In situ hybridisation studies of selected mRNA
species related to corticotroph function in
the anterior pituitary in pregnancy
3.1 Introduction
CRH and vasopressin are the two major ACTH secretagogues from the hypothalamus
and their actions are mediated by CRHR1 and Vlb receptors on the corticotrophs
respectively. Vasopressin alone is a less effective stimulator of ACTH secretion in
rodents, but is the most potent among the co-secretagogues that acts synergistically
with CRH to induce ACTH secretion from the anterior pituitary (Gillies et al. 1982).
Previous studies indicate reduced CRH receptor binding to corticotrophs in pregnancy
(Neumann et al. 1998). Decreased vasopressin binding to the anterior pituitary has
been reported at the end of pregnancy (Toufexis et al. 1999), but CRHR1 and Vlb
receptor mRNA expression has not been measured.
The inhibitory effects of corticosterone on HPA axis function are believed to be
transduced primarily by intracellular steroid receptor proteins that function as
hormone-activated transcription factors, GR and MR. In the anterior pituitary, GR is
the main receptor to mediate the negative feedback effects of corticosterone (Herman
et al. 1989; Ozawa et al. 1999). There is already an indication, from measurement of
increased 113-HSD activity in the anterior pituitary in pregnancy (Johnstone et al.
2000), of enhanced corticosterone negative feedback. Increased GR expression could
contribute to increased feedback sensitivity. Measurement of changes in anterior
pituitary POMC mRNA expression after removal of corticosterone would be valuable
to understand negative feedback exerted by glucocorticoids during pregnancy.
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The POMC gene encodes a common precursor protein for a family of peptides
including ACTH (Lowry et al. 1980; Chretien & Seidah 1981; King & Baertschi
1990). In corticotrophs, POMC is cleaved into ACTH, (3-lipotropin ((3-LPH) and
small amounts of (3-endorphin (Lazarus et al. 1976; Lowry et al. 1980; Chretien &
Seidah 1981; Lundblad & Roberts 1988; King & Baertschi 1990). Reduced POMC
gene expression in corticotrophs in pregnancy might underlie the reduced ACTH
secretory response.
In corticotrophs, CRHBP is mainly associated with secondary lysosomes,
multivesicular bodies, and endosome-like vesicular structures. This suggests that
CRHBP is in a position to participate in the signal transduction of the CRH-CRH
receptor complex. CRHBP facilitates the dissociation of the complex, with
consequent freeing of the receptor for recycling to the cell surface, and/or acting as
chaperone to direct internalised CRH to the lysosomal system of digestion (Peto et al.
1999). CRHBP is not in secretory granules in the pituitary cells, suggesting that it is
not co-secreted with ACTH (Peto et al. 1999). Altered CRHBP expression might lead
to altered CRH action on corticotrophs in pregnancy.
The release of ACTH induced by CRH from the corticotrophs is largely dependent on
cAMP-mediated stimulation of Ca2+ influx through voltage-gated L-type Ca2+
channels (Luini et al. 1985; Guerineau et al. 1991). CRH-induced membrane
depolarisation is due, in part, to inhibition of large-conductance Ca2+-activated K+-
channel (BK-channel) by PKA. The secretion of ACTH stimulated by vasopressin
through the IP pathway requires extracellular Ca2+ influx through L-type voltage-
sensitive Ca2+ channels (Nishizuka 1984; Won et al. 1990). This increased
intracellular Ca2+ then triggers the ACTH secretion from the corticotrophs. A splice
variant of the BK channel a-subunit, stress axis regulated exon (STREX), was
identified and subsequently cloned in AtT20 cells (Shipston et al. 1999). The a-
subunit containing this splice variant is inhibited by cAMP-mediated protein
phosphorylation. In AtT20 cells, about 90% of endogenous BK channels are
comprised of the high calcium sensitive STREX splice variant. However, the
proportions of the BK channels containing the STREX splice in rat corticotrophs, and
the changes of this proportion in the pregnancy state, are not known.
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3.2 Aims
During pregnancy, the ACTH response(s) to stress are attenuated, which may be
partly due to changes in corticotroph sensitivity, including sensitivity to decreased
stimulatory effects and/or increased inhibitory effects. So the knowledge of
expression of the factors that mediate stimulatory (CRHR1, Vlb receptor), or
inhibitory (GR, CRHBP, BK channels and STREX) responses in the corticotrophs is
valuable to understand the mechanism of ACTH secretion regulation during
pregnancy. Measurement of the expression of POMC gene which encodes the
precursor of ACTH would provide some evidence of changes in ACTH synthesis, and
thus secretion.
In this study, to seek changes in expression of mRNA species that may underlie
altered responsiveness of corticotrophs to secretagogues in pregnancy, we measured
the mRNAs of these proteins by in situ hybridisation.
3.3 Materials and methods
The animals were housed in the animal facility (MFAA) in the University of
Edinburgh Medical School. For details see Chapter 2.1.E For CRHR1, Vlb receptor,
GR, POMC, BK and STREX mRNA measurement, individually housed virgin, day
10 and day 21 pregnant rats, or virgin and day 18 pregnant mice were transferred
separately to the post mortem room where they were decapitated between 09.30 h and
10.30 h to minimise the acute effects of stress. The pituitaries were rapidly removed,
immediately frozen on dry ice and stored at -70°C. CRHBP attenuates ACTH
secretion stimulated by CRH (Behan DP 1989; Linton et al. 1990), so it is valuable to
investigate whether CRHBP expression is changed in pregnant rats at basal level
compared with in virgin rats. The changes of CRHBP mRNA are very rapid in the
anterior pituitary (significantly increases with 30 min) (McClennen et al. 1998), so it
permits us to measure this gene expression after stress in the morning. Virgin and
pregnant (day 21) rats were restrained in a cylinder (ID: 70mm) for 30 min between
08.00h and 10.30 h. One hour after restraint stress, all rats were killed and pituitaries
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were removed, frozen on dry ice and stored at -70°C. Control rats were left in their
cages and killed at the same time when the stressed rats were killed.
Enhanced corticosterone negative feedback may exist in pregnant rats (Johnstone et
al. 2000). To test whether attenuated ACTH response to stress is due to a greater
inhibition of POMC mRNA expression by elevated plasma corticosterone
concentration in late pregnancy, we removed endogenous corticosterone by
pharmacological adrenalectomy (phADX) (Plotsky & Sawchenko 1987). The
pituitaries were taken from virgin and pregnant rats prepared and treated by Paula
Brunton. To block glucocorticoid synthesis the rats were administered either 100
mg/kg metyrapone or saline vehicle subcutaneously at 8 h intervals over a 48 hour
period (beginning at 08.00 h on day 19 of pregnancy). The final metyrapone injection
(at 08.00 h on day 21 pregnancy) was followed 75 min later by a subcutaneous
injection of 200 mg/kg aminoglutethimide/dimethyl-sulphoxide) (Johnstone et al.
2000). Controls received vehicle injection. One hour after the last injection, all rats
were killed and pituitaries were removed and frozen on dry ice for in situ
hybridisation.
Coronal sections were cut at 14 |tm using a cryostat at -18°C, then mounted onto
gelatin (for oligonucleotide probes: POMC, BK and STREX) or poly-L-Lysine (for
riboprobes: CRHR1, Vlb receptor, GR, CRHBP) coated slides and stored at -70°C
until in situ hybridisation. Details of in situ hybridisation with oligonucleotide probes
or riboprobes, and film autoradiograph silver grain counting are in Chapter 2.2.3.
Statistics
Data were expressed as silver grain density mean ±SEM. Data from CRHR1, Vlb
receptor, GR, BK and STREX mRNAs were analysed with t-tests. Data from POMC
and CRHBP mRNAs were analysed with one-way ANOVA followed by post-hoc
Student-Newman-Keuls tests.
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3.4 Results
The signal in the sections incubated with the labelled sense probe was always much
less than that with the respective antisense riboprobe or oligonucleotide probe.
CRHR1 mRNA
CRHR1 mRNA expression (Figures 3.1a and 3.1b) in pituitaries from virgin and day
21 pregnant rats was measured by in situ hybridisation with a radiolabeled riboprobc.
There was signal in the anterior pituitary, and strong signal in the intermediate lobe,
but no signal in the posterior pituitary. The silver grain densities in virgin and day 21
pregnant rat anterior pituitaries were not different (t-test, p=0.92; virgin, n=9;
pregnant, n=7).
VI b receptor mRNA
With a radiolabeled probe corresponding to the 5' end UTR sequence of the Vlb
receptor gene, Vlb receptor mRNA expression reflected by silver grain density was
detected to be in the anterior pituitary. By semi-quantitative measurement, Vlb
receptor mRNA expression was decreased by 19% in the anterior pituitary from day
21 pregnant rats (Figures 3.2a and 3.2b, t-test, *p<0.05 vs virgin, t-test; virgin, n=9;
pregnant, n=7).
GR mRNA
GR mRNA was found abundantly in the anterior and intermediate pituitary, and
expression in the anterior pituitary in pregnant rats was increased by 26% compared
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POMC mRNA
Figures 3.4a and 3.4b show anterior pituitary POMC mRNA expression in virgin and
pregnant rats. Silver grain density was quantified in film autoradiographs of anterior
pituitary section hybridised with a radiolabeled oligonucleotide probe. POMC mRNA
expression was significantly reduced in day 21 pregnant rats (by 45%, *p<0.0001 vs
virgin, one-way ANOVA; virgin, n=16; pregnant day 10, n=9; pregnant day 21,
n=18). As the technique of in situ hybridisation with the POMC oligonucleotide probe
is well established in our lab, we did not use a sense probe as a control in this study.
Effect ofphADX on anterior pituitary POMC mRNA expression
Anterior pituitary POMC mRNA expression in vehicle-treated controls was reduced
in pregnancy (Student's t-test, p<0.05, but one-way ANOVA on all four groups did
not show a significant difference). After 48 h pharmacological adrenalectomy POMC
mRNA expression was elevated in both virgin and pregnant rats (p<0.05, one-way
ANOVA), but the increase was greater in virgin rats (Figures 3.5a and 3.5b).
BK channel mRNA and STREX tnRNA
Anterior pituitary BK channel and STREX mRNA expression in the anterior pituitary
was evaluated in virgin and pregnant mice. Silver grain density was measured in film
autoradiographs of hybridised anterior pituitary sections. Neither BK channel nor
STREX mRNA expression was changed in day 18 pregnant mice compared with
virgins (Figures 3.6a, 3.6b, 3.7a, 3.7b and 3.8; values are means ±SEM; virgin, n=7;
pregnant, n=8).Using oligonucleotides probes, we measured the BK channel and
STREX mRNA expression in virgin and pregnant anterior pituitaries in both rat and
mouse species. The reason for measuring expression of these two genes expression in
mice is because most of the literature on their function is about studies on AtT20
cells, a mouse corticotroph tumor cell line. ACTH secretory responses to stress are
reduced in pregnant mice as in pregnant rats (Douglas et al. 2001a; Douglas et al.
2001b). In the present study, BK channel and STREX mRNA expression in rats and
mice showed a similar pattern. Expression of neither was different between virgin and
pregnant rats (Figures 3.9a, 3.9b, 3.10a, 3.10b and 3.11; values are means ±SEM; t-
test, p>0.05; virgin, n=5, pregnant, n=8).
89
Figure3.4aAnteriorpituitaryPOMCmRNAexpressioni rats














Figure3.4b,POMCmRNAexpressioninthant riorpi u tarycollectedfromv gi ,d y10nd21 pregnantrats.Filmautoradiographsofpituitarysecti nsbedwith35Soligonucleo i erobefPOMC mRNAwereanalysedbcomputer-bas dim geanal isys mtme sur filverg ins,ndhd ta expressedamean±SEMsilvergr indensityov ru ta ea.Ant riopituitarPOMCmRNAexpr ssioni y 21pregnantrats(n= 8)wareducedcomparithvi in( 6,on yANOVA*p<0.001)a dd y1 pregnantrats(n=9,onewayANOVA,#p<0.001)
Figure3.5aPhADXonanteriorpi u taryOMCmRNAexpressionpregna trats

















Figure3.5b.POMCmRNAexpressionnthanteriori u tarycoll c edfr m48phar acologicaladrenalectomised (phADX)orvehicletreatedvirginand y21pre nantrats.F lmutoradiographsfpi ui arys ctionspr bedw35S riboprobesofPOMCmRNAweranalysedbc mputer-basedi geanaly issy t mtm a urear afsilverrains, andthed taexpr ssedmean±SEMsilv rg ind ityo runrea.POMCmRNAxpressionw seducedi pregnancy(Stud nt'st-t st,<0.05,butone-wayANOVAallf urgroupsdidotshowignific ntdifferen e).Af er 48hphADXPOMCmRNAexpressionwaselevatedinbothvirgianre nantts(p<0.05,o -wayANOVA),but e increasew sgreatervirginat .*p<0.05virginphADXts;#p<0.05resp ctivevehicl -treateda s.




Figure3.6aRepresent tiveautoradiographsfrominsituhybridi tionist chemistryf pituitarysectionshybridisedw h35S-la elles nsea dntisenseoligonucl tidpr bef rBK channelmRNA.AandBwerehybridisedithla elles sriboprobefromv rgiandd y18 pregnantmicerespectively;CandDw rehybridisedthla ellanti ensriboprobfrom virginandd y18pregnantmicerespectively.Sc lb r=0.5m(obj ctiv :5x).
Figure3.7aAnte iorpituitarySTREXmRNAxpr ssionpregn tm ce
LT\
fsfcftt-ii-U.AA*' «W ,v.>" .'v rW'Wi'iZ V-*"'
?<•'w.K•• -r.fc/fA.' .'Ay ...' .i- -...■ )rA--. '.
Figure3.7aRepresentativea toradiographsfromi uhybridis ionistoch mistryfp t itasecti s hybridisedwith35S-la ellsenseant enseoligo ucleotideprob sf rSTREXmRNA.AaBw r hybridisedwithla ellsenseriboprobefromvirginad y18pre nantmicre pectively;Ca dDw re hybridisedw thla elleantis nseiboprobfromvirginnday18pre antmicre p tively.Scalr= 0.5mm(objective:5x).










Figure3.9aRepresent tiveautoradiographsfrominsituhybridisa ionist chemi tryfp tuitaryec ion hybridisedw th35S-la elledsen eantisenseoligonucl otidp obesf rBKcha lmRNA.Aer hybridisedw thlabelledsenseriboprobfromvirginandd y21pr g a tatrespectively;CDwhyb idise withlabelledantis nseriboprobfromvirginndd y21pr gna tratsespectively.Scb=0.5m(obj ct : 5x).
Figure3.10aAnteriorpituitarySTREXmRNAxpressioni pr gna tts



















inratanteriorpi u tary 1







Figure3.9b,.10band1BKmRNAaSTREXexpressionithnt ri rpi u tarycoll ct dfromvirgind y2 pregnantrats.Filmautoradiographsofituitarysect nsrobedwith35Slig nucleoti eBKmRNAdSTREXw r analysedbcomputer-baseim g issystemthmeanr filv rg indd texpressedea ±SEMsilv rgr in densityperunitareofsection.Th rw reniffer c siBKSTREXmRNAxpr s on,ortr tSTREX/BKbetw n virginandpregna trats(n=5,8fortespectively,t-t>0.05)
In situ hybridisation studies ofselected mRNA svecies Chapter 3
CRHBP mRNA
Anterior pituitary CRHBP mRNA expression was measured with a 969 bp riboprobe.
CRHBP mRNA expression (Figures 3.12a and 3.12b) was found in the anterior
pituitary and there was no signal from the sense probe control. There was no
difference in CRHBP mRNA expression between virgin and pregnant rat anterior
pituitaries (one-way ANOVA, p>0.05). One hour after a 30 min restraint stress,
CRHBP mRNA was increased in both groups (one-way ANOVA, p<0.05), but with
no difference between virgin and pregnant rats (p>0.05; virgin non stress, n=5; virgin
stress, n=8; pregnant non stress, n=5; pregnant stress, n=8).
3.5 Discussion
CRHRl mRNA expression
Anterior pituitary CRHRl density measured by [l25I] CRH binding is decreased at the
late stage of rat pregnancy (Neumann et al. 1998). However, CRHRl mRNA
expression in the anterior pituitary in the present study did not change in pregnant rats
compared with virgin rats. This inconsistency between receptor and receptor mRNA
expression suggests that there is a difference in the post-translation regulation
between virgin and pregnant rats. This may be due to the difference in efficiency of
mRNA transcription, and/or mRNA and receptor degradation. In this respect, the
increased circulating corticosterone concentration in late pregnancy may play a role,
because some receptor mRNAs, such as insulin receptor, are more stable in the
presence of dexamethasone (Hines et al. 1994). The reduced CRH receptor number
previously reported may however partially account for the reduced in vivo ACTH
response to stress or CRH during pregnancy. However, in vitro, the ACTH response
to CRH is not decreased, but rather increased at low concentration (0.1 nM, see
Chapter 6). Hence, decreased CRH receptor binding in pregnancy could reflect
increased turnover.
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Previous combined in situ hybridisation and immunohistochemistry studies found
CRHR1 mRNA signals are located in the intermediate lobe and in subsets of anterior
pituitary cells. Although a few non-ACTH reactive cells are CRHR1 mRNA positive,
the majority of CRHR1 mRNA positive cells are ACTH reactive (Potter et al. 1994).
The CRH receptor is one of the primary targets for negative feedback on the pituitary
by glucocorticoids. The administration of dexamethasone causes a decrease in
corticotroph CRHR1 mRNA expression either in vivo or in vitro (Luo et al. 1995;
Makino et al. 1995; Pozzoli et al. 1996; Iredale & Duman 1997). Glucocorticoids can
inhibit CRHR1 mRNA expression directly (Pozzoli et al. 1996; Iredale & Duman
1997) or inhibit CRH and vasopressin expression in the PVN by negative feedback,
with a subsequent effect on CRHR1 expression in the corticotrophs. So it is
reasonable to consider that the unchanged CRH R1 mRNA at late pregnancy is
partially due to the counter-balanced chronic effects of modestly elevated
corticosterone concentration in the plasma (Atkinson & Waddell 1995).
CRH is an inhibitor of corticotroph CRHR1 mRNA expression (Pozzoli et al. 1996;
Rabadan-Diehl et al. 1997b). CRH mRNA expression in the PVN is reduced during
pregnancy, so it is proposed that portal blood levels of CRH decrease as well (see
Chapter 5). The consequent decreased inhibitory effect of CRH on anterior pituitary
CRHR1 mRNA expression, together with the prolonged direct inhibitory
corticosterone effect, could result in the unchanged CRHR1 mRNA expression in late
pregnancy.
The effect of vasopressin on CRHR1 mRNA expression in the anterior pituitary is
controversial. In vitro studies show vasopressin decreases CRHR1 mRNA expression
and augments the downregulatory effect of CRH (Pozzoli et al. 1996). However, in
vivo, chronic administration of vasopressin increases the levels of CRHR1 mRNA in
the anterior pituitary (Rabadan-Diehl et al. 1996). It is not known what is the possible
mechanism(s) of the vasopressin regulatory action on CRHR1 mRNA expression
during pregnancy.
The positive correlation between anterior pituitary CRHR1 and POMC mRNA levels
in saline and dexamethasone treated male Fischer rats (Zhou et al. 1996) was not
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found in the present study between the SD strain virgin and pregnant rats. This
disruption of the positive correlation suggests that there must be other factors except
corticosterone such as sex steroids that contribute to CRHR1 expression regulation
(Nappi & Rivest 1995).
Vlb receptor mRNA expression
Vasopressin is a weak ACTH secretagogue alone, but augments the effect of CRH
significantly. Vasopressin secreted from parvocellular neurones in the PVN is
secreted into portal blood from axon terminals in the external zone of the median
eminence, is responsible for ACTH stimulation (Antoni 1993). The ACTH
stimulation effect of vasopressin is mediated by Vlb receptors on the surface of
corticotrophs.
Vlb receptor is expressed in the majority of pituitary corticotrophs and only a small
proportion is in thyrotrophs (Michael et al. 1986; Lolait et al. 1995). The changes in
anterior pituitary vasopressin receptor and Vlb receptor mRNAs thus mainly
represent those in corticotrophs (Aguilera et al. 1994; Rabadan-Diehl et al. 1995;
Rabadan-Diehl et al. 1997a; Rabadan-Diehl & Aguilera 1998).
Toufexis et al have reported that anterior pituitary Vlb receptor density is reduced in
day 18 or 19 gestation rats in a [I25I]-vasopressin binding study (Toufexis et al. 1999).
To further investigate Vlb receptor mRNA expression we used in situ hybridisation
technique. The results showed that anterior lobe Vlb receptor mRNA expression was
decreased in pregnancy as well, which is consistent with the receptor density study.
Though at the end of pregnancy oxytocin content accumulated in the posterior
pituitary increases by 50% (Russell & Leng 1998), oxytocin leakage to the anterior
pituitary is supposed to be very low and oxytocin binds only weakly to Vlb receptor
(Lutz-Bucher B 1983), so it is unlikely that the reduced receptor density is due to
oxytocin occupancy. The expression of CRH and vasopressin mRNAs in the
parvocellular hypothalamus is reduced during pregnancy (Johnstone et al. 2000), so it
is apparent that the reduced receptor density in corticotrophs is not due to an increase
in occupancy by vasopressin, but to a decrease in receptor synthesis and/or enhanced
receptor degradation. The reduced Vlb receptor mRNA expression during pregnancy
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in the present study supports the former hypothesis. However, how the turnover rate
of Vlb receptor may be altered is not known.
Vasopressin stimulation of ACTH secretion is resistant to glucocorticoid negative
feedback (Abou-Samra et al. 1986; Bilezikjian et al. 1987). Indeed, Rabadan-Diehl et
al. reported glucocorticoid or dexamethasone administration in vivo or in vitro
potentiated vasopressin-stimulated inositol phosphate formation (Rabadan-Diehl &
Aguilera 1998). This glucocorticoid potentiation of IP formation is calcium
independent and involves increasing cellular levels of GTP binding protein in the
pituitary and facilitating Vlb receptor coupling with phospholipase C. So the reduced
Vlb receptor density and mRNA expression in the anterior pituitary may contribute to
the attenuated ACTH secretory responses during pregnancy, but the Vlb receptor
mRNA cannot be a major reason, because corticotrophs have a substantial pool of
spare Vlb receptor mRNA and the amount of this mRNA is not the primary
determinant of receptor content (Rabadan-Diehl et al. 1995; Rabadan-Diehl et al.
1997a) (see Chapter 6, in vitro CRH/vasopressin on ACTH secretion).
It could be that at the late stage of pregnancy, increased corticosterone secretion
(Atkinson & Waddell 1995) may increase the production of IP3 in corticotrophs in
response to vasopressin as well, and increase ACTH secretion as a consequence.
However, this increase in ACTH secretion may not compensate the possible reduced
vasopressin input from the PVN (Chapter 5) and the decreased receptor density on
corticotrophs.
Adrenalectomy and dexamethasone replacement studies show glucocorticoids up-
regulate Vlb receptor mRNA expression (Rabadan-Diehl et al. 1997a; Rabadan-Diehl
& Aguilera 1998). The increase in corticosterone during pregnancy clearly does not
have a net stimulatory effect on Vlb receptor mRNA expression in the anterior
pituitary, from the present study. The role of endogenous CRH and vasopressin in
regulating Vlb receptor mRNA expression is not clear. But chronic stress models
(repeated immobilisation, chronic hypoglycemia, and chronic psychosocial stress)
suggest that vasopressin positively regulates Vlb receptor mRNA. Hypothalamic
vasopressin mRNA expression in parvocellular CRH neurones and vasopressin, but
not CRH, release into the portal blood is increased in these models (de Goeij et al.
1991; de Goeij et al. 1992a; de Goeij et al. 1992b). Vlb receptor mRNA expression is
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reported to increase following daily immobilisation or intraperitoneal hypertonic
saline injection for 8-14 days (Rabadan-Diehl et al. 1995). However, acute
intraperitoneal hypertonic saline injection causes Vlb receptor mRNA expression to
decrease, which is prevented by vasopressin antagonist administration (Rabadan-
Diehl et al. 1995). Since vasopressin is secreted by the hypothalamus into the portal
circulation in a pulsatile fashion in the conscious sheep (Engler et al. 1989), the
divergence between inhibitory and stimulatory vasopressin effects on Vlb receptor
mRNA expression in chronic and acute models is considered to be the result of
different patterns of vasopressin secretion. So the vasopressin secretion pattern may
play a role in the reduced Vlb receptor mRNA expression, but it is difficult to know
the pattern of vasopressin secretion in rats. Decreased Vlb receptor mRNA
expression may be because of reduced gene transcription, but the possibility cannot be
ruled out of increased in-stability of receptor mRNA in the context of changes in
corticosterone, regulatory proteins and sex steroids during pregnancy.
GR mRNA expression
GR is expressed in a variety of cells within the anterior pituitary including 99% of the
growth hormone and ACTH cells, 67% of TSH cells, 93% of the folliculostellate cells
and 94% of the marginal layer cells (Ozawa et al. 1999). The measurements made on
the anterior pituitary in the present study reflect the overall change of GR expression
in these cell types.
Glucocorticoid, the end product of the HPA axis, is an important regulatory factor in
the ACTH secretory response. Corticosterone is considered to act on the
hippocampus, hypothalamus and pituitary to inhibit the HPA axis system. There are
dual receptor mechanisms that mediate this negative feedback. Occupancy studies
showed that GRs mediate the negative feedback of elevated glucocorticoid levels to
restrain HPA drive, whereas MRs mediate the tonic inhibitory control of the
hippocampus on HPA basal activity (de Kloet & Reul 1987; Reul et al. 2000).
At the anterior pituitary level corticosterone might influence POMC expression in
vivo at least at three levels: by alteration of stimulatory CRH input to the corticotroph,
by changing CRH receptor responsiveness of the corticotroph itself to CRH input, and
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by decreasing expression of the POMC gene. This inhibitory effect of glucocorticoid
is mediated by GR located within corticotrophs. Upon glucocorticoid entry into cells,
after intranuclear translocation, the GR-GR dimers are constituted. The receptor
dimers bind to glucocorticoid response elements (GREs) in the flanking region of
target genes and induce transcription of hormone-regulated genes (Trapp et al. 1994)
In late pregnancy the elevated plasma corticosterone levels (Atkinson & Waddell
1995) suggest a possible enhanced negative feedback mechanism. The results
reported by H A Johnstone et al. show that there is no change in PVN GR mRNA
expression, but an increase in dentate gyrus only among the hippocampus subareas
across pregnancy. However MR mRNA expression is not altered in the brain in
pregnant rats compared to virgins (Johnstone et al. 2000). Anterior pituitary GR
immunoreactivity in the cytosol measured by a western blot is increased in pregnant
ewes (Roesch & Keller-Wood 1999). In the present study, GR mRNA expression in
the anterior pituitary was increased near the end of pregnancy. It is not known during
pregnancy in which cell type(s) GR mRNA was expressed among the multiple cell
phenotypes of the anterior pituitary, including whether GR mRNA expression is
increased in corticotrophs. However, increased GR mRNA expression suggests an
increase in sensitivity of glucocorticoid negative feedback and a possible enhanced
inhibitory role in regulating ACTH secretion during pregnancy. In contrast with the
finding in this study, there is no change in GR in the rat pituitary assessed in a
[ H]dexamethasone binding study (Meaney et al. 1989) during the first two weeks of
lactation, which suggest that different regulation exists between the pregnant and
lactation states, permitting a sustained elevation in pituitary-adrenal activity during
lactation (Stern et al. 1973; Lightman 1992).
The mechanism(s) of altered GR expression during pregnancy are not clear. Anterior
pituitary GR gene expression is self-regulated by increased glucocorticoid
concentrations. Chronic corticosterone or dexamethasone administration increases
anterior lobe GR mRNA expression (Sheppard et al. 1990). 5 day small dose
dexamethasone replacement after adrenalectomy significantly increases GR mRNA
content (Sheppard et al. 1990). GR mRNA expression is also regulated by CRH In
vivo studies showed that adrenalectomy or CRH alone treatment does not change
pituitary GR binding capacity (McEwen 1979) or GR mRNA (Sheppard et al. 1990),
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whereas CRH decreases and dexamethasone increases GR mRNA in
adrenalectomised rat pituitary (Sheppard et al. 1990). In the AtT20 cell line, CRH
administration causes a rapid time-dependent decrease in GR mRNA levels that
precedes a dose- and time-dependent decrease in GR binding capacity. Treatment
with either forskolin or 8-bromo-cAMP, mimicks the CRH-induced decrease in GR
binding, and in addition forskolin decreased GR mRNA levels (Sheppard et al. 1991).
During pregnancy the decreased CRH mRNA expression (Johnstone et al. 2000),
reduced CRH content in the median eminence (Chapter 4) and increased basal
glucocorticoids (Johnstone et al. 2000) may cause the increased GR mRNA
expression in the anterior pituitary.
In the past 10 years, several studies suggest that sex steroids influence GR gene
expression. In the anterior pituitary, sex-dependent differences in corticosteroid
binding were assessed in individual pituitaries from adult male and female rats that
had been adrenalectomised 12 h before they were killed. Gonadally intact females
showed significantly less GR content than did intact males. When ovariectomised
females were compared with gondadectomised males, there was no difference in
receptor concentration. Estrogen was able to reverse the effect of ovariectomy:
ovariectomised females receiving estrogen had significantly fewer receptors than
intact males. Progesterone did not antagonise the effect of estrogen in the pituitary
(Turner 1990). Administration of 17P-estradiol completely reverses the ovariectomy-
induced increase in GR mRNA content of the pituitary gland (Peiffer & Barden
1987).
Estrogen increases amygdala (Peiffer et al. 1991), but decreases hippocampus and
pituitary GR mRNA expression (Carey et al. 1995; Turner 1990). Hypothalamic GR
mRNA levels increase after 17[3-estradiol treatment, and this increase is reversed by
progesterone (Redei et al. 1994). Progesterone can also regulate the binding of
glucocorticoids to GR by interacting with the GR binding domain (Roesch & Keller-
Wood 1999) to increase the dissociation rate of glucocorticoid from GR (Chou &
Luttge 1988).
In pregnant rats plasma progesterone levels are high until the day before partuition,
and estrogen level continues to increase. From the above studies, it seems unlikely
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that these sex steroids are responsible for increased anterior pituitary GR mRNA
expression in pregnancy.
As GR mRNA is not only expressed in the corticotrophs, but also in other cell types
in the anterior pituitary (Kononen et al. 1993; Ozawa et al. 1999), the present study
cannot rule out the possibility of increased GR mRNA expression in other cell types,
rather than in corticotrophs, during pregnancy.
POMC mRNA expression
POMC mRNA expression is mainly regulated by two ACTH secretagogues, CRH and
vasopressin, and by glucocorticoid negative feedback (Bruhn et al. 1984). In this
study, POMC mRNA expression in the anterior pituitary was reduced in day 21
pregnant rats, but not on day 10 of pregnancy compared with virgins. In late
pregnancy, portal blood levels of CRH and vasopressin are suggested to be decreased
from the in situ hybridisation studies that show that PVN CRH and vasopressin gene
expression at this time is reduced (Johnstone et al. 2000), and plasma glucocorticoid
levels are increased (Atkinson & Waddell 1995). The reduced stimulation and
increased negative feedback can be at least partly the reason for the reduced POMC
mRNA expression in pregnancy.
This presumed decrease in ACTH precursor suggests biosynthesis of ACTH may be
reduced in day 21 pregnant rats. However, POMC processing and/or ACTH secretory
patterns may change during pregnancy as well. The secretion of ACTH per 24 h near
the end of pregnancy is decreased as the afternoon rise in secretion is essentially
abolished (Atkinson & Waddell 1995). Furthermore, ACTH content in the anterior
pituitary and the secretory capacity are not decreased (see Chapter 6). Chronic
immobilisation and Brattleboro rat studies provide some support for changes in
processing. Chronic immobilisation increases pituitary POMC mRNA levels, while
does not change the basal ACTH levels of adrenalectomised rats, which suggests that
chronic stress might also alter POMC processing and/or ACTH secretory patterns in
the anterior pituitary in adrenalectomised animals (Marti et al. 1999). The results from
studies in homozygous (di/di) Brattleboro rats show that vasopressin does not change
pituitary POMC mRNA levels, but plasma ACTH and P-endorphin are reduced. This
is the evidence that vasopressin may also take a role in POMC biosynthesis, with
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decreased degradation or blunted release of POMC products from the pituitary
(Canny et al. 1988).
PhADX on anterior pituitary POMC mRNA expression
Anterior pituitary POMC mRNA expression in the vehicle treated pregnant rats was
less than that in vehicle treated virgin rats, which is consistent with the results above.
In late pregnancy, plasma corticosterone levels are increased in rats, which suggests a
mechanism of enhanced negative feedback by glucocorticoids may exist. In the
present study, after blocking corticosterone production by phADX, POMC mRNA
expression was elevated significantly in both virgin and pregnant groups. This
indicates that POMC mRNA expression in the anterior pituitary is under tonic
inhibition by glucocorticoids in both virgin and pregnant rats. Indeed, it is consistent
with the plasma ACTH concentration changes after phADX, where ACTH
concentrations were increased from about 9 pg/ml in both virgin and pregnant
vehicle-treated rats to about 65 pg/ml in phADX virgin rats and to only about 30
pg/ml in pregnant rats (PJ Brunton, unpublished, personal communication; measured
in the same groups of rats). Plasma corticosterone concentrations were greater in
vehicle treated pregnant rats (about 120 ng/ml) compared with vehicle treated virgin
rats (about 82 ng/ml); 48 h phADX did not block plasma corticosterone production
completely with still substantial levels of corticosterone in plasma (about 50 ng/ml
and 35 ng/ml in virgins and pregnant rats respectively (PJ Brunton, unpublished,
personal communication; measured in the same groups of rats). Pharmacological
adrenalectomy caused a greater reduction of corticosterone concentration in pregnant
rats (by 32 ng/ml and 85 ng/ml in virgin and pregnant rats respectively). However, the
increases in POMC mRNA expression were about the same in virgin and pregnant
2 2
rats after phADX (ca. 0.19 and 0.16 silver grain density mm"/mm", for virgin and
pregnant rats respectively). As plasma corticosterone concentration was lower in the
phADX pregnant rats than in the phADX virgin rats, this suggests, together with the
similar increases in POMC mRNA expression, that sensitivity of POMC mRNA
expression to glucocorticoid feedback inhibition is greater in pregnancy. Furthermore,
the greater elevation of plasma ACTH concentrations in phADX virgin than in
phADX pregnant rats also indicates greater slow feedback sensitivity of ACTH
synthesis and secretion to glucocorticoid in pregnancy. The increased anterior
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pituitary GR mRNA expression in pregnancy described above may underlie enhanced
glucocorticoid negative feedback in anterior pituitary corticotrophs in pregnancy.
BK channel mRNA and STREXmRNA
The release of ACTH from corticotrophs is largely dependent on stimulation of Ca2+
influx through voltage-gated L-type Ca2+ channels (Nishizuka 1984; Luini et al. 1985;
Won et al. 1990; Guerineau et al. 1991). The CRH-induced membrane depolarisation
is due to inhibition of BK-channel by PKA. The inhibition of BK channels leads to
increased intracellular calcium levels, with the consequence of ACTH release. A
splice variant of the BK channel a-unit, STREX, is the functional unit existing in
about 90% of BK channels (Shipston et al. 1999). In the present study, we did not
find a different expression of BK channel or STREX mRNA in the anterior pituitary
in pregnancy. These results suggest that the contributions of BK channels to the
regulation of corticotrophs are not different between virgin and pregnant.
CRHBP mRNA expression
In this study, CRHBP mRNA was detected in the anterior pituitary which is consistent
with a previous report (Potter et al. 1992). One hour after a 30 min restraint, CRHBP
mRNA expression in the anterior pituitary was increased 50% compared with the non-
stress groups in both virgin and pregnant rats. Previous studies show that CRHBP
gene expression in the anterior pituitary is positively regulated by CRH, cAMP,
stress, and glucocorticoids (Woods et al. 1994; Cortright et al. 1997; McClennen et
al. 1998). The mechanism of stress-induced elevated CRHBP mRNA expression is
not known. It may be due to the high levels of CRH, cAMP and glucocorticoids after
stress. However, we did not measure any difference in CRHBP mRNA expression
between virgin and pregnant rats before or after restraint stress. So even if CRHBP is
a regulator of the corticotroph response to stimulation by CRH, it may not be an
important factor in the attenuated ACTH response to stress during pregnancy.
The lack of a difference in the increase in CRHBP mRNA expression in the anterior
pituitary after stress between virgin and pregnant rats, in contrast with the attenuated
secretion of ACTH in pregnant rats, may reflect regulation of CRHBP mRNA
expression by glucocorticoid. The corticosterone response to restraint stress in
pregnancy is reduced, but it is attenuated much less than the ACTH response
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(Neumann et al. 1998). Hence, stimulation of CRHBP mRNA expression by
glucocorticoid may be similar in pregnant and virgin rats. CRH release may not be
changed in pregnant rats compared to in virgins after stress (Chapter 4), and cAMP
effect may be enhanced in pregnancy as suggested from secretion studies (Chapter 6).
All together, these factors may contribute to no changes in CRHBP mRNA expression
in the anterior pituitary.
Summary: in anterior pituitary glands from pregnant rats, there was no change in
CRHR1 gene expression, but decreased Vlb receptor mRNA expression. The latter
corresponds to a previously reported decrease in V lb receptor binding; but a previous
study found decreased CRH receptor binding. Together these changes might lead to
reduced effectiveness of CRH and vasopressin (see Chapters 4 and 5). No change of
BK channel and STREX mRNA expression suggests no change in the role of these
channels in regulating ACTH secretion. Reduced POMC mRNA expression probably
reflects reduced stimulation of ACTH secretion. Elevated GR gene expression
indicates an enhanced glucocorticoid negative feedback in the pregnant rats.
Expression of the mRNA for CRHBP, another factor indirectly inhibiting ACTH
secretion, and its stimulation by stress, are similar in pregnant rats as in the virgin
ones.
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Chapter 4
Role of CRH in ACTH secretion during pregnancy in vivo
4.1 Introduction
CRH is the major stimulatory regulator of pituitary ACTH secretion in rodents and its
effect on ACTH secretion is potentiated several times by vasopressin (Antoni 1986;
Gillies et al. 1982). CRH is synthesised in the parvocellular neurones in PVN of the
hypothalamus and is transported in the axons of these neurones projecting to the
median eminence and then is released into the portal vessels to regulate ACTH
secretion from the anterior pituitary (King & Baertschi 1990). CRH as a secretagogue
of ACTH secretion from corticotropins acts through specific plasma membrane
receptors, CRHR1. CRHR1 exists in corticotrophs and in discrete brain areas
including the cerebral cortex, several regions related to the limbic system and
peripheral tissues (Baigent & Lowry 2000; De Souza et al. 1985; Millan et al. 1987).
During pregnancy, the HPA axis responses to physical and emotional stress are
attenuated (Neumann et al. 1998). The effectiveness of exogenous CRH on ACTH
and corticosterone secretion is also reduced (Neumann et al. 1998). The sensitivity of
corticotrophs during pregnancy may be changed as suggested from receptor
autoradiography studies: CRH receptor binding in the anterior pituitary is decreased
in pregnant rats compared with virgins (Neumann et al. 1998; Toufexis et al. 1999).
Lower basal CRH mRNA expression in the PVN of pregnant rats suggests reduced
CRH availability for driving the secretion of ACTH (Johnstone et al. 2000).
To investigate the effect of CRH on ACTH secretion in vivo during pregnancy, we
prevented its action by administrating a non-peptide CRHR1 antagonist, N-butyl-N-
ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo[2,3-d]pyrimidine-4-yl]-
amine, antalarmin, to rats. Antalarmin is a pyrrolopyrimidine compound which has a
high affinity for the CRHR1 (Bomstein et al. 1998). It blocks CRH-stimulated ACTH
release (Webster et al. 1996) by acting on corticotroph CRHR1. Antalarmin also acts
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in the brain to delay parturition: fetuses infused with vehicle were delivered at a mean
gestational age of 141.8 ± 0.9 days compared with antalarmin-infused sheep at 148.8
±1.6 days (Chan et al. 1998). Behavioural responses are also modified by antalarmin:
in rhesus macaques, antalarmin inhibits the behaviours associated with anxiety and
fear such as body tremors, grimacing, teeth gnashing, urination, and defecation and
increases exploratory and sexual behaviours that are normally suppressed during
stress (Habib et al. 2000) and in rats, antalarmin impairs CRH-mediated the induction
or expression of conditioned fear by cold condition, and also impairs the enhanced
fear induced by exposing to inescapable shock (Deak et al. 1999). The release of CRH
from the hypothalamus may be changed during pregnancy, so CRH contents in the
median eminence may be crucial for CRH concentrations in the portal blood.
4.2 Aims
The studies in this chapter were to elucidate the roles of CRH in the attenuated ACTH
response to stress during pregnancy: whether reduced CRH release into the portal
blood from the hypothalamus may be the underlying mechanism of attenuated ACTH
responses to stress. CRH contents in the median eminence and hypothalamus were
measured to evaluate the stores of CRH in pregnancy.
4.3 Materials and methods
CRHR1 antagonist and stress-stimulated ACTH secretion
To study CRH action on ACTH secretion, individually caged pregnant and virgin
animals had a silastic jugular cannula implanted by the method as described in
Chapter 2.1.2.1. The experiment was carried out four to five days following surgery to
allow the animal to recover. On the day of experiment (day 21 of pregnancy), the
jugular cannula was flushed and connected to a syringe filled with sterile heparinised
saline (at 0800 h). Antalarmin (20 mg/kg, a kind gift from Dr. Manolis Zoumakis,
NIH, USA) or vehicle (1 ml/kg) was injected intraperitoneally at 08.30- 09.00 h; the
vehicle was 10% ethanol and 10% Cremaphor EL in double distilled water.
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Antalarmin was dissolved at 60°C and kept at this temperature. Two basal blood
samples (0.4 ml) were taken 60 min and 90 min after intraperitoneal injection. All the
rats were forced to swim for 90 s in deep water (19°C), and further blood samples
were taken after 5, 15 and 70 min. Each blood sample was collected into a tube
containing 15 pi 5% EDTA per 100 pi blood. Blood was replaced with 0.9% saline.
Blood samples were cooled on ice, centrifuged at 12,000 g for 5 min and plasma
separated and stored at -70°C until assayed.
ACTH stimulation by exogenous CRH
These rats were from the experiment in which the CRHR1 antagonist was used. 70
min after stress, all rats were injected with CRH 20 ng/kg (Neumann et al. 1998)
intravenously and blood samples were collected 10 min later. Immediately another
CRH (200 ng/kg) dose (Toufexis et al. 1999) was given and blood samples were
collected 10 min later. Each blood sample was collected into a tube containing 15 pi
5% EDTA per 100 pi blood. Blood was replaced with 0.9% saline. Blood samples
were cooled on ice, centrifuged at 12,000 g for 5 min and plasma separated and stored
at -70°C until assayed.
At the end of all of the experiments, the animals were killed by an intravenous
overdose of anaesthetic (Sagatal, 36 mg in 600 pi per rat) and pregnancy status
checked. ACTH concentrations were assayed with commercially available ACTH kits
from ICN, for details see Chapter (details in Chapter 2.2.2.5).
Median eminence and hypothalamic CRH content measurement
Pregnant and virgin animals were caged singly five days before use with food and
water available ad libitum. On the morning of the experiment (day 10 or day 21 of
pregnancy), immediately after the rat was decapitated, the median eminence and the
hypothalamus were dissected under a binocular microscope. The brain was placed on
a glass slide and the median eminence, with the attached pituitary stalk was separated
using microscissors. A block containing the hypothalamus was then prepared with a
scalpel blade (coronal cuts just anterior to the optic chiasma and caudal to the
mammillary bodies; sagittal cuts along the hypothalamic sulci, and a horizontal cut
just ventral to the thalamus). The median eminence and the hypothalamic blocks were
snap-frozen on dry ice, and later sonicated in a solution of 0.5 M acetic acid and 0.1
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M HC1. The median eminence contents were sonicated in 50 pi solution and the
hypothalamus contents in 250 pi. The sonicants were sent by airfreight on dry ice to
Prof. Pierluigi Navarra (Catholic University Medical School, Italy) for CRH
radioimmunoassay. The study on day 10 pregnant and virgin contents was several
months before the study on day 21 pregnant and virgin contents, but CRH
measurements were made in the same radioimmunoassay (Details are described in
previous reports (Dello et al. 2000; Navarra et al. 1991), with intra- and interassay
coefficients of variation of 5% and 10% respectively). CRH contents per median
eminence or hypothalamus were calculated by multiplying the radioimmunoassayed
CRH concentration by the respective sonication solution volume. The total
hypothalamic CRH content was calculated by adding CRH content of the median
eminence and that of the cognate hypothalamus together.
Statistics
Data from the study of CRH effects and of the CRHR1 antagonist on the ACTH
response to stress were analysed with two-way ANOVA for repeated measurements
followed by post-hoc Student-Newman-Keuls tests. Data about CRH content in the
hypothalamus were analysed with t-tests.
4.4 Results
Effect ofCRHR1 antagonist, antalarmin, on the ACTH response to stress
To investigate the role of CRH in the ACTH response to stress in virgin and pregnant
rats, we suppressed CRH action by an intraperitoneal injection of a CRHR1
antagonist, antalarmin. One and half hours after antalarmin administration, the basal
ACTH concentrations before swim stress did not differ between groups (Figure 4.1,
p>0.05). Following swim stress the ACTH plasma concentrations were significantly
increased in all groups at 5 and 15 min (p<0.05). Plasma ACTH concentrations
returned to close to the basal levels by 70 min post swim stress. The peak ACTH
response occurred at 5 min after the stress in all groups (p<0.05). Plasma ACTH
concentration was lower in response to swim stress in vehicle- treated pregnant rats
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compared to vehicle- treated virgins (p<0.05) 5 min after swim stress. Antalarmin
decreased plasma ACTH levels after swimming in both virgin and pregnant groups
compared to the respective vehicle- treated groups at 5 and 15 min after swim stress
(p<0.05). 70 min after swimming stress, there was no difference in plasma ACTH
concentrations between the pregnant and virgin vehicle or antalarmin- treated groups,
although the vehicle- and antalarmin- treated pregnant groups tended to be higher
(p>0.05).
The histograms (Figure 4.2) present the changes (delta) in plasma ACTH
concentrations at 5 min and 15 min post swim stress relative to the pre-swim mean
basal concentrations. The increments were less in vehicle-treated pregnant rats than in
the respective vehicle-treated virgin groups. Antalarmin attenuated the ACTH
increments to swim stress by about 55- 57% in both virgin and pregnant rats (virgin
vehicle, n=8; virgin antalarmin, n=5; pregnant vehicle, n=9; pregnant antalarmin,
n=10) at 5 min, and also decreased ACTH increments at 15 min.
CRH on ACTH response secretion in vivo
All groups were intravenously injected CRH 20 ng/kg 70 min after the swim stress.
Ten min after this dose, plasma ACTH concentrations in all groups tended to increase,
but did not significantly differ with respect to 70 min basal levels nor among each
other (Figure 4.3). Ten min after a further injection of a larger dose of CRH (200
ng/kg), plasma ACTH concentrations increased significantly in all groups. The
increases in ACTH concentrations of vehicle-treated virgin rats were significantly
higher than those in any other groups (p<0.05, two-way ANOVA for repeated
measurements) (Figure 4.3). There were no significant differences in plasma ACTH
concentrations between vehicle- and antalarmin-treated pregnant groups.
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Hypothalamic and median eminence CRH content
The contents of CRH in the median eminence and in the hypothalamus are presented
in Figure 4.4-7 and summarised in Table 4.1-2. CRH content was about 4-8 times
greater in the median eminence than in the hypothalamus. CRH content in the median
eminence was reduced in pregnancy both on day 10 and day 21 compared with virgins
(t-test, p<0.05). There was a tendency for CRH content in the hypothalamus of both
pregnant groups (day 10 and day 21) to be greater than in virgins but this was not
significant (t-test, p=0.33, 0.17 respectively). Compared to virgins, the total CRH
contents in the whole hypothalamus of both the day 10 and day 21 pregnant groups
were not changed. CRH content in the median eminence expressed as a percentage of
that in the total hypothalamus, representing the proportion of total CRH available for
secretion, was reduced significantly only in the day 21 pregnant group (t-test,
p<0.05), but not in the day 10 group.
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4.5 Discussion
Stress or exogenous CRH and ACTH secretion
Results from this investigation demonstrate that pregnancy in rats causes a reduction
in the release of ACTH in response to exogenous CRH and swim stress. This is
consistent with the previously reported attenuated ACTH response to CRH and swim
stress in pregnancy (Neumann et al. 1998). Although there is no study to investigate
the clearance rate of ACTH during pregnancy so far, it is reported that ACTH
clearance rate is not altered by sex steroids during the estrous cycle (Viau & Meaney
1991), and it is unlikely that the attenuated ACTH response is due to an increase in
ACTH degradation during pregnancy in the context of the fast secretion time course
(within 5 min) after swimming stress or exogenous secretagogue.
In the present study, we applied exogenous CRH (200 ng/kg) at a dose that mimicked
the ACTH secretory response to stress. In response to exogenous CRH, the magnitude
of the plasma ACTH response was attenuated in late pregnancy compared to virgins.
This phenomenon suggests a decrease in pituitary sensitivity to CRH and/or a change
in the levels of CRH and vasopressin in the portal blood secreted in response to stress
during pregnancy. The endogenous CRH and vasopressin concentrations in the portal
blood in pregnancy are not known yet, however, CRH and vasopressin mRNA
expression in the PVN of pregnant rats is reduced, as shown with by in situ
hybridisation (Johnstone et al. 2000). So the reduced ACTH secretion in response to
exogenous CRH in pregnancy can be deduced to be at least partly due to the
interaction with reduced endogenous vasopressin.
The plasma volume is increased in pregnancy by 50% (Nadel et al. 1988), but
whether and how the distribution of secreted or injected CRH changes in pregnancy is
not known. The dose of CRH in this study was given by body weight, so it is unlikely
that the reduced ACTH response is due to the different blood drug concentrations
(also see Chapter 5).
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CRHR1 antagonist and ACTH secretion
CRHR1 contents measured by binding are reduced in the anterior pituitary of
pregnant compared with virgin rats (Neumann et al. 1998). This suggests the
sensitivity of corticotrophs to CRH might change during pregnancy. Furthermore, the
basal and CRH-stimulated cAMP levels in pituitaries from pregnant rats are lower
than those from virgins (Neumann et al. 1998), and this also supports the possibility
of reduced sensitivity of corticotroph cells during pregnancy. But the results in this
study showed that the CRHR1 antagonist, antalarmin, decreased ACTH increments 5
min after swimming stress similarly in virgin and pregnant rats by about 55-57% of
the respective vehicle-treated groups, indicating there is no reduction in CRH
effectiveness in pregnancy. Rather, action of the augmenting secretagogue,
vasopressin, may be decreased in pregnancy (see Chapter 5)
As there is only one report of antalarmin pharmakokinetics in the case of intravenous
and oral administration (Habib et al. 2000), but not intraperitoneal administration, the
elimination half-life of antalarmin in the blood in the present study is not known. The
timing of antalarmin injection and the stress exposure (90 min after antalarmin) in the
present study took into account previous tests on behaviour (Deak et al. 1999). In
virgins, exogenous CRH (200 ng/kg) was more effective in the vehicle-treated group
compared with the group given antalarmin 3 h previously. This indicates antalarmin
acts directly on CRHR1 on the corticotrophs in the anterior pituitary to block ACTH
secretion. However, we cannot explain why antalarmin was not effective in reducing
the ACTH response to CRH in pregnant rats at that time (Figure 4.3). It may be due to
differences in antalarmin degradation between virgin and pregnant rats, or different
sensitivities and time courses of brain actions. As antalarmin is a non-peptide CRH
receptor antagonist that can pass through the blood-brain barrier, so its effect in
attenuating the ACTH response to stress can reflect both its central and peripheral
actions. In the brain, CRHR1 is localised widely in the structures of the brain, such as
primate neocortex, amygdala, hippocampus, hypothalamus, and in the locus coeruleus
(Chalmers et al. 1995; Primus et al. 1997). It is possible that antalarmin acts on the
PVN in the hypothalamus directly and/or on other brain structures indirectly
inhibiting stimulation of stressor- processing and hence CRH secretion.
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CRH stores
The hypothalamus contains small stores of CRH under basal conditions (Lightman
1992), and changes in CRH mRNA expression are considered to be a reliable index of
CRH secretion (Harbuz & Lightman 1989; Harbuz et al. 1990). The results from in
situ hybridisation show (Johnstone et al. 2000) that CRH mRNA expression is
decreased in the hypothalamus at the late stage of rat pregnancy, which supports the
hypothesis of reduced exposure of the anterior pituitary to CRH from the
hypothalamus during pregnancy. As CRH is the major ACTH secretagogue, it is of
interest to know the changes in the production of CRH peptide in the hypothalamus
and its transport to the median eminence, and then into portal blood during pregnancy.
It is very difficult to measure stress-induced ACTH secretagogue concentrations in
the portal blood in rats. In this study, we measured the hypothalamus and median
eminence CRH contents from the decapitated virgin and pregnant rats to see if
reduced store of CRH might contribute to reduced ACTH secretion in pregnancy.
CRH content in the hypothalamus tended to be higher in pregnancy, but not
significantly. In pregnancy, CRH content was about 10% lower in the median
eminence than in virgins with no change in the total hypothalamus content in
pregnancy. This suggests that the production of CRH might not be altered, but that
transported from the hypothalamus to the median eminence is decreased in pregnant
rats. However, the changes in content and distribution of CRH in the hypothalamus in
pregnancy may also reflect decreased production, as indicated by decreased
parvocellular PVN CRH mRNA content (Johnstone et al. 2000). Decreased CRH
daily release is also suggested by loss of the evening increase in ACTH secretion
(Atkinson & Waddell 1995): basal morning plasma ACTH concentrations do not
change during pregnancy, but there is a loss of the diurnal increase in the afternoon.
This decrease in CRH in the median eminence may lead to a decrease in CRH release
and portal blood concentration after stress during pregnancy. However, in day 10 and
day 21 pregnant rats, CRH contents in the median eminence were 87% in day 10
(90% in virgin controls) and 72% in day 21 pregnant rats (82% in virgin controls) of
that in the whole hypothalamus respectively. Compared with respective virgin groups,
there was a reduction of this percentage by about 3% in day 10 or by 9% in day 21
pregnant rats. This modest decrease in CRH in the median eminence suggests that
there is still substantial CRH available for release in the median eminence during
stress in pregnancy. In the present study, we can't exclude the possibility that an
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increase in CRH release may contribute to the reduced CRH contents in the median
eminence in day 21 pregnant rats.
In summary, in the present study, as determined from the actions of a CRHR1
antagonist, CRH contributed similarly to stress-stimulated ACTH secretion in
pregnant and virgin rats. However, CRH available for stimulating ACTH secretion in
the median eminence was lower in pregnancy, although this may reflect reduced CRH
production because of reduced secretion under basal condition in the pregnant rats.
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Chapter 5
Effect of vasopressin and the interaction of
CRH/vasopressin on ACTH secretion in vivo
5.1 Introduction
Vasopressin produced in the parvocellular CRH neurones of the PVN is transported
via nerve fibres to the external zone of the median eminence and released into the
capillaries of the portal system is responsible for stimulating ACTH secretion (Antoni
1986; Antoni et al. 1990; Holmes et al. 1986). The action of vasopressin on
corticotrophs is mediated through plasma membrane Vlb receptor (Jard et al. 1986).
Vasopressin is co-localised in the parvocellular neurones of the PVN of the
hypothalamus with CRH (Whitnall et al. 1985; Makara 1992). The proportion of
vasopressin-positive neurones increases following adrenalectomy, acute and chronic
stress paradigms associated with hypersensitivity of the HPA axis (Whitnall 1988;
Whitnall 1989; de Goeij et al. 1992; Bartanusz et al. 1993; Paulmyer-Lacroix et al.
1994).
Vasopressin alone is a less effective stimulator of ACTH secretion, but is the most
potent among the co-secretagogues that act synergistically with CRH to induce ACTH
secretion (Gillies et al. 1982; Bruhn et al. 1984).
During pregnancy, the HPA axis responses to physical and emotional stress are
attenuated (Neumann et al. 1998), which could be partly due the hypothalamic
secretagogue inputs. There is some evidence of lower basal vasopressin mRNA
expression in the parvocellular PVN of pregnant rats, suggesting reduced vasopressin
availability for driving the secretion of ACTH (Johnstone et al. 2000). However, the
roles of vasopressin on ACTH secretion in vivo during pregnancy are not clear.
Exogenous vasopressin administration and blocking the actions of vasopressin in vivo
with a potent Vla/b receptor antagonist, dP(Tyr(Me)2,Arg-NH29)AVP (Manning et al.
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1992), are useful pharmacological tools for studies on vasopressin effects on the Vlb
receptor-mediated release of ACTH from corticotrophs.
The sensitivity of corticotrophs during pregnancy may be changed as suggested from
the receptor autoradiography studies: vasopressin receptor binding is decreased in the
anterior pituitary in pregnant rats compared with virgins (Toufexis et al. 1999), but
there is no direct evidence on whether and how the sensitivity is changed during
pregnancy.
5.2 Aims
The studies in this chapter were to elucidate the role of vasopressin by giving
exogenous vasopressin and by blocking vasopressin effect with Vla/b receptor
antagonist, and to examine the sensitivity of corticotrophs by injecting both CRH and
vasopressin together in the attenuated ACTH response to stress during pregnancy.
5.3 Materials and methods
ACTH stimulation by exogenous vasopressin in vivo
To study vasopressin action on ACTH secretion, individually caged pregnant and
virgin animals had a silastic jugular cannula implanted as described in Chapter
2.1.2.1. The experiment was carried out four to five days following surgery to allow
the animals to recover. On the day of experiment (day 21 of pregnancy), the jugular
cannula was flushed and connected to a syringe filled with sterile heparinised saline
(at 0800 h). Two basal blood samples (0.4 ml) were taken 1 and 1.5 h later.
Immediately after the second basal sample, each rat received either vasopressin (1.7
yu.g/kg; after D.J.Toufexis (Toufexis et al. 1999)) or saline vehicle (500 /xl/kg)
intravenously, and further blood samples were taken after 5, 15, 30 and 60 min. The
aim was to achieve circulating levels of vasopressin which were identical to to those
in the hypophyseal vessels. Each blood sample was collected into a tube containing 15
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/xl 5% EDTA per 100 /xl blood. Blood was replaced with 0.9% saline. Blood samples
were cooled on ice, centrifuged at 12,000 g, and plasma separated and stored at -70°C
until radioimmunoassay for ACTH.
Vasopressin receptor antagonist and stress-stimulated ACTH secretion
Virgin and pregnant rats were implanted with a jugular cannula, connected as in the
vasopressin study. After two basal blood samples (0.4 ml) were taken at 08.30- 09.00
h 60 min and 90 min after connection, the vasopressin receptor antagonist
[dP(Tyr(Me)2,Arg-NH29)AVP, (10 /xg/kg, i.v. MW= 1210.5, a mixed Via and Vlb
receptor antagonist, with essentially no V2 activity, kindly donated by Prof. M.
Manning) or vehicle (500 jttl/kg) was given.
The effective dose of this antagonist on Via receptors in vivo, to reduce the
effectiveness of vasopressin on blood pressure by 50%, is 0.21±0.02 nmol/kg
(Manning et al. 1992). In vitro, tested in a radioligand competition study, this
compound's affinity to Via receptors (in rat liver) is 26.8 times greater than to Vlb
receptors (in porcine pituitary cells) (Arsenijevic et al. 1994). So the expected
effective concentration for blocking vasopressin binding to Vlb receptors in the
anterior pituitary was calculated to be 6.8 /xg/kg (26.8 x 0.21 nmol/kg, with MW:
1210.5). In a previous in vivo study, 10 /xg/kg of a related compound (d(CH2)5,
Tyr(Me)AVP) was found to prevent stimulation by CRH (after dexamethasone
suppression) of ACTH secretion in aged, but not young rats (Hatzinger et al, 2000). It
reduced blood pressure and increased heart rate similarly in aged and young rats,
indicating that its actions on ACTH secretion were via Vlb receptors in the anterior
pituitary. The compound used in the present study was selected for its greater affinity
at Vlb receptors than d(CH2)5, Tyr(Me)AVP, and its relatively greater effectiveness
on Vlb receptors (Arsenijevic et al., 1994). The peak concentration of the antagonist
in extracellular fluid (volume=67ml/ kg (Dyckes DF et al, 1974)) at the dose used in
this study is calculated to be 120 nmol/1. This is less than the concentration that was
found to be effective in vitro in blocking the augmentation by vasopressin of CRH-
stimulated ACTH secretion (between 100 [no effect] and 10000 nmol/1, Chapter 6).
Immediately after the third basal sample was taken 15 min later, all the rats were
forced to swim for 90 s in deep water (19°C), and further blood samples were taken
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after 5, 15 and 60 min. To test the effectiveness of the antagonist, immediately after
the 60 min sample, another injection of vasopressin receptor antagonist (10 /xg/kg) or
saline vehicle (500 /xl/kg) was given; 15 min later, a blood sample was taken, then
vasopressin (1.7 /xg/kg) was given to all rats and 10 min after the vasopressin
injection, a blood sample was taken. Each blood sample was collected into a tube
containing 15 pi 5% EDTA per 100 pi blood. Blood was replaced with 0.9% saline.
Blood samples were cooled on ice, centrifuged at 12,000 g for 5 min and plasma
separated and stored at -70°C until assayed.
The combination ofCRH and vasopressin on ACTH secretion in vivo
To study the effect of a combination of exogenous CRH and vasopressin on ACTH
secretion, virgin and pregnant rats were implanted with a jugular cannula, connected
as in the vasopressin alone study. Blood samples were taken, stored and assayed as in
the exogenous vasopressin administration study but each rat received a combined
intravenous injection of CRH (200 ng/kg) and vasopressin (1.7 /xg/kg) instead.
At the end of all of the experiments, the animals were killed by an intravenous
overdose of anaesthetic (Sagatal, 36 mg in 600 pi per rat) and pregnancy status was
checked. ACTH concentrations were assayed with the ACTH kits from ICN (for
details see Chapter 2.2.2.5).
Statistics
Data were analysed with two-way ANOVA for repeated measurements followed by
post-hoc Student-Newman-Keuls tests, except data from the ACTH increment at 5
min post-swim stress after Vla/b receptor antagonist administration, which were
analysed with one-way ANOVA followed by post-hoc Student-Newman-Keuls test.
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5.4 Results
Pituitary ACTH response to exogenous vasopressin administration
There were no differences in basal concentrations of ACTH between virgin and
pregnant rats. The plasma concentration of ACTH was increased significantly
following vasopressin injection in both virgin and pregnant rats (Figure.5.1). Both
virgin and pregnant rats exhibited significant increases in plasma ACTH
concentrations at 5 min and 15 min after vasopressin injection (p<0.0001, two-way
ANOVA followed for repeated measurements by post-hoc Student-Newman-Keuls
tests). Peak secretion was seen at the 5-min time point in both virgin and pregnant
rats. In both virgin and pregnant rats, there was no ACTH response to vehicle
injection (plasma ACTH: basal: virgins=56.2±12.3 pg/ml n=6; pregnant=52.3±l 1.0
pg/ml n=7; 5 min after vehicle: virgins=64.0±5.0 pg/ml, n=7; pregnant=48.5±12.9
pg/ml, n=9, p>0.05). Vasopressin stimulated a large ACTH release that was
significantly different at 5 min (p<0.01), and 15 min (p<0.05) in virgin compared with
pregnant rats (ACTH at 5 min: virgins=1414.5±260.8 pg/ml, n=7,
pregnant=791.4±76.5 pg/ml, n=9, p<0.05). Vasopressin-administrated rats lay
prostrate for several minutes after injection: perhaps a consequence of vasopressor
actions.
Effect of vasopressin 1 a/b receptor antagonist on ACTH response to swimming stress
The results are shown in Figure 5.2. Two-way ANOVA for repeated measurements
followed by post-hoc Student-Newman-Keuls test showed a significant interaction
between time and group for plasma ACTH concentration (Figure 5.2, p<0.0001).
There was no significant difference in basal ACTH levels between virgin and
pregnant rats (p>0.05). The administration of the Vla/b receptor antagonist did not
change plasma ACTH levels in any group 15 min after injection. Swim stress
increased plasma ACTH concentrations at 5 and 15 min in all groups (p<0.05). The
peak ACTH response occurred at 5 min after swimming in all groups (p<0.05). Five
min after the end of the 90 s swim stress, ACTH concentrations were significantly
lower in the Vla/b receptor antagonist- treated virgin rats compared with the vehicle-
treated virgin rats (p<0.05). However, the Vla/b receptor antagonist treatment did not
reduce plasma ACTH concentration in pregnant rats at 5- min time point (p>0.05).
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Compared to the respective vehicle-treated groups, 15 min after stress there were no
differences between the antagonist and respective vehicle-treated groups, although
there were still significant differences between vehicle- treated pregnant and virgin
rats at this time point. By 60 min post stress, plasma ACTH concentrations had
returned to near basal and were not significantly different among groups, although in
the pregnant-vehicle group, ACTH concentration was not less than at 15 min.
Increases in plasma ACTH concentration at 5 min after swim stress are expressed
relative to the pre-swimming basal value in Figure 5.3. Swimming increased plasma
ACTH concentration more in the vehicle-injected virgin that in the vehicle-injected
pregnant rats. There was significant inhibition of the ACTH response to swimming
stress by the Vla/b receptor antagonist in virgin rats (p<0.05), but not in the pregnant
group.
To test the effectiveness of the vasopressin antagonist on vasopressin actions on
ACTH secretion, the same dose of the vasopressin antagonist or vehicle was given
intravenously to the treatment group or vehicle group respectively at 60 min after
stress. 15 min later, a dose of vasopressin (1.7 pg/kg) was given to all groups (Figure
5.4). Vasopressin induced a significant increase in ACTH in both virgin and pregnant
vehicle-treated groups. Consistent with the above study of the effects of exogenous
vasopressin, vasopressin at this dose caused a much greater ACTH response in the
vehicle-treated virgin rats compared with the vehicle-treated pregnant rats. The Vla/b
receptor antagonist, (dP(Tyr(Me)2,Arg-NH29)AVP, largely prevented (by 89.5% and
91.3% in virgin and pregnant rats respectively) the ACTH response to vasopressin in
both virgin and pregnant groups.
It was observed that rats injected with vasopressin rapidly adopted a prostrate posture,
resuming a normal posture after several minutes. This effect of vasopressin was
completely prevented by prior injection of the Vla/b receptor antagonist.
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Combined CRH and vasopressin injection on ACTH secretion in vivo
A combination of CRH (200 ng/kg, i.v., same dose as the CRH study in Chapter 4)
and vasopressin (1.7 /xg/kg, i.v., same dose as above vasopressin study) significantly
increased plasma ACTH concentrations at 5 min and 15 min after injection (Figure
5.5, p<0.01). The peak ACTH secretion was observed at the 5-min time point for both
groups. Plasma ACTH concentrations in the virgin and pregnant groups were not
different from each other at any time point. (p>0.05, two-way ANOVA for repeated
measurements).
5.5 Discussion
Reduced effect ofexogenous vasopressin on ACTH secretion in vivo in pregnancy
In this study, we applied exogenous vasopressin (1.7 pg/kg) at a dose aimed to mimic
hypothalamic secretion of vasopressin in stress, which elicits a high ACTH response
in male and female rats (Toufexis et al. 1999). Like the response to CRH, in response
to exogenous vasopressin, the magnitude of the plasma ACTH response was also
attenuated in late pregnancy compared to virgin rats. This phenomenon suggests a
decrease in pituitary sensitivity to vasopressin, and/or a decrease in CRH secretion in
the portal blood occurs under basal conditions during pregnancy. The robust increase
in ACTH release after exogenous vasopressin injection greatly exceeded peak
amounts normally seen in virgin and pregnant rats during stress or after exogenous
administration of CRH. Part of the effect of vasopressin on ACTH secretion may have
been indirect, via the stimulation of hypothalamic CRH neurones (Laszlo et al. 2001),
consequent on vasoconstrictor action of vasopressin through other effects, such as
discomfort. The indirect action of vasopressin on ACTH secretion may be significant
when vasopressin is administrated in vivo, because it is known to have marked
cardiovascular effects through Via receptors even in low concentrations (Mormede et
al. 1985) and Via receptor antagonist is effective in inhibiting the release of ACTH
(Rivier & Vale 1983).
Furthermore cardiovascular effects of vasopressin are reduced in pregnancy (Paller
1984), so differences between pregnant and virgin rats could be partly a consequence
of different central processing of inputs from the vascular effects of vasopressin. We
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have not studied this further. The Via receptor mediates the vasoconstrictor and
hepatic glycogenolytic action of vasopressin (Fishman et al. 1987; Estrada et al.
1991), but differences between pregnant and virgin rats were greatest at just 5 min.
Similar to the results from study of CRH effects on ACTH secretion, the results in this
study showed that the ACTH response to vasopressin in the pregnant rats was
decreased compared with the virgins. This suggests that a possible reduced sensitivity
to exogenous ACTH secretagogues exists in pregnant rat corticotrophs. Vasopressin
potentiates CRH effects on ACTH secretion (Gillies et al. 1982; Bruhn et al. 1984;
Norman & Challis 1987). So the reduced ACTH secretion in response to exogenous
vasopressin in pregnancy would have been the result of the interaction with
endogenous CRH. The results in Chapter 4 show that the CRH content in the median
eminence was less in the late pregnant rats, and this may indicate that CRH
production and the release of CRH into the portal blood, under basal conditions, is
less as well. The reduced ACTH secretory response may be the result of interaction of
the reduced endogenous CRH release and the same concentration of exogenous
vasopressin.
The endogenous CRH and vasopressin concentrations in the portal blood in pregnant
rats are not known. Vasopressin stores in the external zone of the median eminence in
the parvocellular terminals is considered to be responsible for pituitary ACTH release,
whereas vasopressin produced in magnocellular neurones of the PVN and SON is
transported via nerve fibres in the internal zone of the median eminence to the
posterior pituitary lobe and secreted into the peripheral circulation in response to
osmotic and related stimuli (Antoni 1986; Holmes et al. 1986; Morris & Pow 1988;
Antoni et al. 1990). As vasopressin in the median eminence is from both parvocellular
and magnocelluar origin, it is difficult to assess any change in stored vasopressin of
parvocellular origin by measuring vasopressin content here. A change in vasopressin
content in the external zone of the median eminence could be investigated by
immunohistochemistry methods. However, a reduced secretion into portal blood of
CRH and vasopressin is suggested by reduced vasopressin and CRH mRNA
expression in PVN neurones in pregnancy (Johnstone et al. 2000).
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Effect of the Vla/b receptor antagonist on ACTH secretion in vivo in pregnancy
This Vla/b receptor antagonist should not enter the brain from the blood as it is a
peptide, so it exerts its anti-ACTH secretory function through Vlb receptors on
corticotrophs directly and through Via receptor on blood vessels indirectly (Manning
et al. 1992). Actions of the Vla/b antagonist on corticotrophs were shown in vitro
(see Chapter 6). In the present study, as the Vla/b antagonist decreased the ACTH
response to swim stress in virgin but not in pregnant rats (Figure 5.3) and as
exogenous vasopressin induced less ACTH secretion in pregnancy (Figure 5.1), this
implies that vasopressin is less effective in pregnancy, or that less is released in
response to swim stress.
The Vla/b receptor antagonist was very effective in blocking the ACTH response to
exogenous vasopressin both in virgin and in pregnant rats (Figure 5.4). The Vla/b
receptor antagonist reduced the ACTH stress response in virgin, but not in pregnant
rats, so it seems reasonable to conclude that vasopressin secretion contributes less to
the stimulation of ACTH secretion in response to stress in pregnant than in virgin rats.
Interestingly, the vasopressin receptor antagonist decreased the stress response at 5,
and not at 15 min in virgin rats. It is in contrast to the CRH antagonist, which
decreased this response at both 5 min and 15 min both in virgin and pregnant rats.
This suggests that vasopressin is more important in the rapid ACTH response to the
stress.
The rats developed a prostrate posture soon after injection of vasopressin alone
intravenously. This effect was not seen after administration of the Vla/b receptor
antagonist prior to vasopressin injection. This may have been a consequence of
blocking pressor effects of vasopressin through Via receptors (Ervin et al. 1993).
Without a selective Via or Vlb receptor antagonist, we have not investigated this
issue further. However, the antagonist was as effective in pregnant and virgin rats in
blocking this response as well as blocking ACTH secretion, yet ineffective in
reducing ACTH secretion in response to stress in pregnant rats in contrast with
virgins, and that Vlb action of the antagonist were shown in vitro (Chapter 6).
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In addition to decreased vasopressin secretion in pregnancy, a small difference in
effective Vlb receptor number on corticotroph cells (Toufexis et al. 1999) may be
crucially important for the different ACTH response to stress in pregnancy because of
the synergistic effect of vasopressin on CRH (Gillies et al. 1982). The Vlb receptor
content in the anterior pituitary of pregnant rats is reduced compared with virgin rats
(Toufexis et al. 1999), as is Vlb receptor mRNA expression (Chapter 3). This
suggests the sensitivity of corticotroph cells to vasopressin might decrease during
pregnancy.
No difference in exogenous CRH plus vasopressin on ACTH secretion in vivo between
virgin and pregnancy
To test the sensitivity of corticotropins in vivo, we gave CRH and vasopressin in
combination at the same doses as in the previous two studies (Chapter 4 and this
chapter). The lack of a difference between virgin and pregnant rats in the ACTH
response to this combined administration of CRH and vasopressin indicates that the
reduced response to either alone in pregnancy is due to reduced basal CRH or
vasopressin secretion, or both, and that the sensitivity of the corticotropins to the
secretagogues might not be decreased during pregnancy. However, not ruled out is
the possibility of a change in CRH and vasopressin interaction at the pituitary during
pregnancy (see Chapter 6, in vitro studies).
Nonetheless, in summary, the similar ACTH response to combined injection of CRH
and vasopressin in virgin and pregnant rats sugests that: 1) the secretory capacity of
the corticotrophs in vivo in pregnancy is not diminished; 2) it is likely that the reduced
effect in pregnancy of CRH or vasopressin alone on ACTH secretion is a consequence
of reduced basal endogenous secretion of vasopressin or CRH respectively; 3) the in
vitro studies (Chapter 6) of interactions between CRH and vasopressin in pregnancy
can be extended to the in vivo situation; 4) as there are changes in expression of
mRNAs related to signalling and secretion in corticotrophs in pregnancy (Chapter 3),
these adaptations maintain secretagogue responsiveness, even though endogenous
CRH and vasopressin secretion are reduced; 5) during stress it seems that reduced
ACTH secretion is primarily a consequence of reduced vasopressin secretion by the
parvocellular PVN neurones.
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Chapter 6
Cellular signalling in corticotrophs in vitro
6.1 Introduction
CRH and vasopressin are the major regulators of the secretion of ACTH from the
corticotrophs in the anterior pituitary (Antoni 1986). CRH is the most potent
stimulator of POMC transcription and ACTH biosynthesis and secretion from the
anterior pituitary (Vale et al. 1981; Antoni 1986) via the stimulation of CRHR1 (Chen
et al. 1993). In the corticotrophs, CRHR1 is positively coupled to the cAMP
signalling cascade (Labrie et al. 1982), leading to a transient increase in intracellular
cAMP concentrations (Litvin et al. 1984; Battaglia et al. 1987). This increase in
intracellular cAMP accumulation stimulates ACTH biosynthesis and secretion
(Antoni 1986; King & Baertschi 1990).
Vasopressin from parvocellular PVN neurones is responsible for regulating ACTH
secretion (Aguilera 1994) and this action of vasopressin on the corticotrophs is
mediated by Vlb receptors. Vasopressin greatly potentiates the ACTH response to
CRH in vivo and in vitro in rats (Gillies et al. 1982; Fischman & Moldow 1984). This
potentiating action of vasopressin involves increase in cAMP formation by
stimulation of adenylate cyclase (Abou-Samra et al. 1987) and a decrease in cAMP
degradation by inhibiting phosphodiesterase activity (Giguere & Labrie 1982) in rat
anterior pituitary cells. VI receptor antagonists are effective in inhibiting the release
of ACTH (Rivier et al. 1984; Buckingham 1987; Watanabe et al. 1989). A Vla/b
receptor antagonist, dP(Tyr(Me)2,Arg-NH29]AVP (Manning et al. 1992) is useful in
studies on the role of vasopressin in the Vlb receptor- mediated release of ACTH
from corticotrophs (see Chapter 5).
During pregnancy, the ACTH response to stress and exogenous CRH is attenuated
(Neumann et al. 1998). It is reported that cAMP accumulation stimulated by CRH in
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segments of anterior pituitaries from the pregnant rats is reduced compared with those
from virgin rats (Neumann et cil. 1998) and that CRH receptor binding in the anterior
pituitaries of the pregnant rats is also decreased, which suggests reduced CRH
signalling in the corticotrophs of the pregnant rats. However, whether CRH cellular
signalling transduction via cAMP results altered ACTH release or whether
CRH/vasopressin interaction is changed is not known.
6.2 Aims:
In vitro studies are useful for understanding CRH and vasopressin signalling and their
interaction on ACTH secretion in corticotrophs by excluding the interference of other
pathways. This study was to investigate the sensitivity of the corticotrophs in vitro
and to find any cellular signalling changes in pregnancy. We measured ACTH
secretion from acutely isolated anterior pituitary cells incubated with CRH,
vasopressin, CRH and vasopressin together, and with a cell membrane permeable
cAMP analogue (8-CPT-cAMP).
6.3 Materials and methods
Details of measurement of ACTH release from acutely isolated anterior pituitary cells
are in Chapter 2.2.2.1. Briefly here, the anterior pituitary glands were removed from
decapitated virgin and pregnant (day 10 and day 21, around 0900 h), and acutely
dispersed, and incubated with vehicle (DMEM-BSA), ACTH secretagogues, or 8-
CPT-cAMP (a cell membrane permeable cAMP analogue) in the study of vasopressin
and CRH interaction in vitro. In the case of measurement of the effects of the Vla/b
receptor antagonist, on ACTH secretion by corticotrophs from virgin rats, medium
containing [dP(Tyr(Me)2,Arg-NH29)AVP was added to tubes containing cells, which
were left on ice; 5 min later the secretagogues were then added, and the cells
incubated for 1 h at 37°C in a shaking water bath. To measure total ACTH content of
cells, 200 pi aliquots (100,000 cells) were frozen directly at -70°C without any
incubation or addition of secretagogues. Samples were stored at -70°C until
radioimmunoassay.
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ACTH concentrations were measured using a double antibody precipitation
radioimmunoassay (Dayanithi & Antoni 1989) after 5 times dilution in RIA buffer
(details in Chapter 2.2.2.2). The concentration of ACTH was calculated as in Chapter
2.2.2.3.
Statistics
The secretion and ACTH concentration experiments were repeated 4-7 times, to
explore different features of changes in pregnancy. Within an experiment, the data
were analysed with two-way ANOVA with post-hoc Student-Newman-Keuls Method.
The summary data were analysed with Kruskal-Wallis One-way ANOVA on Ranks
and followed by Mann-Whitney Rank Sum Test.
Data from corticotropin ACTH content measurement were analysed with t-test.
The data from the Vla/b receptor antagonist measurement in virgin rats were analysed
with one-way ANOVA with post-hoc Student-Newman-Keuls Method.
6.4 Results
The sensitivity of anterior pituitary cells to CRH, vasopressin, the combination of
CRH and vasopressin, and cAMP in virgin and day 21 pregnant rats
Dispersed anterior pituitary cells were incubated in vehicle (DMEM-BSA), CRH
alone, vasopressin alone or CRH plus vasopressin. ACTH release was calculated per
100,000 cells. For CRH alone, for both virgin and pregnant rats, ACTH secretion was
dose-dependently related to CRH concentration (Figure 6.1). Vasopressin alone had
no effect on ACTH secretion at the doses used. Vasopressin (2 nM) potentiated the
stimulatory effect of CRH (0.1 nM and 1 nM) on ACTH secretion (p<0.05), and this
augmentation effect was greater in pregnant rats (p<0.05, two-way ANOVA). 8-CPT-
cAMP treatment also caused ACTH release. The effects of 8-CPT-cAMP were greater
on cells from pregnant rats (p<0.05, two-way ANOVA). To correct for differences
(p>0.05) in basal release between cells from virgin and pregnant rats, ratios were
calculated by comparing all values with the basal ones. The pattern of the data
presented by ratio (Figure 6.2) showed greater effects of CRH alone on cells from
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pregnant versus virgin rats, and greater vasopressin augmentation of CRH stimulation
of ACTH secretion, and greater stimulation by 8-CPT-cAMP.
To enable combination of data from several experiments and thus compare the effects
of secretagogues and cAMP on ACTH secretion by the virgin and pregnant pituitary
cells across experiments, we calculated the ratio (Rl) of total release of ACTH to
basal release for each treatment. Then the ratio (R2) of pregnant to virgin was
calculated by dividing the pregnant Rl by the virgin Rl for each treatment (to
describe the difference in effects of treatment between pregnant and virgin rats; the
virgin for Rl values were thus set to be 1). The mean of these values (R2) across
experiments was then calculated. The summary data for day 21 and day 10 of
pregnancy are shown (Figure 6.3 and Figure 6.5). In order to analyse the results, the
data presented as ratios in Figure 6.3 and Figure 6.5 were compared with 1 (virgin), to
test the null hypothesis that R2=l.
We also calculated the increment of each treatment compared with the basal (delta
value). The difference between the pregnant delta value and the virgin delta value was
then calculated for each treatment (Figure 6.4 and Figure 6.6, the virgin value was
thus set to be 0). The data presented as the differences between pregnant delta values
and virgin delta values were compared with 0 (virgin).
By the ratio calculation (Figure 6.3), the anterior pituitary cells from day 21 pregnant
rats secreted more ACTH than the cells from virgin rats in response to the stimulation
by 0.1 nM CRH, 1 nM CRH alone, and 0.1 nM CRH plus 2 nM vasopressin (p<0.05
vs control, Kruskal-Wallis One-way ANOVA on Ranks and followed by Mann-
Whitney Rank Sum Test). Whereas by calculating the differences between the
pregnant delta values and the virgin delta values (Figure 6.4), the results showed 0.1
nM CRH, 0.1 nM CRH plus 2 nM vasopressin, and 8-CPT-cAMP were more
effective in stimulating ACTH secretion from day 21 pregnant rat anterior pituitary
cells (p<0.05 vs control, Kruskal-Wallis One-way ANOVA on Ranks and followed by
Mann-Whitney Rank Sum Test).
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Comparing virgin rats, by the ratio calculation (Figure 6.5) or by calculating the
differences between the pregnant delta values and the virgin delta values (Figure 6.6),
secretion of ACTH by anterior pituitary cells from the day 10 pregnant rats were not
significantly different in response to any secretagogue (p>0.05, Rruskal-Wallis One¬
way ANOVA on Ranks).
The total ACTH content in the anterior pituitary cells
The total ACTH contents were assayed from 200 pi frozen dispersed anterior pituitary
cells. There was no difference in ACTH contents from 100,000 acutely dispersed
anterior pituitary cells between virgin and either day 10 pregnant rats or day 21
pregnant rats (Figure 6.7, p>0.05, t-test).
2 9
The effectiveness of a Vlci/b receptor antagonist, \dP(Tyr(Me) ,Arg-NH? )AVP, on
ACTH secretion from incubated acutely dispersed anterior pituitary cells
To investigate the in vitro effectiveness of the Vla/b receptor antagonist,
[dP(Tyr(Me)2,Arg-NH29)AVP, used in the stress study (Chapter 5), we measured
ACTH secretion from acutely dispersed anterior pituitary cells by incubation with this
Vla/b receptor antagonist added 5 min before the secretagogues. After 1 h incubation,
vasopressin at 2 nM and CRH at 0.1 nM alone increased ACTH release compared
with basal release, but the increases were not statistically significant (Figure 6.8;
p>0.05, for vasopressin and CRH respectively, one-way ANOVA). Vasopressin
potentiated the stimulatory effect of CRH on ACTH secretion, increasing ACTH
release significantly (p<0.05, one-way ANOVA). As it is known from previous
measurement that vasopressin at 2 nM does not have a significant effect on ACTH
release from isolated anterior pituitary cells (this chapter), we did not test the effect of
the Vla/b receptor antagonist on ACTH secretion directly by incubating this
antagonist with vasopressin. The Vla/b receptor antagonist at the high dose (10~5 M)
did not change the basal nor 0.1 nM CRH stimulated ACTH secretion (p>0.05, one¬
way ANOVA), but significantly reduced ACTH release stimulated by CRH plus
vasopressin to the basal levels (p<0.05, one-way ANOVA). However, this Vla/b
receptor antagonist at a low dose (10~7 M) did not affect the ACTH secretion
stimulated by CRH plus vasopressin (p>0.05, one-way ANOVA).
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6.5 Discussion
The effects ofsecretogogues and cAMP on ACTH secretion by anterior pituitary cells
Consistent with previous findings (Gillies et al. 1982), the virgin rats showed a dose-
dependent pattern of ACTH secretion from isolated anterior pituitary cells stimulated
by CRH ranging from 0.01 to 10 nM. However, vasopressin alone at the doses we
used (from 0.01 nM to 10 nM) did not significantly stimulate ACTH release. In this
present study, we found the isolated anterior pituitary cells from the pregnant rats also
showed a dose-dependent ACTH response to CRH, but not to vasopressin. Similarly,
vasopressin potentiated the stimulatory effect of CRH on ACTH secretion from virgin
and pregnant anterior pituitary cells. 8-CPT-cAMP, a membrane permeable cAMP
analogue, also increased ACTH concentrations in virgin and pregnant rats. These
results indicate that corticotrophs from pregnant rats do not have reduced
responsiveness compared with virgin rats. Indeed, further analysis indicates increased
responsiveness.
Increased effects of0.1 nM CRH and 8-CPT-cAMP
The result from the present study showed that CRH at 0.1 nM produced a greater
ACTH secretory response by the anterior pituitary cells from the day 21 pregnant rats
than from the virgin rats (Figure 6.2, 6.3), whereas the number of CRH receptors on
the corticotrophs, CRHR1, is reported to decrease in the pregnant rat (Neumann et al.
1998). So these data together suggest that enhanced post- receptor signalling and/or
greater efficiency of the receptor recycling of CRHR1 mechanisms exist in
pregnancy. The former hypothesis was supported by the results of the incubation with
8-CPT-cAMP. CRH stimulates the accumulation of cAMP in the corticotrophs
(Labrie et al. 1982) and cAMP activates the PKA pathway leading to the release and
also biosynthesis of ACTH. A cell membrane permeable cAMP analogue, 8-CPT-
cAMP, resistant to hydrolysis by cyclic nucleotide phosphodiesterases was used in the
present study to sustain a high level of intracellular cAMP. Anterior pituitary cells
from day 21 pregnant rats released more ACTH in response to 8-CPT-cAMP,
suggesting that the post receptor signalling is increased in pregnancy. This
enhancement was not evident at day 10 of pregnancy, but this may be because the
number of experiments at this stage was small. cAMP accumulations in anterior
pituitary segments incubated with CRH were lower in pregnancy than in virgin
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(Neumann et al. 1998), so the enhanced effect of cAMP in pregnancy may
compensate for the reduced accumulation of cAMP stimulated by CRH. Increased
CRHR1 efficiency may not be the explanation of the increased ACTH secretion in
pregnancy in vitro, as cAMP accumulation is not increased from the anterior pituitary
cells after incubation with CRH in pregnancy, on the contrary, it is reduced (Neumann
et al. 1998). However, in the present study, the administration of 8-CPT-cAMP,
which is resistant to hydrolysis by phosphodiesterase, prevented the degradation, so.
the possibility that the degradation of cAMP by phosphodiesterase may increase in
pregnancy cannot be ruled out, that is: cAMP degradation in pregnancy is enhanced,
and the production of cAMP by the stimulation of CRHR1 is not changed or even
increased, overall resulting in reduced cAMP accumulation.
The incubation of isolated anterior pituitary cells with the low dose of CRH (0.1 nM)
showed a statistically significant greater release of ACTH in cells from day 21
pregnant rats than in virgins, by both ratio and increment calculations, but the effect
of the high dose of CRH (1 nM) was significantly greater only by comparison of
increments. It seems then that in vitro, without addition of vasopressin, CRH is more
effective in stimulating ACTH secretion by corticotrophs from pregnant rats. This
suggests that the reduced effect of CRH in vivo in pregnancy may be due to reduced
secretion of another secretagogue, such as vasopressin (see Chapter 5), rather than to
reduced effectiveness of CRH alone.
Increased effect of0.1 nM CRH and 2 nM vasopressin
By receptor binding studies, CRH and vasopressin receptors in the anterior pituitary
are reduced in pregnancy (Toufexis et al. 1999), indicating a mechanism for possible
reduced corticotroph sensitivity to secretagogues. However, ACTH release from
acutely dispersed anterior pituitary cells incubated for 1 h with CRH plus vasopressin
was greater in pregnancy. This discrepancy may be due to faster turnover of these two
receptors in pregnancy, associated with increased efficiency. This increased secretion
in response to the combination of secretagogues may not reflect differences in number
of CRH or Vlb receptors, or in the expression of Vlb mRNA, but rather a change in
post receptor signalling.
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Vasopressin stimulates ACTH secretion through activation of PKC with subsequent
generation of IP3 and diacylglycerol. IP3 is believed to cause the release of calcium
from intracellular stores, and diacylglycerol acts in concert with calcium to translocate
PKC from cytosolic sites to the plasma membrane coincident with enzyme activation
(King & Baertschi 1990). Vasopressin potentiates the effect of CRH on ACTH
secretion by a synergistic increase in intracellular cAMP accumulation in the
corticotrophs (Giguere & Labrie 1982). The potentiating action of vasopressin on
CRH stimulation of ACTH secretion involves increase in cAMP formation by
stimulation of adenylate cyclase (Abou-Samra et al. 1987) and an decrease in cAMP
degradation by inhibiting phosphodiesterase activity (Giguere & Labrie 1982),
increasing intracellular cAMP accummulation, leading to potentiated ACTH
secretion. In the present study, ACTH secretion stimulated by CRH plus vasopressin
was greater in pregnancy. However, the ratio (R2) of ACTH release for the pregnant
versus virgin groups was not different (p>0.05, one way ANOVA) between CRH
treatment alone (1.37, 1.25 for the 0.1 nM and 1 nM CRH treatment respectively) and
CRH plus vasopressin (1.60, 1.54 for vasopressin plus 0.1 nM and 1 nM CRH
treatment respectively), so it is unlikely the potentiation mechanism by vasopressin
acts is enhanced in pregnancy in vitro, and the greater ACTH secretion is likely to be
mainly due to the increased CRH effect through enhanced cAMP signalling.
The combination of CRH (200 ng/kg) and vasopressin (1.7 pg/kg) treatment by
intravenous injection increased plasma ACTH concentrations similarly in virgin and
pregnant rats (see Chapter 5). This is similar to lack of a reduction in vitro in the
combined effects of CRH and vasopressin. However, the greater effect of CRH alone
in vitro was not seen in vivo: this may be because the in vivo dose did not compensate
for a likely lack of vasopressin secreted by the parvocellular CRH/vasopressin
neurones in pregnancy.
There were no differences in ACTH secretion stimulated by any secretagogues
between day 10 pregnant rats and virgin rats, suggesting that corticotroph cellular
signalling and sensitivity are not altered in early pregnancy. This is consistent with the
POMC mRNA expression (see Chapter 3) and ACTH response to swim stress studies
(Neumann et al. 1998).
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ACTH contents
ACTH belongs to a family of peptides derived from a common precursor protein
encoded by the POMC gene (Chretien & Seidah 1981; King & Baertschi 1990; Lowry
et al. 1980). Although POMC mRNA expression in the anterior pituitary was reduced
in pregnancy (Chapter 3), the ACTH contents in the anterior pituitary measured in the
present study were not different between virgin and pregnant rats, suggesting the
processes of the POMC gene transcription and the precursor protein modification is
faster, and/or the degradation of ACTH is slower in pregnancy.
The diurnal pattern of ACTH secretion disappears, the afternoon peak lost, so the
secretion of ACTH per 24 h near the end of pregnancy is decreased (Atkinson &
Waddell 1995). In the present study, total ACTH contents in the corticotrophs were
far more than required for secretion after incubation with secretagogues (about 5-10
times higher than basal secretion and 3-6 times higher than incubation with 0.1 nM
CRH and 2 nM vasopressin), so the reduced ACTH secretion in response to acute
stress or CRH, or circadian basal release in vivo is mainly due to decreased release
from the corticotrophs.
Vlb receptor antagonist
The effectiveness of the Vlb receptor antagonist we used in vivo (see Chapter 5) on
ACTH secretion in vitro from acutely dispersed anterior pituitary cells from virgin
rats was investigated. This antagonist decreased ACTH secretion in vivo (Chapter 5).
In the present study, the Vla/b receptor antagonist did not affect basal secretion. This
antagonist decreased the stimulation of ACTH secretion by CRH plus vasopressin
incubation, as this antagonist did not change CRH-induced ACTH secretion,
indicating it does not interact with CRHR1, so its antagonistic effect was via the Vlb
receptors on the corticotrophs, blocking the potentiation effects of vasopressin.
In summary, the present study showed a dose-dependent effect of CRH in vitro, and
the potentiation by vasopressin of CRH action on ACTH secretion, by corticotrophs
from pregnant rats. The finding that corticotrophs from day 21 pregnant rats released
more ACTH when incubated with a low dose (0.1 nM) of CRH, and with CRH plus
vasopressin, and showed a greater effect of a cAMP analogue suggests changes in
post receptor signalling mechanisms in pregnancy.
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Chapter 7
Effect of neurosteroids on the ACTH response
to stress during pregnancy
7.1 Introduction
It is well established that plasma progesterone levels increase progressively during
pregnancy in humans and rats, and reach their highest levels one or two weeks before
delivery in humans (Mathur et al. 1980) or 1-2 days before delivery in rats (Concas et
al. 1999). The neuroactive steroids, allopregnanolone and THDOC (the metabolites of
progesterone) concentrations are also at the peak values prior to parturition in the
brain (Concas et al. 1999). Both brain and plasma allopregnanolone and THDOC
concentrations are also elevated after acute stress or ACTH infusion (Schambelan &
Biglieri 1972), which are released from the adrenal gland (Purdy et al. 1991). These
neurosteroids exert an important inhibitory effect on the HPA system by interacting
with GABAa receptor in the brain (Breier et al. 1992; Owens et al. 1992; Patchev et
al. 1994; Patchev et al. 1996; Bernet et al. 2000; Cullman 2000). So it is postulated
that these neurosteroids may participate in the stress response as a homeostatic factor
to terminate the response (Jessop 1999). This mechanism may be crucial for the
attenuated ACTH response to stress at the late stage of pregnancy.
Allopregnanolone is a 5a-reduced metabolite of progesterone and acts as a major
GABAa receptor allosteric modifier by increasing the duration and frequency of
GABA-stimulated chloride channel openings (Majewska et al. 1986; Lan et al. 1991;
Paul & Purdy 1992). THDOC, another 5a-reduced derivative from progesterone via
deoxycorticosterone (DOC), is also a potent GABAa receptor active neurosteroid
(Schneider & Honour 1992; Winkel et al. 1980), but the quantity of THDOC
produced through this pathway is small compared with the synthesis of
allopregnanolone, so it is unlikely that THDOC is as important as allopregnanolone.
163
Effect ofneurosteroids on the ACTH response to stress during pregnancy Chapter 7
In the brain these neurosteroids are synthesised by oligodendrocytes and glial cells
(Baulieu & Robel 1990).
Neurosteroid concentrations in plasma and extracts from brain are markedly increased
shortly after application of different stress paradigms (Purdy et al. 1991; Barbaccia et
al. 1994; Barbaccia et al. 1998). In particular, during the stress response brain content
of allopregnanolone reaches a high value (Korneyev et al. 1993; Purdy et al. 1991).
Allopregnanolone can attenuate the activity of the HPA axis challenged by various
stresses (Guo et al. 1995; Patchev et al. 1996; Bernet et al. 2000). THDOC is also
reported to be able to attenuate mild stress-induced increases in plasma corticosterone
concentrations via GABAergic mechanisms (Owens et al. 1992). These data indicate
that neurosteroids such as allopregnanolone and THDOC are part of the negative
feedback mechanism in the stress response.
The conversion of progesterone into allopregnanolone and THDOC is catalysed by
5a-reductase irreversibly (see Chapter 1.5.2) (Abul-Hajj 1972; Winkel et al. 1980;
Schneider & Honour 1992). Two types of 5a-reductase, type I (Andersson & Russell
1990) and type II (Andersson et al. 1991), have been isolated and identified from
human and rat. 5a-reductase is widely expressed in mammalian tissues (Li et al.
1995) and the brain is a rich source of this enzyme (Melcangi et al. 1993). The
enzyme required for converting dihydroprogesterone (the reduced form of
progesterone) to allopregnanolone, 3a-hydroxysteroid dehydrogenase (3a-
hydroxysteroid oxidoreductase), is also broadly distributed in the brain (Li et al.
1997). 17(3-N,N-diethylcarbomyl-4-aza-4-methyl-5a-androstan-3-one (4-MA) is a
potent competitive inhibitor of type I a- reductase and a less potent inhibitor of type II
a- reductase (Li et al. 1995). 4-MA inhibits 5a-reductase activity in many tissues
including the brain and peripheral tissues (Bitran et al. 1995; Mellin et al. 1993).
7.2 Aims
As neurosteroids can attenuate the activity of the HPA axis and brain levels increase
during the late stage of pregnancy, we hypothesized that neurosteroids may attenuate
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HPA axis activity during pregnancy. To investigate possible roles of neurosteroids in
the late stage of pregnancy in attenuating stress responses of the HPA axis, we
blocked conversion of progesterone to allopregnanolone and THDOC with a
competitive 5a- reductase inhibitor, 4-MA.
7.3 Materials and methods
5a-reductase antagonist, 4-MA, and stress-stimulated ACTH secretion
To study neurosteroid actions on ACTH secretion, individually caged pregnant and
virgin rats had a silastic jugular cannula implanted by the method described in detail
in Chapter 2.1.2.1. The experiment was carried out four to five days following surgery
to allow the animals to recover. 4-MA (a kind gift from Prof. Ian Mason, University
of Edinburgh) was dissolved in sesame oil (90% v/v, in absolute alcohol). It has been
reported that 4-MA administration (33 mg/kg, 2 h before) blocks the anxiolytic effect
induced by progesterone. Furthermore, 4-MA blocks the production of
allopregnanolone on administration of exogenous progesterone (Bitran et al. 1995). In
the present study, we adopted a similar dose and time course with minor modification
by giving an extra dose of 4-MA (33 mg/kg) 18 h before the experiment. At 16:00 h
on the day before experiment, the rats were given 4-MA (33 mg/kg), or vehicle (10%
ethanol and 90% sesame oil, 660 pl/kg) subcutaneously. On the day of experiment
(day 21 of pregnancy), the rats were administered the same dose of 4-MA or vehicle
at 08:00 h in the following morning. The jugular cannula was then flushed and
connected to a syringe filled with sterile heparinised saline. Two basal blood samples
(0.4 ml) were taken 60 min and 90 min after the second subcutaneous injection. All
the rats were forced to swim for 90 s in deep water (19°C), and further blood samples
were taken after 5, 15, 30 and 70 min. Each blood sample was collected into an
Eppendorf tube containing 15 pi 5% EDTA per 100 pi blood. Blood was replaced
with 0.9% saline. Blood samples were cooled on ice, centrifuged at 12,000 g for 5
min and plasma separated and stored at -70°C until assayed.
4-MA and exogenous CRH-inducedACTH secretion
Immediately after the 70 min sample in the same experiment above, each rat received
200 ng/kg CRH intravenously, to examine the effect of 4-MA on pituitary responses
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to exogenous CRH, and a further blood sample taken after 10 min. Each blood sample
was collected into an Eppendorf tube containing 15 pi 5% EDTA per 100 pi blood.
Blood was replaced with 0.9% saline. Blood samples were cooled on ice, centrifuged
at 12,000 g for 5 min and plasma separated and stored at -70°C until assayed. Plasma
ACTH concentrations were assayed by RIA with the ACTH kits from ICN (details in
Chapter 2.2.2.5)
All rats were killed by decapitation, the number of fetuses counted and fetal viability
was assessed.
Statistics
The effect of 4-MA on the ACTH response to stress were analysed by two-way
ANOVA for repeated measures followed by post-hoc Newman-Keuls tests. Data from
the effects of CRH stimulated ACTH secretion after the stress study were analysed by
one-way ANOVA and post-hoc Student-Newman-Keuls tests.
7.4 Results
Effect of4-MA on the ACTH response to stress
One and half hours after the second 4-MA administration, the basal ACTH
concentrations before swim stress did not differ between groups (Figure 7.1, p>0.05,
two-way ANOVA for repeated measures). Following swim stress the ACTH plasma
concentrations were significantly increased in all groups at 5, 15 and 30 min (virgin
vehicle, n=6; virgin 4-MA, n=7; pregnant vehicle, n=7; pregnant 4-MA, n=9. p<0.05).
The peak ACTH response occurred at 5 min after the stress in all groups. Plasma
ACTH concentration was lower in response to swim stress in vehicle-treated pregnant
rats compared to vehicle-treated virgins at the 5-min time point (p<0.05). 4-MA
treatment increased plasma ACTH concentrations 5 min after swimming in the
pregnant group, but not in the virgins, compared to the respective vehicle-treated
groups (p<0.05). Plasma ACTH concentrations remained at high levels in both the 4-
MA treated virgin and pregnant groups compared with the vehicle groups at 15 and 30
min after stress, although there were no statistically significant differences. Plasma
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ACTH concentrations returned close to the basal levels by 70 min post swim stress in
both the virgin and pregnant vehicle-treated groups, but remained significantly higher
in the 4-MA treated groups (p<0.05).
The histograms (Figure 7.2) present the changes (delta) in plasma ACTH
concentrations at 5, 15, 30 and 70 min post swim stress relative to the pre-swim basal
concentrations. 4-MA increased the ACTH response to swim stress only in the
pregnant rats at the 5 min time point, and in both pregnant and virgin rats at 70 min
(p<0.05, two-way ANOVA for repeated measures).
4-MA and exogenous CRII-inducedACTH secretion
All groups were intravenously injected with CRH 200 ng/kg at 70 min after the swim
stress. Data presented as actual plasma ACTH concentrations and ACTH increments
are in Figure 7.3 and Figure 7.4 respectively. Ten min after this dose of CRH, ACTH
concentration was greater in 4-MA treated both virgin and pregnant rats compared to
respective vehicle treated rats (Figure 7.3, p<0.05, two-way ANOVA for repeated
measures). ACTH concentrations were also greater in the vehicle treated virgin rats
than those in the vehicle treated pregnant rats (Figure 7.3, p<0.05). The elevation of
plasma ACTH concentrations in vehicle-treated virgins was significantly greater than
that in the vehicle-treated pregnant rats (Figure 7.4, p<0.05, one-way ANOVA for
repeated measures). 4-MA treatment did not change ACTH increment in response to
exogenous CRH in virgins or in pregnant rats (Figure 7.4, p>0.05). There was no
difference in ACTH increment after CRH stimulation between 4-MA- treated virgin
and pregnant rats (Figure 7.4). However, because samples could only be obtained
from 3 pregnant rats treated with 4-MA and CRH, and the increments in ACTH
concentrations in these rats were small, there were no significant differences between
this and the other groups when increments were compared (Figure 7.4).
Fetal viability was checked after the experiment. The fetuses (about 10-15 fetus per
pregnant rat) were alive and moving in both the 4-MA treatment group and the
vehicle group, with no placental detachment or intrauterine bleeding; however, uterine
blood vessels appeared more distended in the 4-MA treated pregnant rats.
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7.5 Discussion
Effect of4-MA on the ACTH response to stress
Allopregnanolone is a neuroactive steroid involved in modulating behavioural
functions, stress responses, and the neuroendocrine axis in rats. Changes in plasma
allopregnanolone levels throughout the menstrual cycle have been reported in healthy
women (Schmidt et al. 1994; Wang et al. 1996) and in the rat brain during the estrous
cycle (Palumbo et al. 1995). Previous findings suggest progesterone may exert its
inhibitory effect on the HPA axis system following metabolism to neurosteroids and
subsequent interaction with GABAa receptors (Majewska et al. 1986; Jessop 1999).
However, progesterone receptor has not been detected in the PVN by either
progesterone binding study (Sar 1988) or a progesterone receptor an
immunohistochemistry study (Fenelon & Herbison 2000). Thus it is unlikely that
progesterone has a role in the function of PVN neurones through genomic actions
directly. Subcutaneous 4-MA administration increased ACTH secretion in response to
swim stress in pregnant rats, which suggests that progesterone metabolites may
contribute to the regulation of HPA activation.
It is well established that allopregnanolone and THDOC are powerful allosteric
modulators of the GABAa receptor (Lambert et al. 1995). 4-MA inhibits 5a reductase
activity, thus blocking the conversion of progesterone to allopregnanolone. 4-MA has
been reported to reduce progesterone anti-seizure actions in the absence of estrogen
(Frye 1995). In ovariectomised rats, the anxiolytic effect observed (increasing
proportion of time spent on the open arms in the plus- maze test and reducing the
duration of burying behaviour in the defensive burying test) after progesterone
administration is prevented by 4-MA pre-treatment (Bitran et al. 1995). 4-MA
blocked the production of allopregnanolone in the plasma from exogenous
progesterone (Bitran et al. 1995). The effect of 4-MA on behaviour is paralleled by a
block of the potentiating effect of progesterone administration on the GABA-gated CI"
channel response in cortical synapatoneurosomes from ovariectomised rats, which
suggests that 4-MA at this dose and time course reduced allopregnanolone levels in
the brain. 4-MA will also block the production of THDOC, another GABAa receptor
active neurosteroid, which is derived from progesterone via DOC catalysed by 5a
reductase (Abul-Hajj 1972; Schneider & Honour 1992; Winkel et al. 1980).
172
Effect ofneurosteroicls on the ACTH response to stress during pregnancy Chapter 7
In rats, plasma progesterone levels are increased throughout pregnancy reaching a
peak at around day 16-20 when they are about 10-fold greater than the estrus values,
then returning to the control values at day 22, just before parturition. Cerebrocortical
progesterone levels change with a similar pattern to plasma concentrations during
pregnancy (Concas et al. 1999). The plasma and cerebrocortical concentrations of the
metabolites of progesterone, allopregnanolone and THDOC, are at their highest levels
around day 20 of pregnancy (Concas et al. 1999) and are still at high levels compared
with the virgins on day 21 of pregnancy (Frye & Bayon 1998).
Although progesterone has been considered only as a female reproductive hormone,
substantial evidence has been reported that stress can increase progesterone levels in
the plasma (Deis et al. 1989; Nequin et al. 1975; Purdy et al. 1991; Schaeffer & Aron
1987). Elevated levels of plasma progesterone accompany the increase in
corticosterone after stress in male rats (Nequin et al. 1975; Purdy et al. 1991;
Schaeffer & Aron 1987). Stress induced progesterone secretion in male and female
rats is derived from the adrenal gland, because the response is abolished after
adrenalectomy (Deis et al. 1989; Nequin et al. 1975; Purdy et al. 1991).
The physiological role of this progesterone in the HPA axis is not clear, but it is well
established that the circulating progesterone can enter the brain, providing
allopregnanolone to interact with GABAa receptors. Thus progesterone of adrenal
origin is also considered as a precursor of allopregnanolone in the brain. Brain tissues
can also produce progesterone and its metabolites after stress (Barbaccia et al. 1998).
In pregnancy, allopregnanolone has enhanced actions on GABAa receptors on
oxytocin neurones at the end of pregnancy. The cellular levels of GABAa receptor al
subunit mRNA are elevated with the progression of pregnancy in oxytocin neurones
of the SON and PVN and are reduced about 30-40% in the last two days before
pregnancy (Fenelon & Herbison 1996). In ovariectomised female rats, a progesterone
implant for 9 days increased GABA receptor al subunit mRNA expression both in
vasopressin and oxytocin rich PVN and SON neurones (Fenelon & Herbison 2000).
The increased GABAa receptor al subunit expression and cerebral levels of
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allopregnanolone together may be important for the attenuated HPA axis response to
stress during pregnancy, if similar changes occur in the GABAergic mechanisms
regulating PVN CRH/vasopressin neurones in pregnancy. However, nothing is
presently known about this.
It is well known from in vivo studies that GABAergic mechanisms are involved in
inhibiting the HPA axis (Makara & Stark 1974) and that the hypothalamus is a major
site of action as GABAa receptors and a dense network of glutamate decarboxylase
(GABA synthesising enzymej-positive nerve fibres are present in the hypothalamus.
Secretion of CRH, the major stimulator of the HPA axis, is negatively regulated by
the GABAergic system. GABA is detected in the CRH-containing parvocellular
neurones in the PVN (Meister et al. 1988), and potentially influences CRH expression
via GABAergic neurones within the bed nucleus of the stria terminalis and preoptic
nuclei which project into the PVN (Herman & Cullinan 1997). A GABAa receptor
agonist inhibits CRH secretion from the hypothalamus in vitro (Calogero et al. 1988)
and CRH secretion from the hypothalamic PVN into the hypophysial-portal
circulation (Plotsky et al. 1987). Vasopressin is also believed to be inhibited by the
GABAergic system. Administration of allopreganolone to rats decreased vasopressin
mRNA expression in the ventromedial subdivision of the hypothalamic PVN (Patchev
et al. 1996). In the present study, removing the inhibitory effect of allopregnanolone
through GABA receptors, by administration of 4-MA, increased the ACTH response
in pregnant rats after swimming stress. It is proposed that this is the result of increased
CRH and/or vasopressin secretion by the hypothalamus during stress which is
normally enhanced without the inhibitory action of allopregnanolone.
Another 5a-reductase inhibitor, finasteride, does not change either cerebral cortex or
plasma progesterone concentration, however it reduces significantly allopregnanolone
and THDOC concentrations in the brain and plasma in day 20 (Concas et al. 1998;
Concas et al. 1999) or in day 21 pregnant rats (Frye & Bayon 1998), from their high
values during pregnancy, to close to the low values of estrus. The concentrations of
these two neurosteroids in the cerebral cortex were measured by Concas et al. (Concas
et al. 1998) after finasteride administration. Two hours after giving finasteride,
neurosteroid concentrations in day 20 pregnant and estrus rats were reduced to similar
levels (allopregnanolone: from 3.0±0.3 to 0.710.08 ng/g in estrus, from 12.211.6 to
174
Effect of neurosteroids on the ACTH response to stress during presnancv Chapter 7
1.2±0.1 ng/g in pregnant rats; THDOC: from 1.5±0.2 to 0.4±0.07 ng/g in estrus, from
2.8±0.4 to 0.3±0.09 ng/g in pregnant rats). Although finasteride decreases both
neurosteroid concentrations in estrus, the actual values of these neurosteroids before
finasteride administration were lower than in pregnancy.
An interesting result from the present study was the prolonged increase in ACTH
secretion after stress in the 4-MA treated virgin and pregnant rats. This suggests that
both neurosteroids, produced during stress, and GABAa receptors, are involved in the
negative feedback that returns HPA axis activity to basal after the stressor is removed
(Jessop 1999). Intraventricular injection of 10 pi anti-allopregnanolone serum
significantly potentiates plasma corticosterone response to an acute cold water
swimming stress (Guo et al. 1995). The administration of allopregnanolone and its
precursor progesterone also resembles glucocorticoids in their suppression of the
pituitary-adrenal response to emotional stress (Patchev et al. 1996). The prolonged
ACTH responses to stress in the 4-MA treated rats provides indirect evidence for the
effectiveness of 4-MA in inhibiting neurosteroid formation.
Allopregnanolone and GABAa receptors are localised in a broad distribution in the
brain and exert many behaviour roles apart from the inhibitory action on the HPA axis
system, such as anticonvulsant (Belelli et al. 1989), and anxiolytic effects, but effects
of 4-MA on these aspects were not assessed in the present study.
4-MA and exogenous CRH-inducedACTH secretion
In the present study, the injection of CRH (200 ng/kg) 70 min after the swim, showed
there was no statistically significant difference in ACTH increment within the virgin
and pregnant groups (Figure 7.4), whether they were given vehicle or 4-MA. This
suggests that the reduced allopregnanolone production induced by 4-MA
administration may not have directly affected the corticotrophs. However, we cannot
be certain about this due to the small number of samples, because in the pregnant 4-
MA group the 3 rats that were able to be sampled may not have been representative
(Figure 7.4). The tendency for a greater response to CRH in the pregnant 4-MA group
is consistent with increased endogenous vasopressin secretion after 4-MA treatment
(see Chapter 5). It is unlikely that allopregnanolone directly affects corticotrophs, as
in vitro studies, the neurosteroids dehydroepiandrosterone, pregnenolone and
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pregnanolone do not affect POMC mRNA expression in pituitary AtT 20 cells, even
at the highest concentrations employed (Vedder et al. 1993). Although some studies
reported that GABA has a stimulatory effect on ACTH secretion directly on
corticotrophs (Anderson & Mitchell 1986; Tominaga et al. 1989), others found
GABA has no direct effect on the anterior pituitary (Loeffler et al. 1986) and GABA
receptors are not reported in the corticotrophs so far.
Immediately before parturition, progesterone, allopregnanolone and THDOC
concentrations in plasma and brain are reduced to close to basal levels (Concas et al.
1999). This reduction of the concentrations of these hormones is believed to trigger
parturition. In the present study, the artificial decrease in allopregnanolone and
THDOC levels by 4-MA did not lead to signs of pre-term birth.
GABAa receptors have been identified in both the uterine myometrium and
endometrium (Amenta et al. 1988). Allopregnanolone has a stronger effect than
progesterone on inhibition of uterine contraction both in vivo (Majewska & Vaupel
1991; Putnam et al. 1991) and in vitro (Cabral et al. 1994; Thornton et al. 1999)
through GABAa receptors. Allopregnanolone is considered to participate in regulation
of GABAa receptors (Majewska et al. 1989) and their subunits (Fujii & Mellon 2001)
in the uterus during pregnancy. In the present study, the changes (uterine blood
vessels appeared more distended in the 4-MA treated pregnant rats) in the uterus may
be due to the reduction of allopregnanolone production by 4-MA administration,
however, the mechanisms of uterine blood vessels distended by 4-MA treatment is not
clear.
5a-reductase also catabolises other hormones besides progesterone (review: (Celotti et
al. 1992)): testosterone to 5a -androstan-17P-ol-3-one (5a-dihydrotestosterone) and
androstenedione to 5a- androstan-3,17-dione (androstandione), so 4-MA would also
block these conversions. However, there is little basis for considering interference
with these conversions by 4-MA as a mechanism for reversing the attenuated HPA
axis responses to stress in pregnancy. 5a-reductase also catalyses the conversion of
corticosterone to 5a -pregnan-1 ip,21-diol-3,20-dione (dihydrocorticosterone) and
also the conversion of deoxycorticosterone to 5a -pregnan-21-ol-3,20-dione
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(dihydrodeoxycorticosterone). But the possible physiological role of the 5a-reduction
of corticoids is unknown.
In conclusion, high brain and plasma concentrations of neurosteroids in late
pregnancy are important for the attenuated ACTH response to stress. This action is
through allopregnanolone inhibition of secretion (and possibly production) of CRH
and vasopressin by parvocellular PVN neurones, rather than inhibition of ACTH
secretion through direct action on corticotrophs in the anterior pituitary. Neurosteroids
are involved in the switching-off of the HPA axis response to stress in virgin and
pregnant rats.
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Chapter 8
General discussion
In late pregnancy, ACTH secretion from anterior pituitary corticotrophs in response to
stress is attenuated and the sensitivity of the adrenal cortex is increased. This
attenuated ACTH secretion would provide a protective mechanism for the fetuses, as
high levels of corticosterone in the plasma damage the development, growth, and
future mental health of the pups. The mechanisms underlying the attenuated ACTH
response many comprise two broad mechanisms: changes in corticotroph sensitivity
and in secretagogue exposure.
The changes underlying the attenuated ACTH secretion from corticotrophs during
pregnancy are summarised in Figure 8.1.
8.1 changes in gene expression of controlling ACTH secretion factors
in the anterior pituitary
The density of the two major ACTH secretagogue receptors, the CRHR1 and Vlb
receptors, on corticotrophs are reduced in pregnancy as shown by receptor binding
studies (Neumann et al. 1998; Toufexis et al. 1999). In the present study, we found no
change in CRHR1 and reduced Vlb receptor mRNA expression during pregnancy.
Glucocorticoid negative feedback mediated by GR was likely to be enhanced as
suggested from the increased GR mRNA expression in the anterior pituitary. This
enhanced mechanism was also supported by the effect of phADX on POMC mRNA
expression: phADX caused a greater reduction of corticosterone concentration in
pregnant rats (by 32 ng/ml and 85 ng/ml in virgin and pregnant rats respectively), but
the increases in POMC mRNA expression were about the same in virgin and pregnant
rats after phADX.
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Expression of the mRNA for CRHBP, another factor indirectly inhibiting ACTH
secretion, and its stimulation by stress, were similar in pregnant rats and in virgin rats,
suggesting that this protein may not be important in regulating the effectiveness of
CRH for ACTH secretion during pregnancy. No change of BK channel and STREX
mRNA expression suggests no change in the role of these channels in regulating
ACTH secretion in pregnancy. The changes in mRNA expression in the anterior
pituitary that were found may contribute to reduced ACTH secretion, or be secondary
to changes in the hypothalamic secretagogue input. To further investigate the
importance of possible change in the exposure of corticotrophs to the secretagogues,
we measured the ACTH response to CRH and vasopressin in vivo (Chapter 4 and
Chapter 5), and the effects of CRH and vasopressin receptor antagonists on stress
responses.
8.2 CRH and vasopressin on ACTH secretion in vivo and in vitro
CRH and vasopressin act synergistically to stimulate ACTH secretion. Thus the
attenuated ACTH response to exogenous CRH and vasopressin in pregnancy indicates
either decreased corticotropin sensitivity, or reduced basal CRH and vasopressin
release in pregnancy. However, the combination of CRH plus vasopressin stimulated
ACTH secretion similarly in virgin and pregnant rats, suggesting the ability of the
corticotrophs to secrete ACTH is not different between virgin and pregnant rats and
that the reduced ACTH response to CRH or vasopressin alone is due to lower basal
levels of endogenous CRH and vasopressin in pregnancy.
Blocking CRH action using the CRHR1 antagonist, antalarmin, reduced the ACTH
response to swim stress similarly in virgin and pregnant rats indicating that stress-
induced CRH release may not be changed in pregnancy. However, CRH available for
stimulating ACTH secretion in the median eminence was lower in pregnancy,
although this may reflect reduced CRH production related to reduced daily secretion
under basal conditions in the pregnant rats. The Vla/b receptor antagonist reduced the
ACTH response to swim stress only in virgin rats, but not in pregnancy, which
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suggests that stimulated vasopressin secretion is decreased in pregnancy and this may
be the important reason for the attenuated ACTH response to stress in pregnancy.
In contrast to the results from the in vivo studies, ACTH secretion by corticotrophs in
vitro was greater in pregnancy in response to CRH. This is probably due to enhanced
cAMP post receptor signalling in corticotrophs, despite the receptors for CRH and
vasopressin on the corticotrophs being reduced in pregnancy. Consistent with the in
vivo result, the effect of combination of CRH plus vasopressin on ACTH secretion in
vitro was not reduced in pregnancy. In pregnancy, CRHR1 density in the anterior
pituitary is reduced, however, the signalling through cAMP is increased, this
increased efficiency may be important to maintain an ACTH response.
8.3 A role for neurosteroid in the attenuated ACTH response in
pregnancy
Progesterone and its neurosteroid metabolite levels are increased progressively during
pregnancy, reaching peak values around day 20, then returning to basal just before
parturition. Inhibitory effects of progesterone and allopreganolone on the HPA axis
are already known. In the present study, blocking production of neurosteroids from
progesterone by 4-MA enhanced the ACTH responses to swim stress in pregnant rats,
but not to exogenous CRH. The enhanced inhibitory effect exerted by progesterone
metabolites in pregnancy may be the reason for the attenuated ACTH response to
stress in pregnancy. As exogenous CRH- induced ACTH secretion was not changed
by administration of 4-MA, the neurosteroid metabolites may act on the hypothalamus
to reduce CRH and/or vasopressin synthesis and release, rather than inhibit ACTH
secretion directly from the corticotrophs, although the sample size for the interaction
of 4-MA and exogenous CRH on ACTH secretion was small.
It was evident that in both virgin and pregnant 4-MA treated rats the increase in
ACTH secretion was more prolonged after stress than in the vehicle-treated rats. This
may reflect a role for inhibitory neurosteroids in terminating the stress response.
Inhibitory neurosteroids are expected to act by interaction with GABAa receptors,
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which mediate inhibitory actions of GABA pathways on CRH neurones. This requires
further investigation.
8.4 Physiological importance
The HPA axis and the female reproductive system exhibit a complex relationship, the
HPA axis exerting profound, mostly inhibitory effects, on the reproductive axis, with
CRH and CRH-induced POMC peptides inhibiting hypothalamic GnRH secretion,
and glucocorticoids inhibiting pituitary LH and ovarian estrogen and progesterone
secretion, and suppressing the gonadal axis at the levels of the hypothalamus,
pituitary, gonads, and end-target tissues (Rivest & Rivier 1995).
Pregnancy is associated with an increased incidence of mental illness and mood
disturbance in both the immediate antenatal and post-natal period. Plasma levels of
CRH, from the placenta, are markedly elevated in pre-eclamptic mothers (Perkins et
al. 1995), and in healthy pregnant women during normal labour. Placental CRH is
proposed to be the biological clock that times labour and delivery in women from the
evidence that women who deliver prematurely have higher levels of CRH, about the
same values of those of women close to term; and lower levels of CRH in women
with post-mature delivery (McLean et al. 1995). The postpartum period is
characterised by an increased incidence of psychiatric problems: "postpartum blues",
a mild form of transient depression (Magiakou et al. 1996). This may be linked to
altered HPA axis regulation, perhaps involving action of placental CRH.
Marked changes in concentrations of circulating hormones are observed during
pregnancy. Much interest has focused on the potential changes in the HPA axis during
pregnancy and the development of maternal postnatal depression and affective
disorders. However, the mechanisms of these changes are not clear. The finding of
decreased CRH gene expression in the PVN during pregnancy in the rats suggests that
reduced hypothalamic CRH secretion occurs during pregnancy (Johnstone et al.
2000). In humans, secretion of CRH from the placenta into the circulation has been
postulated to influence the maternal HPA axis (Waddell 1993), however,
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measurements of the plasma levels of CRH during pregnancy do not correlate with
the development of mood disorder (Smith et al. 1990). It is interesting to note that the
abnormalities in HPA axis activity continue for several weeks after delivery when the
plasma levels of CRH have returned to pre-pregnancy levels (Owens et al. 1987) and
altered HPA axis activity occurs in pregnancy in species such as rodents (Atkinson &
Waddell 1995) which do not possess elevated levels of plasma CRH during
pregnancy. The development of postnatal mood disturbances was found to be
significantly related to plasma Cortisol levels measured at 38 week of pregnancy
(Handley et al. 1980).
It is also clear that exposure of fetuses to stress, and particularly to glucocorticoids
has lifelong adverse effect (Welberg & Seckl 2001), a "programming" with persistent
organisational effects including hyperactive HPA system, increased anxiety and
reduced ability in cognition. Maternal stress during week 28-30 of gestation is
associated with birth outcome: increased levels of psychosocial stress are significantly
related to gestational age at birth and infant birth weight. Maternal stress during the
third trimester was associated with increased maternal plasma levels of ACTH and
Cortisol (Sandman et al. 1997). Prenatal maternal stress has been related to neonatal
activity and irritability. Animal research demonstrates that prenatal stress feminises
and demasculinises the sexual behaviour of males and reduces fertility and fecundity
in females, producing estrous cycle disorders, spontaneous abortions, or vaginal
hemorrhaging and high neonatal mortality (Herrenkohl 1986).
The neuroendocrine response of the HPA axis is required for the survival of the
organism during times of stress, Therefore progressive a reduced stress response
would be expected to be harmful to the mother. However, pregnant rats survive acute
experimental stress well (Neumann et al. 1998). We deduced that vasopressin
secreted from the hypothalamus into the portal blood during stress is reduced, and
there were secondary adaptive changes in the signalling system of the corticotropins in
pregnancy of rats, suggesting rats may protect themselves and their offspring by these
mechanisms.
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8.5 Future studies
To further elucidate the mechanisms underlying the attenuated ACTH secretion from
corticotrophs during pregnancy, the following information would be valuable. 1)
direct measurement of hypothalamic changes in vasopressin release; 2) measurement
of vasopressin or CRH action on ACTH secretion alone in vivo\ 3) details of changes
in post receptor signalling in corticotrophs; 4) roles of neurosteroids in the brain.
1) Knowledge of changes in the median eminence vasopressin content in pregnancy,
including after stress, will be important for understanding the attenuated ACTH
response to stress. Although it is difficult to measure vasopressin of PVN
parvocellular neurone origin in the median eminence directly, as the median eminence
contains vasopressin from both the parvocellular (external zone) and magnocellular
(internal zone) neurones, vasopressin levels in the median eminence can be evaluated
by immunohistochemistry.
2) In the present study, we used the Vla/b receptor antagonist to investigate the role
of vasopressin and CRH in ACTH secretion. This antagonist blocked the effects of
vasopressin via Vlb receptors as well as Via receptors, so in order to elucidate the
exact action of vasopressin on the corticotrophs through the Vlb receptors in
pregnancy, a more specific Vlb receptor antagonist (or a Via receptor antagonist)
would be useful. The CRHR1 antagonist used in the present study, antalarmin, is a
non-peptide compound which can pass the blood-brain barrier and have central
actions via the CRHR1 in the brain, so to elucidate CRH action on the corticotrophs
use of a peptide antagonist would be valuable. To further confirm importance of the
reduced basal CRH and stress-stimulated vasopressin release and to remove the
interaction of vasopressin and CRH respectively, treatment with a specific Vlb
antagonist and then exogenous CRH, and a peptide CRHR1 antagonist and then
exogenous vasopressin, and measurement of ACTH secretion in pregnancy would be
appropriate.
3) CRH post-receptor signalling is enhanced in pregnancy as suggested by the
incubation of acutely isolated anterior pituitary with 8-CPT-cAMP. This increased
effect of cAMP may be via calcium influx through L-type calcium channels, so it
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would be interesting to know the changes in intracellular calcium concentrations in
response to CRH or cAMP, and the calcium channel function and electrophysiological
properties in pregnancy.
4) 4-MA is a 5a-reductase inhibitor preventing the metabolism of progesterone to its
metabolites and has been reported to affect behaviour by blocking the production of
progesterone neurosteroid metabolites. However, in the present study, we did not
measure the plasma and brain concentrations of progesterone metabolites,
allopregnanolone and THDOC. Measurement of changes in these neurosteroid
concentrations would offer more evidence of the role of the neurosteroids on the
ACTH response to stress in pregnancy. The 5a-reductase inhibitor, 4-MA, prevents
not only the production of allopregnanolone and THDOC, but also blocks production
of other metabolites of steroid hormones such as dihydrotestosterone from
testosterone, androstandione from androstenedione, and dihydrocorticosterone from
corticosterone. To further investigate the role of allopregnanolone in the ACTH
response, the administration of allopregnanolone after 4-MA would be a useful
option. To investigate the sites of the neurosteroid action, after 4-MA or
allopregnanolone administration, CRH and vasopressin gene expression in the PVN,
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(I0"6 M),and mimicked by an agonist,4-Thr-7-Gly-OT (I0-7 M).Analysis of immu-
noidentified profiles showed that as in vivo, the changes were specific to OT neu¬
rons. Finally, the unbiased disector method revealed that OT application induced
an over 30% increase in the overall synaptic density of the SON.
(1) El Majdoubi et a!., Biochem. Cell. Biol., 2000,78, I -1 I.
(2)Theodosis et al„ Nature, 1986, 322,738-740.
P2-3
Generation of burst activity in supraoptic oxytocin neurones in vivo:
role of dendro-dendritic interaction and intracellular Ca2+.
Leng G., Ludwig M. & Sabatier N.
Div. Biom. Clin. Lab., Edinburgh, uk
Dendritic release of peptides from supraoptic nucleus neurones is thought to
play an important role in the regulation of these neurones. Oxytocin (OT) has
been shown to have feed-back action on OT neurones: it facilitates the genera¬
tion of milk-ejection bursts in rats in vivo, induces its own dendritic release both
in vitro and in vivo and triggers an increase in intracellular Ca2+ concentration
([Ca2+]i) through mobilisation of internal Ca2+ stores. Interestingly, variations in
[Ca2+]i seem to be a key factor in determining the firing pattern, either conti¬
nuous or phasic, of supraoptic neurones. In this study, we combined [Ca2+]i
increase and dendritic release within the supraoptic nucleus to investigate the
effect of these factors on firing pattern in OT neurones.Thapsigargin, an intra¬
cellular Ca2+ mobiliser, was applied through a microdialysis probe placed on the
exposed ventral surface of the supraoptic nucleus in adult virgin female rats. In
combination with thapsigargin administration, we triggered dendritic release by
using the technique of constant collision stimulation. Extracellular single cell
recordings were performed in OT neurones.We found that the electrical activi¬
ty of OT neurones switched from a continuous pattern to short clusters of
action potentials (5 to 7 spikes long) and in some cases, milk ejection-like bursts
were observed. Fine analysis showed that the relationship between each inter-
spike interval and the interval that precedes turns into a positive correlation,
indicating that short intervals are more likely followed by short intervals. The
correlation is lost when intervals are randomised and negative correlation
appears when a number of intervals exceeding the cluster length is analysed. In
conclusion, our results suggest that local feed-back mechanisms involving varia¬
tions of intracellular Ca2+ concentration generate a switch in the activity of OT
neurones into a pattern more favorable for the appearance of milk ejection
bursts.
P2-4
Vasopressin and the attenuated ACTH responses to stressors during
pregnancy in rats.
Ma S. (I), Shipston M.(2) & Russell J. (I)
(I) Lab Neuroendocrinology, Edinburgh, UK ; (2) MBG, Edinburgh, UK
Vasopressin (VP) is co-produced by parvocellular paraventricular nucleus
(pPVN) corticotropin releasing hormone (CRH) neurones.Alone,VP weakly sti¬
mulates ACTH secretion in rats, but it augments the action of CR.H.ACTH secre¬
tory responses to stressors are attenuated in late pregnant rats, and we have
investigated whether altered release or action ofVP is involved.To test in vivoVP
sensitivity,ACTH was measured in jugular venous blood before and after bolus
i.v.VP injection (1.7 pg/kg) :ACTH secretion increased less in pregnant (day 21)
than in virgin rats (by 44 % at 5 min ; p<0.05, two-way ANOVA).AVIa/b anta¬
gonist (dP(Tyr(Me) 2,Arg-NH29]AVP, 10 mg/kg, i.v., shown to preventVP stimu¬
lation ofACTH secretion ; a gift from M. Manning), or vehicle was given before
swim stress (90 sec): after vehicle,ACTH secretion was increased less by swim-
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ming in pregnant than in virgin rats (by 200 pg/ml vs 483 pg/ml at 5 min) ; the
Vla/b antagonist reduced the increase in ACTH secretion more in virgin than in
pregnant rats. Using aVIb receptor mRNA riboprobe (a gift from S. Lolait), for
quantitative in situ hybridisation (ISH) on pituitary cryostat sections, we found
reduced expression in pregnancy (by 19 % vs. virgins).To test in vitro sensitivity
to VP, pituitaries were removed from virgin and pregnant rats and cell suspen¬
sions prepared ; increasing concentrations of CRH and VP, alone or together,
were added to incubated aliquots for 60 min, and ACTH release measured.
Stimulation ofACTH secretion by CRH was similar for cells from pregnant and
virgin rats, but augmentation of CRH effects byVP was greater in pregnancy.This
may be a result of enhanced post-receptor mechanisms, as a membrane per¬
meable cAMP analogue more effectively stimulated ACTH secretion by pituitary
cells from pregnant rats. Overall, although corticotrophs are more responsive to
VP augmenting actions, this does not compensate for probable reduced CRH
secretion in response to stress.
P2-5
The effects of the afterhyperpolarisation on firing pattern in vivo: a
statistical approach.
MarganiecA. (I), Moos F. (2) & Leng G.(l)
(I) Biomed Sci, Edinburgh, UK ; (2) CNRS UMR5I0I, Montpellier, France
In vitro studies in magnocellular neurosecretory cells (MNC's) of the supraoptic
nuclei (SON) showed that trains of high frequency discharge (20-50 Hz) are fol¬
lowed by an afterhyperpolarisation (AHP), which lasts around Is and is genera¬
ted by the activation of a calcium dependent potassium channel. It has been sug¬
gested that the AHP is of importance in the regulation of continuous and phasic
firing in SON cells, and its inactivation may be necessary to enable MNC's to fire
at the high frequencies that occur during milk-ejection bursts. However, since in
vitro experiments include the injection of a depolarising current and hence crea¬
te an artificial situation the physiological role of the AHP in vivo remained
unclear.To investigate whether the AHP has a role in the in vivo activity of oxy¬
tocin neurones, the present study employed statistical methods to analyse in vivo
extracellular recordings of virgin and lactating rat.
We investigated the relationship between successive interspike intervals (ISI's) of
long recordings of continuous firing cells and the background activity of cell dis¬
playing high frequency discharges associated with milk-ejection burst
We report a non-random distribution of spikes, whereby a short interval is more
likely to be followed by a long interval, and vice versa. If the AHP has an impact
at spontaneous firing rates in vivo, we would expect to find a balancing effect i.
e. a period of slower activity should follow after a period of more intense acti-
vity.This hypothesis is consistent with our observations of in vivo firing patterns.
P2-6
Thymic neurohypophysial peptide-mediated signalling and T-cell diffe¬
rentiation.
Martens H., Hansenne I., Brilot F., Rosier G., Charlet-Renard C. H., Legros J. J. &
Geenen V.
Inst Pathol., CHU-B23, Liege, Belgium
Thymic epithelial cells (TEC) express a repertoire of neuroendocrine-related
genes characterised by the dominance of one member over others.
Recapitulating the dual role of the thymus in T-cell differentiation, this repertoire
of genes codes either for cryptocrine ligands binding to cognate neuroendocri¬
ne receptors expressed by pre-T cells, or for neuroendocrine self-antigens pre¬
sented by thymic MHC to rearranged TCR on thymocytes. In the neurohypo-
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polysialylated NCAM (PSA-NCAM), F3/contactin and its ligand
the matrix glycoprotein, tenascin-C. PSA-NCAM is of particular
relevance since the complex carbohydrate PSA on its extracel¬
lular domain reduces cell adhesion, thereby allowing surface
interactions underlying the dynamic cell changes responsible for
such plasticity. Our recent ultrastructural analyses have provided
direct evidence that PSA-NCAM is indeed a prerequisite since a
single microinjection of endosialidase, an enzyme that selectively
cleaves PSA from NCAM, close to the supraoptic nucleus in vivo,
inhibited the morphological changes normally occuring in
response to lactation (J Neurosci, 1999, 19, 10228). On the other
hand, our in vivo and in vitro observations demonstrate that OT
itself, in synergy with sexual steroids, can induce such plasticity
since its application (by microinfusion into the 3rd ventricle or
perifusion of acute hypothalamic slices) leads to neuronal-glial
and synaptic changes similar to those brought on by parturition
and lactation.
5132
Protective brain adaptations of stress coping mechanisms
in pregnancy and lactation: involvement of oxytocin
and prolactin
I. D. Neumann (Munich, D)
Pregnancy and lactation are accompanied by a reduced respon¬
siveness of the hypothalamo-pituitary-adrenal (HPA) axis and
the oxytocinergic system to a variety of stressors. Studies on rats
have shown that these changes partly triggered by alterations
in circulating steroidal hormones are due to a combination of
attenuated stressor perception and feedforward mechanisms at
limbic, hypothalamic and anterior pituitary levels involving also
the CRH system. Further, maternity is accompanied by dramatic
alterations in the emotionality with an increased level of anxiety-
related behaviour in late pregnant rats. In lactation, anxiety is
reduced which is possibly a prerequisite for increased (maternal)
aggression and defence of the offspring. The robust neuroen¬
docrine and emotional alterations seen in pregnancy and lactation
are independent of the inborn level of anxiety as shown in rats
bred for either high or low anxiety-related behaviour.
Various neuropeptides highly activated at this time to meet
reproduction-related demands like oxytocin, prolactin and
endogenous opioids were shown to significantly regulate the
(re)activity of the HPA axis and/or to exert anxiolytic effects. Such
neuropeptides are, therefore, possible candidates to be involved in
the attenuated neuroendocrine stress responsiveness and altered
emotionality peripartum. These physiological and reversible
adaptations are, in pregnancy, likely to contribute to the protec¬
tion of the fetuses from exposure to excessive, and damaging,
levels of glucocorticoids. In lactation, they may protect the mother
from catabolic processes caused by glucocorticoids. Further,
down-regulation of the activity of the brain CRH system may be a
protective mechanisms to cope with the dramatic hormonal
fluctuations in this period. Disturbance of these mechanisms, e.g.
by repeated exposure to stress throughout pregnancy, results in an
enhanced neuroendocrine stress responsiveness and increased
anxiety in lactation.
Supported by DFG (Ne 465).
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Lactation-induced changes in amygdala-paraventricular
nucleus (PVN) connections: are they mediating emotional
filtering?
C.-D. Walker, S. Deschamps, A. Burlet (Verdun, CDN;
Nancy, F)
Lactation is associated with multiple physiological and behavioral
changes that are optimal for development of the offspring. In
particular, neuroendocrine stress responses and some emotional
responses are blunted, but it is still unclear whether this
phenomenon is dependent upon the nature of the stressor and
whether specific alterations in neuronal circuitry allow to "filter"
stressful stimuli during lactation. Corticotropin releasing factor
(CRF)-containing neurons in the hypothalamic PVN control
neurodendocrine stress responses and are modulated by inputs
from the brain stem, the amygdala, and the bed nucleus of the stria
terminalis (BNST) which integrate emotions. Here, we tested the
hypothesis that 1) lactation induces changes in the PVN-BNST-
amygdala relationships that are directed towards maintaining low
reactivity to infant-irrelevant stimuli and 2) stressors that threaten
survival of the infant can overcome this "filtering" mechanism and
activate important neuroendocrine and behavioral responses in
the mother. Compared to virgins, lactating rats exhibit higher CRF
mRNA expression in neurons of the dorsolateral BNST, which
relay some of the inhibitory hippocampal inputs to the PVN and
reduced CRF mRNA levels in the central amygdala (CeA), which
is considered stimulatory to PVN neurons. Using CRF-directed
immunolesions of the PVN or PVN +BNST neurons, we showed
that in lactating females, PVN neurons containing CRF maintain a
tonic inhibition over neurons in the anterior BNST and the CeA.
This further suggests that reciprocal connections between the
PVN and the BNST/amygdala in lactating females are modified to
lower the influence of stimulatory inputs on stress-responsive PVN
neurons. However, this "filtering" system can be superseeded
since nursing mothers exhibit important neuroendocrine re¬
sponses to a stimulus causing a direct threat to their pups, i.e. a
male intruder, compared to a physical stressor less relevant to
their litter. We are currently testing whether additional brain
structures are recruited after specific stressors, that might
overcome the hyporesponsiveness of the PVN-BNST/amygdala
circuitry during lactation.
S134
Pregnancy reduces neuroendocrine stress responses:
attenuated central processing of stressors and activation of
opioid inhibition
J. A. Russell, P. J. Brunton, H. A. Johnstone, S. Ma, J. R. Seckl,
I. D. Neumann, A. J. Douglas (Edinburgh, UK; Munich, D)
Brain pathways processing different stressors converge onto the
corticotropin-releasing hormone (CRH)/vasopressin (VP) neu¬
rones in the parvocellular paraventricular nucleus (pPVN) of the
hypothalamus, which stimulate ACTH secretion from the anterior
pituitary and hence glucocorticoid secretion from the adrenal
cortex. Simultaneously, centrally-projecting CRH neurones are
activated, eliciting anxiety-related behaviours. We have investi¬
gated changes in the brain mechanisms regulating the neuro¬
endocrine stress response in pregnancy. In late pregnant rats,
basal activity of the pPVN neurones is decreased in terms of
CRH and VP gene expression (measured by in situ hybridisa¬
tion), and the diurnal rhythm in ACTH secretion is sup¬
pressed. Furthermore, pPVN neurone mRNA responses (for the
immediate early gene NGF-IB, and the CRH and VP genes) to
stress are attenuated in late pregnancy. These attenuated
responses underlie reduced ACTH secretory responses to
emotional and mild physical stressors, including immune
challenge. These changes may result from reduced secretory
capacity of the CRH/VP neurones, while the pituitary ACTH
content is normal. Glucocorticoid negative feedback is evidently
enhanced as llbeta-hydroxysteroid dehydrogenase activity
(reactivating corticosterone) in the PVN and glucocorticoid
receptor mRNA expression in the dentate gyrus are increased.
Consequently, decreased activity or effectiveness of excitatory
inputs to CRH/VP neurones is likely. This is supported by finding
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lack of stimulation of NGFI-B mRNA expression in the
ippocampus by stress in pregnancy.
Activation of central endogenous opioid inhibitory mecha-
isms, important in hypoalgesia and in restraining stress activa-
on of oxytocin neurones in pregnancy, is also involved. Hence
ie opioid antagonist naloxone restores ACTH responses to
ress or systemic interleukin-lbeta. The reduced neuroendocrine
ress responses in pregnancy may protect the fetuses from
Iverse programming by excess glucocorticoid, but the underly-
g changes in stressor processing and reduced stress activation in
,e brain have implications for maternal mood changes post
irtum.
Support: BBSRC; DAAD/British Council.
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he neuroendocrine basis of social attachment
. S. Carter (College Park, MD, USA)
he purpose of this presentation is to review the neuroendocrine
echanisms responsible for both the formation of social bonds
id those mechanisms through which social bonds influence
ental health. Social attachments and pair bonds facilitate both
production and survival, providing a sense of safety and
ducing anxiety or stress. Studies of social attachment have
cused on mother-infant and adult pair bonds. The underlying
bstrates of both may rely on shared neuroendocrine substrates,
t the core of the neurobiology of social bonds is an ancient
stem which utilizes several neuropeptides including oxytocin,
lere also is a recurrent association between exposure to stressful
periences [and hormones of the hypothalamic-pituitary-adrenal
fPA) axis] and the subsequent formation of social bonds,
isitive social experiences, including social bonds, may reduce
PA axis activity. In addition, oxytocin is capable both of
cilitating the formation of social attachments and inhibiting
PA and autonomic reactivity. Of particular interest is the fact
at these systems are designed to be modified by social experi-
ices in early life, which can in turn produce long-lasting changes
the neuroendocrinology of social behavior. For example, early
posure to oxytocin or the related peptide, vasopressin can
:rmanently modify both behavior and central peptide receptors,
n understanding of the biological basis of social attachment and
developmental consequences provides insights into the
uroendocrine mechanisms through which social support
nefits mental and physical health. Failures of this system may
lp to explain a variety of emotional disorders, including those
at are characterized by deficiencies in social behavior.
ender differences in the genetics of mental
sorders
36
ender differences in attitudes towards predictive testing
d ethics
. Rietschel, F. Illes, G. Rudinger, M. Angermeyer, W. Maier
onn, Leipzig, D)
le advances in molecular genetics are producing insights into the
alecular basis of a growing number of diseases. This knowledge
ows to diagnose single-gene disorders as well as to identify
edispositions to complex inherited disorders. Such testing may
fer medical or psychological benefits but may also have adverse
le-effects. The knowledge of being a carrier of a disease/
ilnerability gene can help to treat/prevent the disorder, fur-
ermore it may have an influence on family-planning, planning of
e future, work, relationships, concept of an individual's
autonomy and in general on his well-being. Testing can be
performed in individuals at risk for a specific disorder or as
screening of the general population.
Attitudes towards the potential benefits and negative conse¬
quences of this "new genetics" vary considerably, they are influ¬
enced by personal experiences, ethnical, religious, and political
factors.
Women approach ethical dilemmas differently from men. In
psychological studies of moral decision making women tended to
use a relationships-based ethics that see individuals as embedded
in a network of relationships while men were more likely to regard
individuals as isolated agents.
The availability of presymptomatic testing for many different
disorders will have an enormous impact on society in general and
specifically on the relationships of parents/couples. They will have
the option to decide whether to perform prenatal testing, predictive
testing in their children or for themselves for a variety of possible
disorders. Before the introduction of wide-spread DNA testing it
would therefore be desirable to learn what femals and males think
about this issue and if there are gender specific differences.
Within the framework of the German Human Genome Project
we are conducting a representative survey on attitudes toward
genetic research, counseling, potential misuse, and predictive
testing in severe mental disorders. First results will be available
by January 2001.
5137
Gender differences in the genetics of substance abuse
P. Franke (Bonn, D)
The etiology of substance abuse is presumed to be multifactorial.
Within the last decade, family- (Merikangas et al. 1998), adoption-
(Cadoret et al. 1995) and twin studies (Kendler et al. 2000) have
underscored -apart from environmental and individual factors -
the substantial role of genes in the development and maintenance
of addictive behavior (Enoch & Goldman, 1999). The aim of
psychiatric molecular genetics is to identify these genes leading
to substance abuse and dependence.
From an epidemiological point of view prevalence rates of
substance abuse disorders revealed gender differences which may
reflect genetic differences between men and women. However,
only few information is yet available on sex-specific genetic
influences on substance abuse (which is often due to inadequate
power to test for sex-specific transmission).
The following review will focus on this topic based on results of
family-, adoption-, and twin study data as well as molecular genetic
studies.
Cadoret RJ, Yates WR, Troughton E,Woodworth G, Stewart MA
(1995) Adoption study demonstrating two genetic pathways to
drug abuse. Arch Gen Psych 52: 42-52.
Enoch MA, Goldman D (1999) Genetics of alcoholism and
substance abuse. Addictive Disorders 22: 289-299.
Kendler KS, Karkowski LM, Neale MC, Prescott CA (2000) Illicit
psychoactive substance use, heavy use, abuse, and dependence
in a US population-based sample of male twins. Arch Gen
Psych 57: 261-269.
Merikangas KR, Stolar M, Stevens DE, Goulet J, Preisig MA,
Fenton B, et al. (1998) Familial transmission of substance use
disorders. Arch Gen Psychiatry 55: 973-979.
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Genetics of puerperal psychosis
I. Jones (Birmingham, UK)
For bipolar women the postnatal period is a time of heightened
risk with episodes of severe psychiatric disturbance (puerperal
30.13 30.14
HYPTHALAMO-PITUITARY-ADRENAL AXIS
STRESS RESPONSES IN PREGNANCY AND
GLUCOCORTICOID NEGATIVE FEEDBACK
P.J. Brunton, S. Anderson, J. Bell £ J.A. Russell
Dept. of Biomedical Sciences, University of Edinburgh, HRB, George
Square, Edinburgh, EH8 9XD, UK.
Ale tested a role for enhanced glucocorticoid negative feedback in the
lyporesponsiveness of the HPA axis to stressors in late pregnancy. In
Expt. 1, to block corticosterone synthesis and feedback, virgin and
Dregnant rats were given metyrapone 8 hourly for 48h, and killed at
50h. Radioimmunoassayed plasma ACTH was increased, and
;orticosterone decreased. Cryostat sections of the parvocellular
Daraventricular nucleus (pPVN) were hybridised with 35S-oligo-probes
;omplementary to vasopressin (VP) and CRH mRNAs. Film
autoradiograph quantification showed increased VP and CRH mRNA
axpression in virgin and pregnant metyrapone-treated vs. vehicle-
reated rats; expression was greater in the pregnant metyrapone
group. In Expt. 2, to test rapid corticosterone feedback, virgin and
aregnant rats fitted with a jugular vein cannula were blood sampled
during forced swimming (FS; 90s at 19C) with either corticosterone or
/ehicle pretreatment. FS increased plasma ACTH in both vehicle-
reated groups, but pregnant rats showed attenuation. Corticosterone
reatment decreased the ACTH response to FS in virgin but not
aregnant rats. Thus basal pPVN CRH and AVP mRNA expression is
nore sensitive to glucocorticoid feedback in pregnancy, but enhanced
apid feedback by corticosterone does not underlie HPA axis stress




Ma S, Douglas AJ, Shipston MJ & Russell JA
Dept of Biomedical Sciences, University of Edinburgh, EH8 9XD.
Anterior pituitary ACTH secretion is regulated by glucocorticoid
feedback, corticotrophin releasing hormone (CRH) and vasopressin
(VP). ACTH secretory responses to stressors and to CRH are
attenuated in pregnant rats. Here, we quantified receptor (R) mRNAs
for CRH1, VPfb and glucocorticoid (GR) in the anterior pituitary using
in situ hybridisation (ISH). Comparing expression in pituitaries from
virgin (n=9) and pregnant (day 21, n=6) rats: CRHR1 mRNA was not
different; VP1b-R mRNA was reduced and GR mRNA increased in
pregnancy (both p<0.05, t-test), the latter indicating increased
negative feedback. To test in vivo VP sensitivity, ACTH was measured
in jugular venous blood before and after i.v. VP bolus injection
(1.7ug/kg): ACTH secretion increased less in pregnant than in virgin
rats (p<0.05, two-way ANOVA). As CRF and VP synergistically elevate
cAMP in corticotrophs we examined whether cAMP-stimulated ACTH
release was modified in pregnancy using dispersed rat anterior
pituitary cells. The cell permeable cAMP analogue (8-CPT-cAMP,
0.5mmole/l) stimulated ACTH release to a greater extent from cells
isolated from pregnant rats than those from virgins. This enhanced
efficacy of cAMP-stimulated ACTH release may compensate partly for




EFFECT ON HYPOTHALAMIC GENE EXPRESSION
N SIBERIAN HAMSTERS
Mercer JG, Moar KM, Logie TJ, Findlay PA, Adam CL, Morgan PJ.
Aberdeen Centre for Energy Regulation and Obesity (ACERO),
Molecular Neuroendocrinoiogy Group, Rowett Research Institute,
Sucksburn, Aberdeen AB21 9SB, Scotland, UK
t is unknown whether the hypothalamus differentiates between weight
:hange induced by imposed negative energy balance ("inappropriate"
)ody weight) and seasonal weight change ("appropriate" body weight)
n Siberian hamsters. Seasonally-inappropriate weight loss was
nduced in adult males (1) by food restriction in long days (LD) to mimic
short day (SD) weight loss or (2) by food restriction in SD,
superimposed on SD weight loss. SD weight loss was accompanied by
educed POMC but elevated CART mRNA in the arcuate nucleus
ARC) measured by in situ hybridisation. SD hamsters had reduced
eptin receptor (OB-Rb) mRNA in the ARC and ventromedial nucleus
VMN); MC3-R mRNA was reduced in the ARC, but elevated in the
i/MN. Equivalent weight loss and low plasma leptin during LD-
estriction produced mRNA profiles typical of negative energy balance,
with low CART and elevated OB-Rb mRNAs in the ARC; MC3-R
tiRNA levels were indistinguishable from SD. Food restriction in SD
jp-regulated anabolic neuropeptide and OB-Rb mRNAs, indicating
nappropriately low body weight despite ongoing SD weight loss. Thus,
ow plasma leptin is integrated differently in SD and LD-restricted
animals. Many hypothalamic changes in SD are unlikely to be
secondary to the seasonally-appropriate weight loss, but seasonally-
nappropriate body weight in either photoperiod activates
aompensatory neuropeptide systems.
30.16
MODULATION OF NEURONAL ACTIVITY IN THE
SUPRACHIASMATIC NUCLEUS BY AFFERENTS
FROM THE RAPHE NUCLEUS
G.S. Bhumbra and R.E.J. Dyball
Department of Anatomy, University of Cambridge, Tennis Court Road,
Cambridge, CB2 3DY.
Serotonin receptor agonists have been shown to shift the peak of
single unit activity in the suprachiasmatic nucleus forwards or
backwards, depending on the time of day they are applied.
Electrophysiological experiments in vitro have shown that serotonin
receptor agonists and antagonists are able to decrease and increase
the excitability of cells in the suprachiasmatic nucleus. A serotonergic
projection from the anterior group of raphe nuclei to the anterior
hypothalamus has been described anatomically. The present study
was designed to characterise the projection electrophysiologically in
the rat brain. While electrically stimulating the region of the dorsal
raphe, extracellular electrodes were used to record the single unit
activity of cells in the suprachiasmatic nucleus in vivo. All experiments
were carried out in accordance with the Animals (Scientific
Procedures) Act 1986. Peristimulus-time histograms were constructed
to demonstrate that most cells in the suprachiasmatic nucleus
responded to dorsal raphe stimulation. Responses were either
excitatory, or inhibitory, or both, with a range of latency from 0.04
seconds to 0.54 seconds. The results confirm that there is a functional
input to the suprachiasmatic nucleus from the mesencephalon. The
different nature of the responses suggests that the inputs are made up
of a number of separate afferent pathways.
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(P10) ROLE OF CENTRAL VASOPRESSIN (VP) INFUSION ON RHYTHMS OF
HYPOTHALAMO-PITUITARY-ADRENAL (HPA) ACTIVITY. CD Ingram1-2. MH Andrews2, B
Giddings2, AJ Horsfall1, YM Kershaw2, CA Lowry2, RJ Windle3, SA Wood2 and SL Lightman2. 'School of
Neurosciences and Psychiatry, University ofNewcastle NE1 4LP, 2University Research Centre for
Neuroendocrinology, Bristol BS2 8HW, and 3University ofNottingham, Lincoln County Hospital LN2 5QY
The HPA axis displays both uhxadian (pulsatile) and circadian (diurnal) rhythms of secretory activity, with
the amplitude ofpulses being lowest at the time of lights off (nadir) and a peak at the time of lights on
(acrophase). Central VP has been suggested to play a role in the control of these rhythms through its release
from both the paraventricular nucleus and the suprachiasmatic nucleus (SCN), where the circadian clock
resides. The following studies examined the effect ofchronic (5 day) changes in VP levels on basal HPA
activity. In the first study male Wistar rats were cannulated and administered with an i.c.v. infusion ofeither
saline, VP or the Vj, antagonist [^(CH2)5,Tyr(Me)2,Arg']VP via Alzet osmotic minipump for 5 days. Four
days after surgery blood samples were collected every 10 min for 24 h and assayed for corticosterone
(CORT). Rats infused with either saline or VP displayed regular pulses of CORT secretion the amplitude of
which varied according to the predicted diurnal rhythm. In contrast infusion ofthe antagonist resulted in low
amplitude pulses across the whole cycle, suggesting that blockade ofVP neurotransmission disrupts the
circadian input to the HPA. Ageing is associated with a gradual loss ofVP-immunoreactive neurones in the
SCN and we have previously reported that this correlates with a flattening ofthe circadian rhythm ofHPA
activity. To determine whether increasing endogenous VP levels would restore circadian activity, we tested
the effect of continuous VP infusion i.c.v. on HPA activity in young (3-4 month) and aged (24 month) rats.
Young rats displayed a clear diurnal pattern ofCORT secretion with nadir levels of<20 ng/ml rising to peak
levels of 70 ng/ml at the time of lights off. Infusions ofVP had no effect on this pattern. Aged animals
showed a predicted flattening ofthe rhythm, mainly due to an increase in nadir levels, and infusion ofVP
caused a restoration of the nadir levels similar to those in the young group. These data suggest that VP plays
a major role in maintaining the diumal rhythm ofHPA activity, particularly through modulation ofpulse
amplitude in the early light phase period.
(PI 1) ASSESSMENT OF CONTRIBUTIONS OF CRH AND VASOPRESSIN (VP) TO THE DRIVE
TO CORTICOTROPES IN PREGNANT RATS. MaS, Douglas AJ, Shipston MJ & Russell JA; Dept of
Biomedical Sciences, University ofEdinburgh, EH8 9XD.
Stressors are less effective in stimulating ACTH and corticosterone secretion in pregnant rats than in virgins.
Similarly, basal expression of CRH and VP mRNAs in the parvocellular paraventricular nucleus (pPVN) is
reduced, as are responsiveness of corticotropes to CRH in vivo, and CRH receptor binding (Neumann et al
1998 J Physiol 501:289-301). We have further studied corticotrope responses to CRH and VP in vitro and in
vivo. After decapitation, pituitaries were removed from virgin and day 21 pregnant rats and cell suspensions
prepared; after incubation of aliquots for 2 h, increasing concentrations ofCRH and VP, alone or together
were added for 60 min, and ACTH released measured. Stimulation ofACTH secretion by CRH was similar
for cells from pregnant and virgin rats, but augmentation of CRH effects by V^fcor stimulation by 8-cpt-
cAMP, was greater in pregnancy. ACTH content per pituitary cell was simniv^etween pregnant and virgin
rats, but by quantitative in situ hybridisation on pituitary sections, POMC mRNA expression was
significantly reduced at the end ofpregnancy (n= 17; by 45% vs. virgins, n= 15). Evidently the corticotropes
have a normal capacity to secrete ACTH in pregnancy. To test in vivo VP sensitivity, in the context of
endogenous CRH/VP secretion, we measured ACTH concentration in jugular venous blood (cannula
implanted under halothane anaesthesia) before and after i.v. VP bolus injection (1.7 pg/kg): ACTH secretion
increased less in pregnant than in virgin rats. Thus, unlike in lactation (Toufexis et al 1999 J Neuroendocr
11:757-764), corticotrope sensitivity to VP is not increased in pregnancy. To study the contribution ofCRH
to ACTH stress responses, we gave a non-peptide CRH1 receptor antagonist, antalarmin (20 mg/kg, i.p.,
gifted by Drs Chrousos & Zoumakis, NIH), or vehicle, 90 min before swim stress (90 s): after vehicle,
ACTH secretion was increased less by swimming in pregnant than in virgin rats, and antalarmin reduced the
increase in ACTH secretion similarly in pregnant and virgin rats (by 52 and 53%, respectively; n= 10, 4).
This suggests similar contributions by CRH to the ACTH response in pregnant and virgin rats. Together,
the in vitro and in vivo data are consistent with reduced in vivo drive by both CRH and VP to the
corticotropes in pregnancy; this is unlike in lactation, where VP is more, and CRH is less, important.
SM holds an ORS award; supported in part by Wellcome Trus
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THE ROLE OF NEUROPEPTIDE Y IN THE ACTION OF OREXIN-A ON
THE
HYPOTHALAMO-PITUITARY-ADRENAL SYSTEM
M. Jaszberenyi, E. Bujdoso, G. Telegdy
Dept. of Pathophysiology, University ofSzeged
The effects of the recently identified neuropeptide orexin-A on the hypothalamo-
pituitary-adrenal (HPA) system, and the possible interactions between this peptide
and neuropeptide Y (NPY) were investigated. An in vivo system was used to assess
the central effects of orexin-A. Different doses of orexin (2.8-280 pmol) were
administered intracerebroventricularly (icv.) to adult male Wistar rats, and plasma
corticosterone was used as an index of the degree of the activation of the HPA
system. Orexin-A exhibited a clear dose-response action, which showed a downturn
phase, and pretreatment with the corticotropin-releasing hormone (CRH) antagonist
a-helical CRH 9-41 completely prevented the action of orexin-A suggesting that
the site of action is at a central level. As orexin-A is synthesized in the lateral
hypothalamus and neuronal projections from this area to the paraventricular
nucleus (PVN) have been identified, we examined whether NPY, a potent activator
of the CRH secretion, participates in the action of orexin. In these experiments we
injected different concentrations of NPY antiserum icv. to the rats 24 h prior to the
administration of the most effective dose of orexin-A. The inhibitory action of the
antiserum exhibited a dose-response curve, and the highest concentration
completely abolished the action of orexin-A. This study affords strong evidence
that this appetite regulating peptide activates the HPA system at a central level, and
NPY appears to mediate the action of orexin. The animals were kept and handled
during the experiments in accordance with the instructions of the Ethical
Committee of University of Szeged for the Protection of Animals.
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CENTRAL MECHANISMS UNDERLYING REDUCED ACTH STRESS
RESPONSES IN PREGNANT RATS: ATTENUATED ACUTE GENE
ACTIVATION IN THE PARVOCELLULAR PARAVENTRICULAR
NUCLEUS (PPVN).
P.J.Bninton, S.Ma, M.J.Shipston, A.Wigger (1), I.D.Neumann (1), A.J.Douglas,
J.A.Russell
Department of Biomedical Sciences, University of Edinburgh. (I) Max Planck
Institute for Psychiatry, Munich.
ACTH and corticosterone secretory responses to stressors are attenuated in late
pregnant rats (I). Anterior pituitary corticotroph responses to CRH are reduced in
late pregnancy, yet ACTH content of dissociated cells is not decreased. However,
measured by semi-quantitative in situ hybridisation (ISH), POMC mRNA content
in the anterior pituitary decreases to the end of pregnancy, compared with virgin
rats. This may follow reduced basal drive from the hypothalamus as expression of
CRH and vasopressin mRNAs in the pPVN decreases in pregnancy (2). We have
sought reduced central drive during stress by ISH measurement of expression of
NGFI-B mRNA in the hippocampus and pPVN, and vasopressin heteronuclear
RNA in the pPVN, 30 and 60 min, respectively, after the start of 30 min restraint in
a perspex cylinder; rats were killed by decapitation. Restraint increased trunk blood
plasma ACTH concentration significantly less in the pregnant rats. NGFI-B mRNA
expression in hippocampal sub-fields and the pPVN was significantly less in
stressed pregnant rats than in stressed virgins, as determined by silver grain density
measurements on ISH autoradiographs. Similarly stimulation of vasopressin
heteronuclear RNA expression in the pPVN was reduced in pregnancy. Thus
reduced activation of hippocampal and pPVN neurones by restraint stress in late
pregnancy may underlie the reduced ACTH secretion. Such reduced responsiveness
of the maternal hypothalamo-pituitary-adrenal axis in pregnancy may protect the
fetuses from adverse programming by excessive glucocorticoid exposure.
Support; British Council/DAAD;. PJB-Faculty ofMedicine Research Student; SM -
ORS award.
(1) Neumann I.D. etal. (1998) J.Physiol. 508: 289-300.
(2) Johnstone H.J. el al. (2000) J. Neuroendocrinol. (In Press).
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CHRONIC, PRENATAL STRESS INDUCES POSTNATAL DEPRESSION IN RAT
DAMS: REVERSAL WITH NALTREXONE.
J.W. Smythe, J.W. Smith, J.R. Seckl (1), B. Costall
Pharmacy, University ofBradford, Bradford (I) Molecular Medicine Centre, University of
Edinburgh. Edinburgh UK
Prenatal stress (PS) produces behavioural impairments in the offspring, which persist into
adulthood. The mechanism via which PS alters the progeny involves hormonal fluxes in
the mother and fetus; these alter genomic activity. Meaney's group (1) reported that
maternal behaviour alone was sufficient to induce genomic changes in stress sensitivity in
rat progeny. We investigated whether or not PS might produce behavioural changes in rat
dams, which may contribute to effects in the progeny. We chose to use the Porsolt test,
which measures immobility in a forced-swim task, and models depression. There are
similarities between behavioural effects induced by PS, and those following prenatal
exposure to opiates. Therefore, we studied the effects of opiate antagonism on the dams'
responses. Pregnant rat underwent daily restraint stress (lh/day, days 10-20 of gestation),
or were left undisturbed (control). Half of the control and half of the stressed rats were
administered vehicle, while the remainder received naltrexone (NAL;10mg/kg, ip), daily.
On post-parturition day 3, dams were placed into a swim tank, and time spent immobile
was measured during a 10 min trial. All procedures were approved under Home Office
license No. 40/1974. PS significantly elevated immobility scores to approximately 130% of
control values. This response was abolished by NAL treatment, which by itself was without
effect. These data show that PS can alter behaviour in mothers, and this might contribute to
alterations in the offspring. PS may be an important factor in maternal postnatal
depression; endogenous opiate systems appear to play a key role in such effects since
blockade with NAL eliminated stress-induced postnatal depression.
(1) Francis et al. (1999) Science 286; 1155-1158
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TRH DEGRADING ECTOENZYME IN ADENOHYPOPHYSIS:
CELLULAR LOCALIZATION, REGULATION BY TRH AND
TRANSDUCTION PATHWAYS
J.L. Charli, M.A. Vargas, R. Cruz, L. Perez-Martinez, R.M. Uribe, P. Joseph-Bravo
Instituto de Biotecnologia, UNAM, Cuernavaca, Mexico
In the extracellular compartment, TRH is inactivated by a narrow specificity
ectopeptidase, pyroglutamyl peptidase II (PPII). PPII is present in brain and in
lactotrophs of adenohypophysis. We previously demonstrated that various
hypothalamic-paracrine agents, including TRH, slowly (in hours) regulate the
activity of PPII on the surface of adenohypophyseal cells in primary culture. The
purpose of this study was to: 1) precise the cellular distribution of PPII in
adenohypophysis, 2) identify the transduction pathway used by TRH to regulate
PPII activity and 3) determine whether TRH regulates PPII activity in vivo. Using
double in situ hybridization in primary cultures of female adenohypophyseal cells,
we found that 3-6 % of cells express PPII mRNA; only half of these are of
lactotrophs while none are thyrotrophs and the rest are yet unidentified cell types.
In primary cultures of adenohypophysis, treatments enhancing intracellular calcium
levels down-regulated PPII activity; their effect was not additive with the down-
regulation induced by TRH. Regulation of PPII activity by TRH was inhibited by: a
phospholipase C inhibitor, antagonists of L-type calcium channels, intracellular
calcium chelators or, inhibitors of calmodulin or Cam kinase II. Inhibition of PKC
or adenylate cyclase activities was not effective. In male rats, adenohypophyseal
PPII activity and mRNA levels fluctuated during the circadian cycle.
Intraperitoneal injection of TRH transiently reduced PPII activity. In conclusion,
we have shown that PPII is expressed in a small sub-population of lactotrophs, that
TRH down regulates PPII activity either in vivo or in vitro and that TRH-induced
calcium entry mediates TRH effect on PPII activity. (Partially supported by grant
3299P-N9607 from CONACYT).
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EFFECT OF GALANIN ON THE ACTIVITY OF THE
PROOPIOMELANOCORTIN (POMC) SYSTEM OF THE RAT
MEDIOBASAL HYPOTHALAMUS
S. Bouret (1), D. Croix (1), M. Mariot (2), S. Jdgou (3), H. Vaudry (3). J. C.
Beauvillain (1), V. Mitchell (1)
(I) INSERM Unit 422, IFR 22. 1 Place de Verdun, 59045 Lille Cedex France, (2)
Hop Swynghedauw, Lille France, (3) INSERM Unit 413, IFRMP 23, Mt St Aignan
France
It has become apparent that galanin as well as POMC-derived peptides such as (}-
endorphin, play an important role in the hypothalamic circuitry that regulates
endocrine functions and appetite behavior. We have recently shown that GalRl and
GalR2 galanin receptor mRNAs are expressed in POMC neurons of the arcuate
nucleus, suggesting a direct modulatory action of galanin on the POMC neuronal
system. However, the precise role of galanin on the activity of POMC neurons
remains to be determined. To elucidate this question, we examined the effects of
application of 500 nM galanin on the expression of POMC mRNA and on release
of P-endorphin from rat mediobasal hypothalamic (MBH) fragments using an
approach previously described (Prevot et al.. Endocrinology, 1999). The
experiments were performed on tissues maintained in an oxygenated survival
milieu. Using an in situ hybridization technique, we show that exposure of MBH
fragments to galanin increases significantly POMC mRNA levels in the arcuate
nucleus. This increase occurs after at least 60 minutes of application of galanin.
Concurrently, in comparison to controls, this application leads to a decrease of P~
endorphin levels in the survival medium. The effects of galanin on POMC mRNA
expression as well as on P-endorphin secretion in the survival milieu are both
antagonized by galantide.
In conclusion, our data show that application of galanin on rat MBH exerts a
stimulatory effect on POMC mRNA expression and an inhibitory effect on P-
endorphin release into the survival medium. This might implicate a differential role
for galanin on synthesis and release of POMC-derived peptides. However,
additional experiments are still necessary to understand more precisely these
results.
This work was supported by the Lille-Amiens-Rouen-Caen (LARC) network.
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EFFECT OF GONADAL STEROIDS REPLACEMENT ON HYPERTONIC
SALINE STIMULATED VASOPRESSIN RELEASE IN THE FEMALE RAT.
M.J. Evans, S.A.Chaudhary, M.LForsling
Neuroendocrinology Research Group, KCL, Guy's Campus, London, UK.
Basal plasma vasopressin (AVP) levels alter over the oestrous cycle and reflect
progesterone (P) and oestrogen (E) concentrations. The AVP response to raised plasma
sodium levels is reduced in ovariectomized rats. This study was carried out to determine
the effect of ovarian hormone replacement on stimulated AVP release. Procedures were
conducted in female Sprague-Dawley rats weighing approx. 300g in accordance with the
UK Animals (Scientific Procedures) Act 1986. Animals were ovariectomized under
anaesthetic and given P (n=8) only or P+E (n=10) as subcutaneous silicone implants in
concentrations to mimic those of basal levels present on day oestrus. Under anaesthesia,
both venous and arterial cannulae were inserted 5 days later. All studies were conducted
between the hours of 11:00 and 16:00 after 48 hours recovery from surgery. A 30-minute
control period of 0.15M NaCl infusion at 50 pl/min was followed by I.5M NaCl infusion
for a 90 min period and blood samples taken at time points 0, 45 and 90 after the start of
hypertonic infusion. Packed cell volume (PCV) was measured, samples centrifuged for 5
mins and plasma collected for sodium and AVP determination. Plasma AVP concentrations
were determined by radioimmunoassay. Statistical evaluation by AJNOVA and t-test with
Tukey-Kramer multiple correction. The mean plasma AVP levels increased in the presence
of P+E by 8.14 ± 1.42 pU/ml compared with 3.34 + 0.97 pU/ml in P alone (P<0.001). The
slope of regression of plasma AVP to sodium concentrations had a larger gradient in the
case of P+E than P alone (P=0.037). Therefore, addition of ocstradiol, in the presence of
progesterone replacement, provided an increase in both sensitivity and release of the AVP
response to elevated plasma sodium levels.
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